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ABSTRACT 
 
MEMBRANE FORCES AND KEY PROTEIN DETERMINANTS OF 
HEMATOPOIETIC CELL FUNCTION: LAMINS AND MYOSIN-II IN 
HEMATOPOIESIS AND CD47 IN IMMUNOTHERAPY OF CANCER 
 
Kyle R. Spinler 
Dennis E. Discher 
 
 Hematopoiesis in human bone marrow generates every second about 105 – 106 
anucleated platelets and red blood cells as well as nucleated white blood cells that are 
capable of infiltrating distant tissues. The thesis begins in the marrow with a description 
of (1) nuclear membrane ‘lamina’ physicochemical properties that influence marrow-to-
circulation trafficking, and proceeds to detail (2) the physicochemical roles of membrane 
cortex ‘myosin’ in key marrow processes of motility and division as well as platelet 
biogenesis and disease. The thesis finishes with (3) studies of macrophages in peripheral 
tissues far from the marrow and aspects of how such cells distinguish ‘foreign’ cells from 
‘self’ cells.   
Collaborative studies show the lamin-A:B ratio controls nuclear viscoelasticity 
and in turn cell trafficking relevant to marrow escape. Additionally, differential lamin 
expression can direct erythroid and megakaryocyte differentiation. Secondly, xenografts 
show that MIIB is required for blood cell generation, while MIIA is required for long-
term HSC/P engraftment. MII inhibition by blebbistatin prior to xenotransplantation 
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enriches for long-term hematopoietic multilineage reconstituting cells, and also multi-
nucleated megakaryocytes. Cone and plate rheometry demonstrates an optimal shear 
stress for platelet-like-particle generation from MKs that is enhanced by MII inhibition, 
and that MIIA heavy chain phosphorylation at S1943 is shear sensitive. Micropipette 
aspiration of MKs with mutations of the MIIA gene, MYH9, recapitulates MYH9-RD 
macrothrombocytopenia. Comparing MYH9-RD patient and normal donor platelets 
shows a similarity in pre/pro-platelets when normals are treated with blebbistatin. These 
findings provide evidence that regulation of MIIA activity through S1943 
phosphorylation is critical to proper MK fragmentation and proplatelet fission to generate 
platelets of normal size and number.  
The dissertation concludes with an investigation of an immunotherapy approach 
to treat peripheral solid tumors by controlling tumor cell CD47 expression and 
administering an anti-human polyclonal IgG antibody. These in vivo xenograft models 
provide a mechanism of selective tumor clearance driven by FcR stimulation of 
macrophages. In all, this work highlights biophysical factors of cortical and nuclear 
membranes that govern hematopoietic differentiation and trafficking, normal and 
pathological thrombopoiesis, and a mechanism of phagocytic clearance of cancer cells 
through CD47 attenuation and species specific but epitope non-specific antibody 
infusion.  
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CHAPTER 1: INTRODUCTION 
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1.1 SIGNIFICANCE 
 Adult stem cells of many diverse tissue types have been an intense area of 
research since the first human bone marrow transplant (BMT) (Thomas et al., 1957) and 
the discovery of hematopoietic stem cell/progenitors (HSC/Ps) by clonal assay (Becker et 
al., 1963). These cells have the capacity to either integrate in a target tissue or act as 
vehicles to deliver signals without integration (Daley and Scadden, 2008). More than 
50,000 BMT procedures were performed in 2006 saving a large percentage of otherwise 
untreatable patients (Gratwohl et al., 2010). While BMT is successful for many 
recipients, many other patients are not as fortunate. Such limitations have motivated 
researchers to elucidate mechanisms by which a few, or even a single, stem cell(s) can 
generate an entire, regenerating tissue. The demands of the human hematopoietic system 
are exceptionally great. The human body generates 3x1010 nucleated blood cells, 2x1013 
anucleated red blood cells (RBCs), and 1x1011 platelets daily. Factors that regulate HSC 
proliferation, differentiation, and dispersion continue to be defined, and include 
biophysical forces and membrane mechanics that are addressed throughout the following 
chapters.  
 Advances in isolation and identification of HSC/Ps versus committed lineages 
have defined the hematopoietic hierarchy. Of particular importance has been the isolation 
of HSC/Ps by flow cytometry based on particular sets of surface antigens (Weissman and 
Shizuru, 2008) combined with quantification of HSC frequency by means of limiting 
dilution transplantations (Szilvassy et al., 1990). In addition to these methods, numerous 
soluble growth factors have been identified that support and drive differentiation of 
various blood lineages. Despite these advances, much less is known about in vivo 
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physical factors that might govern HSC self-renewal and commitment. A stem cell 
“niche” was proposed to be a requirement for long-term hematopoiesis from HSCs 
(Schofield, 1978). Further understanding of the niche is likely to reveal strategies of 
HSC/P direction ex vivo that will allow enhancement of in vivo engraftment in patients. 
Such efforts will also benefit ex vivo production of mature blood cell products, 
particularly RBCs and platelets that are very commonly transfused. Despite the discovery 
of erythropoietin (Epo) (Miyake et al., 1977) and thrombopoietin (Tpo) (Kaushansky et 
al., 1994) as cytokines that facilitate erythroid and megakaryocyte (MK) differentiation 
from HSC/Ps, in vitro generation of terminally differentiated cells in quantities large 
enough to meet demand has remained elusive. Further, none of the growth factors, 
cytokines, or chemokines has yet proven sufficient to reproduce artificial marrow-like 
environments conducive to generation of all blood cell-types from HSC/Ps.  
 Conversion of extracellular mechanical inputs to intracellular signals, both 
biochemical and biophysical has been termed mechanotransduction (Wang et al., 2009). 
Mechanotransduction is mediated by intracellular tension that is sustained by adhesion to 
matrix or other cells and generated by the actin-myosin-based cytoskeleton (Discher et 
al., 2005), which in turn couples to the nucleus (Pajerowski et al., 2007). Since HSC/Ps 
and derived lineages intimately interact in numerous ways with their microenvironments, 
microenvironment mechanical aspects can in principle regulate stem and progenitor cell 
functionality. Stem cells generate forces in processes ranging from cell division to 
migration, while external stresses in stem cell microenvironments, including fluid flows, 
impact adhesion and associated signaling so do mechanical factors and nuclear elasticity 
of HSC/Ps (Pajerowski et al., 2007; Shin et al., 2011). All of these structures with 
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mechanical functions can impact stem cell maintenance, lineage specification, and 
trafficking. Therefore, nuclear lamin and myosin-II (MII) will be investigated in the 
context of HSC/P lineage commitment and marrow egress followed by an examination of 
the regulation of MII activity and pathology in thrombopoiesis.  
 Cortical and nuclear membranes not only facilitate migration of hematopoietic 
cells within the marrow, out of the marrow, and throughout the circulation, but 
extravasation from the peripheral blood (PB) to surrounding tissue as well. Leukocytes, 
particularly macrophages, actively transit between circulation and tissue in response to 
inflammation. Macrophages can be either pro- or anti-tumorigenic depending on their 
polarization, either M2 or M1 respectively (Mantovani et al., 2002; Murdoch et al., 
2008). The invasiveness of macrophages allows these cells to respond to antigens far 
from circulation. One such signal that triggers macrophage action is cell surface 
expressed CD47. Human tissues ubiquitously express CD47 on their surface to avoid 
their phagocytosis by patrolling macrophages. CD47 expression on circulating blood 
cells is particularly important as these cells encounter macrophages in much greater 
frequency. In fact, as RBCs age, they lose CD47 to effectively mark them for clearance. 
CD47 acts as a “don’t eat me” signal by interaction with SIRPα on the phagocyte 
(Rodriguez et al., 2013). It has been shown in numerous types of cancer that CD47 is 
expressed at abnormally high levels providing tumor cells an immunologic invisibility 
(Jaiswal et al., 2009). Others have shown that patients with tumors expressing higher 
CD47 have worse tumor progression and are less successfully treated (Majeti et al., 
2009). The capacity for macrophages to infiltrate deep into tissue, discriminate between 
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self and foreign, and selectively clear non-self cells introduces the potential to augment 
the efficacy of chemotherapeutic and immunotherapeutic modalities.  
 
1.2 ACTOMYOSIN FORCES IN STEM CELLS AND PROGENITORS 
 Cells generate intracellular forces with actin and MII in response to extracellular 
mechanical cues ranging from matrix adhesion to fluid shear stress. These force 
generating processes are important to a myriad of biological functions relevant to 
differentiation, including cytokinesis, cortical tension, and migration. Of particular 
relevance to the work to follow, MII, is a crucial force generating motor and plays a 
major role in hematopoietic tissues and stem and progenitor cell contexts. Actin is a 
principal filamentous constituent of the cytoskeleton that can also translocate to the 
nucleus as a monomer. Myosin motor proteins pull on actin filaments by dynamically 
crosslinking and translating along the filaments in a process driven by ATP hydrolysis 
(Pollard and Korn, 1973). These activities can impact actin monomer pools (Wilson et 
al., 2010) that in turn can impact serum response factor (SRF), which is an ubiquitous 
actin regulated transcription factor with multiple co-factors that traffic between the 
cytoplasm and nucleus (Olson and Nordheim, 2010). Non-muscle cells express isoforms 
of MII that assemble in small mini-filaments that appear notably less ordered than in 
muscle. MYH9, MYH10, and MYH14 are the genes encoding for the three MII heavy 
chain isoforms A, B, and C respectively. Hematopoietic cells express A and B isoforms, 
but not C, and these cells show dynamic expression patterns during differentiation 
(Engler et al., 2006). Additionally, the A:B ratio increases as megakaryocytes mature 
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ultimately leading to exclusive expression of A type MII in platelets (Lordier et al., 
2012).  
 MIIA knockout is embryonic lethal in mice at E6.5 with defects in visceral 
endoderm morphogenesis and overall tension of the embryo, which appears flaccid 
(Conti et al., 2004). Together, these defects are a result of the inability to differentiate 
despite the capacity to adhere and divide.  MIIB knockout mice survive longer, but die at 
E14.5 due to abnormalities in heart and brain that include more binucleated cells (Takeda 
et al., 2003; Tullio et al., 1997). Myosin-II deletion in Dictyostelium leads to increased 
distortion of the cell membrane and multinucleation in suspension cultures where cells 
cannot crawl apart to facilitate division (Merkel et al., 2000). Pharmacological inhibition 
of MII in adherent cells by blebbistatin also tends to increase the number of binucleated 
cells, indicating a role for MII in efficient cytokinesis (Straight et al., 2003). MII is also 
important in matrix sensing. Blebbistatin eliminates the effect of matrix elasticity on 
lineage specification of MSCs (Engler et al., 2006) and also maintenance of HSC/P 
numbers on highly flexible tropoelastin surfaces (Holst et al., 2010). 
 MII levels vary markedly between cell types as well as during differentiation, and 
MII is capable of rapidly responding to changes in intracellular and extracellular forces 
through changes in its phosphorylation states. MII is comprised of two heavy chains (230 
kDa), two essential light chains (17 kDa), and two regulatory light chains. Myosin heavy 
chain consists of an ATP-hydrolyzing N-terminal motor domain head, which directly 
interacts with F-actin, and a ~150 nm long C-terminal helical tail that forms coiled-coil 
dimers which can further assemble into myosin filaments (Adelstein et al., 1972). 
Essential light chains are required for heavy chain stabilization (Hernandez et al., 2007). 
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Numerous studies, such as the one by Matsumura (Matsumura, 2005), have shown that 
regulatory light chains (RLC) modulate MII activity via phosphorylation by numerous 
kinases, including myosin light chain kinase (MLCK) and Rho-associated protein kinase 
(ROCK), both of which can phosphorylate the Thr18 and Ser19 RLC residues. MII heavy 
chain can be phosphorylated at Ser1943 in the tail and Tyr277 in the head. Protein kinase 
C and casein kinase-II phosphorylate the heavy chain, but additional kinases are likely 
relevant (Dulyaninova et al., 2005; Even-Faitelson and Ravid, 2006). Since the heavy 
chain directly binds with F-actin, regulation of heavy chain phosphorylation seems likely 
to have the most direct impact on MII activity compared to RLC. Recent mutagenesis 
studies implicate MIIA phosphorylation in regulating polyploidization of MKs more 
dramatically than inhibitors of MLCK or ROCK (Shin et al., 2011). 
 Although MII’s functions in early HSC/Ps remain elusive, it nonetheless plays 
critical roles in differentiated hematopoietic lineages. In lymphoid cells, MII plays roles 
in the critical functioning of natural killer cells (Andzelm et al., 2007), T-Cells (Ilani et 
al., 2009; Jacobelli et al., 2010; Rey et al., 2007; Samaniego et al., 2007), and B-cells 
(Vascotto et al., 2007). In myeloid cells, MII is required in dendritic cells (Faure-André et 
al., 2008; Fernandez et al., 2011), neutrophils (Shin et al., 2010), and macrophage 
phagocytosis (Tsai and Discher, 2008). Actin-mediated forces have been shown to 
contribute to enucleation in erythroid lineages (Koury et al., 1989). MYH9 mutations in 
MK lineages are associated with May-Hegglin anomaly, Fechtner Syndrome, Sebastian 
Syndrome (all part of a general classification of MYH9-related disorders). Such mutations 
are responsible for low platelet counts (thrombocytopenia) and abnormally large platelets 
(Kelley et al., 2000; Seri et al., 2000). Transgenic mice recapitulating MYH9-RD show 
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longer bleeding times and defects in clot retraction in addition to thrombocytopenia 
(Zhang et al., 2012). While MYH9 mutations appear to impair platelet generation, other 
previous studies using in vitro MKs show increased proplatelet formation upon MII 
knockout or pharmacological inhibition (Chen et al., 2007; Eckly et al., 2009). Indeed, 
blebbistatin promotes platelet-like fragmentation by the fluid stresses that mimic shear 
stress in capillaries of the marrow (Shin et al., 2011). Despite these complications, 
actomyosin forces are an attractive target for mechanically modulating hematopoiesis in 
lineage specification and/or function. 
 
 
1.3 DEFORMABILITY OF THE CELL CORTEX AND NUCLEUS PERMITS 
EGRESS FROM THE NICHE 
 For stem cells and their progeny, adhesion, retention, migration, and egress from a 
niche are all processes grounded, at least in part, on cell mechanics. While some mature 
blood cells such as RBCs and platelets must enter the circulation to carry out their role, at 
least some of the immature HSC/Ps must be retained in the marrow to sustain long-term 
hematopoiesis. The deformability of hematopoietic cells can change during 
differentiation, thus this property is likely a factor in regulating cell trafficking under 
mechanically constrained conditions that involve migration across the marrow-blood 
endothelial barrier and into 2-3 µm diameter capillaries. An early micropipette study 
showed that a 20-fold increase in aspiration pressure was necessary to deform myeloid 
progenitors (immature myeloblasts) compared to more deformable mature granulocytes 
(Lichtman, 1970). Additionally, myeloblasts cannot transit through 1-8 µm pores under a 
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chemotactic gradient, whereas the deformable mature granulocytes can (Giordano and 
Lichtman, 1973). How hematopoietic differentiation leads to changes in the deformability 
of cells and hence trafficking has, until now, not been deeply investigated. Recent studies 
with MSC migration through 3D gels (Raab et al., 2012) has provided additional 
credence to the hypothesis that both cell cortex and nucleus likely contribute to overall 
cell deformability and thereby impacting cell motility, niche retention, and trafficking.  
 In the context of fluid flow stresses on blood cells, membrane deformability has 
been characterized for platelets (White et al., 1984), megakaryocytes (Smith et al., 1989), 
granulocyte and lymphocytes (Dong et al., 1991), and RBCs (Discher et al., 1994). From 
these studies it is clear that the cytoskeleton specialization is a particularly key part of 
each cell type’s program. In contrast to granulocyte differentiation, erythroid progenitors 
are stiffer than mature RBCs (Waugh et al., 2001). Nucleus stiffening could be a driving 
factor for enucleation to allow egress of RBCs (Lichtman et al., 1989). In general, 
primitive stem cells tend to be soft, perhaps due to the immature cytoskeletal architecture, 
and thus allow cell plasticity to be particularly susceptible to physical changes in external 
forces in their surroundings. For example, undifferentiated ESCs are 10-fold softer than 
differentiated progeny and posses higher sensitivity to a local cyclic stress that triggers 
cell spreading and differentiation (Chowdhury et al., 2010). 
 Since MII regulates cortical stiffness, whether HSC/Ps are softer than 
differentiated cells is likely dependent on the absolute abundance of MII isoforms during 
hematopoiesis. Myosin-II itself is sensitive to external force and has shown to become 
polarized and assemble in regions of high stress (Reichl et al., 2008). In the epithelial-to-
mesenchymal transition, cells undergo MII isoform switching from C to B, promoting 
	   10	  
cell motility and invasion (Beach et al., 2011). In this vein, recent work has shown that 
MII isoform switching between A and B regulates differentiation and motility of 
hematopoietic cells (Shin et al., 2014).  
 Hematopoietic cells have a small cytoplasmic volume, and so in addition to cell 
cortex, the nucleus is likely to contribute to overall cell deformability and trafficking. 
Nuclear deformability is largely understudied in the hematopoietic system and only 
recently has deformability of isolated nuclei or nuclei in living cells been probed with 
micropipette aspiration (Ivanovska et al., 2010). Previous studies from the Discher group 
have indicated that nuclei in human hematopoietic CD34+ cells from marrow were 
slightly stiffer than nuclei from human ESCs but considerably softer than other 
differentiated nuclei suggesting that nuclear deformability is developmentally regulated 
(Pajerowski et al., 2007). Furthermore, the same study demonstrated that nuclear stiffness 
is dependent on lamins, which are intermediate filaments that assemble as coiled-coil 
dimers at the nuclear envelope and associate at least indirectly with chromatin (Shimi et 
al., 2010). Using micropipette and entry into 3D pores, our group has provided further 
evidence to the involvement of lamins in nuclear stiffness which further supports the 
relevance of nuclear deformability in the hematopoietic system (Shin et al., 2013). One 
hypothesis is that the polyploidy nucleus of the MK is too large and rigid to allow egress 
into the blood, but extension of membrane projections is permissive. These extensions 
fragment under shear flow to generate platelets as seen by in vivo imaging (Junt et al., 
2007). Additionally, lamin-A, C is strongly upregulated upon T-cell activation (Andrade 
et al., 2003) and this could similarly favor retention of a T-cell at a site of inflammation. 
Similar to the hypothesis that MII actively regulates deformability of the cell cortex, it 
	   11	  
appears reasonable to propose that differential lamin expression regulate nuclear stiffness 
throughout hematopoiesis and that this influences the ability of cells to migrate through 
and within the dense marrow or tissue and across the endothelium into the blood 
circulation.  
 
1.4 PHYSIOLOGICAL SHEAR FLOW INFLUENCES LINEAGE 
DIFFERENTIATION 
 Fluid shear forces are an important external biophysical factor to consider in the 
context of differentiation. Such forces have been investigated most extensively with 
endothelial cells (due to direct exposure to blood flow) but also to a lesser extent with 
osteocytes which experience distinct fluid flows as bone is stressed in daily activity 
(Weinbaum et al., 1994). Endothelial cells can be differentiated from ESCs upon shear 
flow in vitro via the downstream activation of histone deacetylase 3 (Zeng et al., 2006), 
and osteoblast differentiation from BM-derived MSCs is facilitated by continuous shear 
in vitro (Stiehler et al., 2009). Additionally, controlled shear flow in vitro induces 
differentiation from embryoid-body-derived cells into hematopoietic precursors as 
indicated by a strong upregulation of the Runx1 transcription factor (Adamo et al., 2009). 
Zebrafish models also show that both chemical and genetic ablation of blood flow 
severely reduces HSC number (North et al., 2009). 
 Interplay between intrinsic and extrinsic mechanical factors likely contributes to 
cells fates. Fluid shear produces forces that are balanced by cell adhesions and the 
actomyosin cytoskeleton otherwise fluid shear can be so strong that it dominates to 
convect and disperse cells or even fragment them such as shown in platelet generation 
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(Junt et al., 2007). Additionally, an absence of adhesion to external surfaces for many cell 
types limits cytokinesis, those cells that do survive tend to become multi-nucleated in 
suspension, whereas adhesion-based traction forces help cells pull apart (Ben-Ze’ev and 
Raz, 1981). MK polyploidization is thus inhibited on stiff matrix where increased 
adhesion maximizes the traction forces for cell division even when MII is inhibited (Shin 
et al., 2011). Conversely, cell cycle progression can also be inhibited by soft matrix for at 
least some adherent cells (Klein et al., 2009). Adhesion, matrix elasticity, and external 
forces thus couple MII in processes central to hematopoietic fates such as cell division 
(symmetric or asymmetric) and platelet generation.  
 
1.5 MEMBRANE EXPRESSION OF CD47 PROTECTS CELLS FROM 
PHAGOCYTOSIS BY MACROPHAGES AND IS UPREGULATED IN CANCER  
 CD47 is a cell surface molecule that binds several proteins including integrins 
(Brown and Frazier, 2001) and thrombospondin-1 (Lindberg et al., 1996), and has been 
shown to play roles in physiologic process including cell migration (Jaiswal et al., 2009; 
Lindberg et al., 1996; Liu et al., 2001), T-cell and dendritic cell activation (Sarfati et al., 
2008), and axon development (Miyashita et al., 2004). Additionally, CD47 functions as 
an inhibitor of phagocytosis through association with SIRPα expressed on phagocytes. 
This interaction leads to tyrosine phosphatase activation and inhibition of MII 
accumulation at the phagocytic synapse (Tsai and Discher, 2008). In this role, CD47 acts 
as a “don’t eat me signal” and a marker of self, as loss of CD47 leads to homeostatic 
phagocytosis of aged or damaged cells (Blazar et al., 2001; Gardai et al., 2005; 
Oldenborg, 2000). CD47 is widely expressed on a majority of normal tissues (Reinhold et 
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al., 1995), which suggests that its role in regulating phagocytosis is widespread. While 
expression is ubiquitous on normal cells, multiple tumor types have been shown to 
express increased levels of CD47 (Chao et al., 2010a, 2011a; Jaiswal et al., 2009; Majeti 
et al., 2009). A study in which a CD47-deficient myeloid leukemia cell line was forced to 
overexpress CD47 facilitated aggressive dissemination and fulminant death in xenograft 
mice, in contrast to minimal engraftment upon transplantation of the CD47-deficient cells 
(Jaiswal et al., 2009). Upregulation of CD47 expression in human cancers also appears to 
influence tumor growth and dissemination. Expression of CD47 in several hematologic 
malignancies was found to be associated with a worse clinical prognosis, and was able to 
predict refractoriness to standard chemotherapies in acute lymphoblastic leukemia (ALL) 
(Chao et al., 2010a, 2011a; Majeti et al., 2009). Conversely, shRNA knockdown of CD47 
in human non-Hodgkin’s lymphoma (NHL) led to a dramatic decrease in hematogenous 
dissemination and spread to major organs compared to control NHL cells (Chao et al., 
2011b). Such findings support a hypothesis of cancer progression in that overexpression 
of CD47 enables tumors to escape innate immune system surveillance through evasion of 
phagocytosis.   
 Targeting the CD47-SIRPα pathway has currently been an active area of research. 
Treatment with an anti-CD47 antibody has proven efficacious in mouse models of acute 
myeloid leukemia (AML), ALL (Chao et al., 2011a; Majeti et al., 2009), NHL (Chao et 
al., 2010a), multiple myeloma (MM) (Kikuchi et al., 2005), bladder cancer (Chan et al., 
2009), and breast cancer (Manna and Frazier, 2004). While anti-CD47 antibodies disrupt 
the CD47-SIRPα interaction on tumor cells, these antibodies likewise can bind to CD47 
on normal tissue. However, administration of anti-CD47 antibodies did not result in 
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severe off-target toxicity (Majeti et al., 2009). This paradox can be resolved if in addition 
to blocking the anti-phagocytic an additional pro-phagocytic stimulus is required for 
tumor clearance. Indeed, it has been shown that many hematologic and sold tumors 
express the pro-phagocytic signal calreticulin (CRT) on their cell surface while normal 
cells did not (Chao et al., 2010b).  
 Expanding on the simple therapies targeting only CD47, recent studies have 
combined CD47-SIRPα blocking with tumor-targeting antibodies to maximize efficacy. 
The primary role of tumor-targeted antibody is to stimulate Fc-mediated functions such 
as antibody-dependent cellular cytotoxicity (ADCC) and FcR-mediated phagocytosis to 
augment tumor cell killing. This method stimulates phagocytosis by blocking a negative 
signal and delivering a positive signal. Such treatments have been leveraged in preclinical 
models of NHL using anti-CD47 and the anti-CD20 antibody rituximab leading to 
synergistic elimination of xenografts in mice (Chao et al., 2010a). In another context, 
anti-SIRPα antibody plus the anti-Her2/Neu antibody trastuzumab potentiated ADCC of 
breast cancer cells. Co-administration of macrophage stimulating cytokines, M-CSF and 
GM-CSF, has shown to enhance anti-tumor activity against multiple tumor types 
(Hernandez-Ilizaliturri et al., 2005; Sanda et al., 1992; Stockmeyer et al., 1997; Valerius 
et al., 1993). Concurrent administration of chemo-radiation therapy with anti-CD47 is yet 
another combination strategy that may prove successful. A treatment regimen consisting 
of chemo-radiation prior to anti-CD47 may lead to increased macrophages effector cells, 
as chemotherapy can induce an inflammatory response that attracts infiltrating 
macrophages to tumor sites (Funada et al., 2003; Le et al., 2007; Welsh et al., 2005). 
Prior studies have shown that chemo-radiation leads to increased expression of CRT on 
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tumor cell surfaces (Obeid et al., 2007) thus potentially augmenting the efficacy of anti-
CD47 antibody treatment. The many ways that CD47-SIRPα blocking could lead to an 
efficacious treatment of a variety of cancers with minimal side effects motivates the 
further investigation of the mechanisms behind such ADCC.  
 
1.6 MOTIVATION AND OUTLINE OF THESIS 
 Investigation of hematopoiesis has primarily focused on soluble factors (Metcalf, 
2008), surface antigens (Weissman and Shizuru, 2008), and genetic studies of cell cycle 
components (Orford and Scadden, 2008) and transcription factors (Novershtern et al., 
2011). Only recently have researchers began to understand the role of the niche in stem 
cell maintenance and differentiation. Yet, the roles of cytoskeletal and nuclear membrane 
mechanics and accompanying forces in hematopoiesis have been grossly under 
investigated.  Due to the high nucleus-to-cytoplasm ratio of hematopoietic cells it seems 
reasonable to envision that processes such as partitioning between marrow and blood 
could be, at least partially, dependent on nuclear deformability and that deformability is 
modulated by lamin-A and –B.  
Asymmetric division of stem cells is known to be established by polarization of 
MII (Ou et al., 2010). MIIA is found in most tissues (Ma et al., 2010) including blood 
(Maupin et al., 1994) and is essential to embryonic development (Conti et al., 2004). 
Meanwhile, MIIB is more polarizable, particularly during cell migration, (Raab et al., 
2012; Vicente-Manzanares et al., 2008) and recent studies have demonstrated roles in 
MK differentiation (Lordier et al., 2012) and asymmetric erythroid enucleation (Ubukawa 
et al., 2012). Thus, it is plausible that specific MII isoforms play unique roles in 
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hematopoiesis. We demonstrate critical roles for MIIA and MIIB in adult hematopoiesis 
and use that understanding to enrich highly heterogeneous HSC/Ps for long-term 
hematopoietic stem cells.  
After the investigation of lamin and MII in early hematopoiesis, focus is shifted to 
MII in the terminal stages of platelet production. Intravital imaging of mouse bone 
marrow has captured the process of proplatelet fragmentation from MKs (Junt et al., 
2007) while others have demonstrated that MIIA activity inhibited by blebbistatin results 
in an increase in proplatelet extension length (Chen et al., 2007; Eckly et al., 2010). 
Individuals with genetic mutations of MYH9 encoding MIIA show macro-
thrombocytopenia (Balduini et al., 2011). Recent work has provided additional insight 
into the further processing of sheared proplatelets to smaller platelets, but was chiefly 
focused on microtubules yet likened the process to cytokinesis, which is driven by MIIA 
activity (Thon et al., 2010). Together these findings seem to indicate that precise control 
of MIIA activity is critical to proper proplatelet extension, fragmentation, and processing 
in order to maintain proper platelet size and number.  
To address the issues of early hematopoiesis, we employ either siRNA or shRNA 
knockdown or overexpression of lamin-A, -B, MIIA, or MIIB to explore roles of 
individual isoforms or stoichiometric effects in CD34+ cells. Cells are then assayed by 
means of micropipette aspiration or colony forming assay in vitro and primary, 
secondary, or competitive xenotransplantation in vivo using mice. The role of MIIA in 
platelet generation and fragmentation is addressed by cone and plate rheometry and 
micropipette aspiration either with or without blebbistatin. Mutagenesis approaches are 
used to further explore MIIA phosphorylation as well as known MYH9-RD mutations. 
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All or which leads to imaging and characterization of MYH9-RD patient platelets and a 
comparison with platelets from normal donors in the presence or absence of blebbistatin.  
The thesis then shifts from membrane determinants of hematopoiesis to 
harnessing the membrane recognition and phagocytic capacity of macrophages to treat 
cancer. The Discher lab has already shown that CD47 expression attenuates 
phagocytosis, particularly that phagocytosis of beads opsonized with a peptide 
engineered from CD47 is decreased (Rodriguez et al., 2013). Others have shown 
dramatic tumor shrinking results using an engineered SIRPα variant in combination with 
a monoclonal anti-cancer antibody (Weiskopf et al., 2013), while others have 
demonstrated increased efficacy of rituximab with co-administration of anti-CD47 
antibody (Chao et al., 2010a).  
We use a NSG mouse model to generate human xenograft tumors of either normal 
or near complete knockdown of CD47. Tumor progression is monitored throughout the 
studies by live animal fluorescence imaging. Mice are treated with a human specific 
polyclonal antibody and tumors, spleen, and blood are collected at the termination of 
treatment. These tissues are then analyzed by flow cytometry to assess CD47 levels, 
macrophage number and maturity as well as antibody opsonization and macrophage 
phagocytosis of human material. Anemia and thrombocytopenia are assessed from the 
blood collection. Furthermore, a GFP expressing cell line of normal CD47 expression 
was generated and spiked into CD47 knockdown tumors to determine which, if any, cell 
type was preferentially eliminated.  
The chapters of this thesis are organized to address early hematopoiesis, 
specifically the roles of lamins and myosins, in Chapter 2 including an exploration into 
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the roles of myosins in HSC/P self-renewal, which leads to an in vivo demonstration of 
how perturbation of MII effects hematopoietic reconstitution and long-term engraftment. 
Chapter 3 explores the role of MIIA in fragmentation of proplatelets from MKs and 
further preplatelet fission to normal size and number platelets. This work includes a direct 
comparison of normal platelets with those obtained from MYH9-RD patient PB. The role 
of CD47 attenuation in cancer treatment is presented in Chapter 4. An In vivo solid tumor 
xenograft model provides mechanistic insight into the clearance of tumor cells following 
antibody treatment. Finally, Chapter 5 summarizes the conclusions of the prior three 
chapters and presents future directions, some of which are currently in progress. In all, 
this work highlights biophysical factors of cortical and nuclear membranes that govern 
hematopoietic differentiation and trafficking, normal and pathological thrombopoiesis, 
and provides a mechanism of phagocytic clearance of cancer cells through CD47 
attenuation and species specific but epitope non-specific antibody infusion to stimulate 
macrophages. 
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CHAPTER 2: CORTICAL AND NUCLEAR MECHANICS MODULATE 
DIFFERENTIATION AND THEIR DETERMINANTS ARE LINEAGE SPECIFIC 
 
 
 
 
 
 
 
The work presented in this chapter is a combination of novel contributions to the 
following articles appearing in publication and used with permission of the senior author. 
 
Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular 
projections typical of platelet-producing megakaryocytes. Shin JW, Spinler KR, Discher 
DE, et al. PNAS. 108:11458-11463. (2011) 
 
Lamins regulate cell trafficking and lineage maturation of adult human hematopoietic 
cells. Shin JW, Spinler KR, Discher DE, et al., PNAS. 110:18892-18897. (2013) 
 
Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. 
Swift J, Spinler KR, Discher DE, et al., Science. 341:124014. (2013) 
 
Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells. 
Shin JW, Spinler KR, Discher DE, et al., Cell Stem Cell. 14:81-93. (2014) 
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ABSTRACT 
 Adult marrow niches provide the residence of hematopoietic stem and progenitor 
cell, as well as nucleated erythroblasts and megakaryocytes while other blood cells easily 
cross through endothelial sinusoids into the circulation. Due to the high nuclear to 
cytoplasm ratio in hematopoietic cells, we propose that cells cross microporous barriers 
preferentially due to regulation of nuclear deformability controlled by lamin-A and –B 
and that lamin levels can directly modulate hematopoietic programs. Using micropipette 
aspiration we demonstrate that nuclear flexibility is limited by lamin-A:B stoichiometry 
across hematopoietic lineages. Furthermore, differentiation is altered by disrupting the 
A:B ratio by overexpression or knockdown of either lamin-A or –B. We also show that 
high A:B promotes erythroid differentiation while high ploidy megakaryocytes are 
inhibited by lamin suppression. Thus, lamins contribute to differentiation and trafficking. 
Whereas lamins confer nuclear mechanical properties, nonmuscle MII acts at the cell 
cortex. Self-renewal and differentiation of stem cells rely on asymmetric division and 
polarized motility that is modulated by MII forces and matrix mechanics in other cell 
types. Here, we show in vivo that MIIB is required for generation of blood, while MIIA is 
required for long-term HSC/P engraftment. Reversible pharmacological inhibition of 
either MIIA or MIIB with blebbistatin in vitro enriches for long-term hematopoietic 
multilineage reconstituting cells by at least 5-fold as assessed in vivo. Additionally, 
megakaryocytes become more polyploid and produce 4-fold more platelets. These results 
implicate MII as a multifunctional node in polarized division and niche sensing.  We 
conclude by taking a larger scale look at the relationship between stress and bulk tissue 
stiffness, which reveals that matrix stiffness directly feeds back to adjust lamin-A at the 
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protein level. Particularly, in the context of high stiffness/stress, lamin-A levels increase 
to stabilize the nucleus.  
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2.I PREFACE 
 
The author of this thesis contributed towards the following specific experiments and 
figures (organized by publication):  
 
Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular 
projections typical of platelet-producing megakaryocytes. Shin JW, Spinler KR, Discher 
DE, et al. PNAS. 108:11458-11463. (2011) 
• All micropipette aspiration studies leading to generation of Figure 2.1 and 
accompanying text 
 
Lamins regulate cell trafficking and lineage maturation of adult human hematopoietic 
cells. Shin JW, Spinler KR, Discher DE, et al., PNAS. 110:18892-18897. (2013) 
• All micropipette studies in Figure 2.2 
• Lamin-A and –B transfections and transductions for Figure 2.2 and 2.3 
• Culture of HSCs, colony forming assays, and flow cytometry for Figure 2.3 
• Micropipette aspiration and lamin-B transduction for Figure 2.S1 
• Transfection and transduction of lamin-A and –B, flow cytometry and colony 
forming assay for Figure 2.S2 
 
Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells. 
Shin JW, Spinler KR, Discher DE, et al., Cell Stem Cell. 14:81-93. (2014) 
• MIIB transduction, colony forming assays, and flow cytometery for Figure 2.4 
• Micropipette aspiration for Figure 2.5 
• Cell culture, MIIB transduction, animal husbandry, blood sampling, and flow 
cytometry of bone marrow and peripheral blood for Figure 2.6A, B 
• Tamoxifen administration, animal husbandry, blood sampling, and flow 
cytometry of bone marrow and peripheral blood for Figure 2.6D-G 
• Xentransplants, bone marrow harvest and flow cytometry for Figure 2.7B 
• MIIA transduction for Figure 2.S3 
• Flow cytometry and colony forming assay for Figure 2.S4 
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Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. 
Swift J, Spinler KR, Discher DE, et al., Science. 341:124014. (2013) 
• Micropipette aspiration of tumor tissue for Figure 2.8C 
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2.1 INTRODUCTION 
 In theory, mechanical properties of a given tissue should relate to the physical 
stress exerted on said tissue. The dissipative capacity of soft brain and fat may explain 
why these tissues are soft compared to the rigidness characteristic of adult bone necessary 
to endure ambulatory stresses. This stress and tissue feedback has been proposed to be a 
“mechanostat” (Frost, 1987). More granularly, cells are deformed by physical stress 
(Vogel and Sheetz, 2006) that can alter gene expression (Chen et al., 2001), yet until 
recently it was unknown whether any specific proteins are capable of matching stiffness 
with stress and determining differentiation (Swift et al., 2013). Animal cells cultured on 
gels or elastomeric substrates have shown to effect differentiation (Engler et al., 2006) 
and cell shape and motility (Pelham and Wang, 1997). Gels designed to match the 
stiffness of brain or fat maximize neurogenesis or adipogenesis, respectively (Dupont et 
al., 2011; Georges et al., 2006; Ulrich et al., 2009). Further, stiffer gels favor myogenesis 
(Engler et al., 2004, 2008; Gilbert et al., 2010) and hard gels give rise to osteogenesis 
(Engler et al., 2006; Huebsch et al., 2010; Kong et al., 2005). Collagen and cytoskeletal 
proteins contribute to sustain forces imparted on cells and within cells proportionally to 
the surrounding tissue microelasticity (Discher et al., 2005; Engler et al., 2006). These 
forces propagate into the nucleus where they are resisted by the nuclear lamina. Nuclear 
stiffness (Lammerding et al., 2006; Pajerowski et al., 2007) and stability (De Vos et al., 
2011) is maintained in part by intermediate filaments known as lamins. In addition to 
conferring mechanical strength to the nucleus, lamins may also modulate transcription 
(Shimi et al., 2008) and thus may mechanoregulate the genome (Shivashankar, 2011; 
Wang et al., 2009).  
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 In addition to providing a link between bulk tissue stiffness and stress, lamins 
may also provide an integral role in hematopoiesis. Hematopoietic cells must traverse the 
marrow, squeeze through small sinusoids, and enter the blood (Sabin, 1928). Therefore, 
cell deformability seems to be a potential regulator of both retention and egress of HSC 
from the marrow niche. Indeed, human polymorphonuclear neutrophils (PMNs) were 
shown decades ago to become more deformable upon differentiation in the marrow 
(Lichtman, 1970), with mature PMNs more capable of entering and exiting small 
capillaries (Lichtman et al., 1989). Leukemic cells are more rigid than normal, potentially 
explaining the interrupted blood flow and marrow hypercellularity in disease (Lam et al., 
2007). Normal hematopoiesis has a well-characterized hierarchy, but it is unclear whether 
deformability factors into the program (Lichtman et al., 1989). Importantly, because of 
the high nucleus-to-cytoplasm ratio of hematopoietic cells, key processes such as sorting 
between marrow and blood could be based in part on nuclear deformability. 
Lamins are intermediate filament proteins that assemble into “lamina” networks at 
the interface between chromatin and the inner nuclear membrane (Dechat et al., 2010), 
conferring stiffness to the nucleus (Pajerowski et al., 2007). In addition, the lamina is 
often proximal to heterochromatin, and, at least with embryonic stem cells, some genes 
alter their interactions with the lamina during cell-fate determination (Peric-Hupkes et al., 
2010). Nearly all mammalian cells express A-type and B-type lamins. Early work 
reported conflicting results of either decreased levels (Gerner and Sauermann, 1999; 
Olins et al., 2008; Röber et al., 1990) or increased levels (Guilly et al., 1990) of both 
lamin types even within the same cell type. One dramatic mutation in human LMNA 
leads to the accelerated aging syndrome Progeria (Dechat et al., 2010), in which protein 
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accumulates at the nuclear envelope and stiffens it (Dahl et al., 2006), affecting many 
tissues and increasing platelet numbers by two- fold or more (Merideth et al., 2008). 
Mice with deletion of Lmna survive 6 weeks postnatal (Jahn et al., 2012), despite 
defective lymphocytes (Hale et al., 2010). Mice deficient in lamina-associated 
polypeptide 2α show hyperproliferation of erythroid progenitors and impaired 
differentiation (Naetar et al., 2008). Mutations of B-type lamins are less common but 
have been shown to result in defective chemotaxis, and elevated lamin-A (Zwerger et al., 
2008). Direct roles for lamins in normal human hematopoiesis, trafficking, and rheology 
have remained elusive until our recent work (Shin et al., 2013). High nuclear flexibility 
coordinate with low lamin levels may facilitate migration of nucleated cells through 
constraining pores. Conversely, egress of enucleated reticulocytes may be the result of 
non-permissive nuclear trafficking due to nuclear stiffening following nuclear 
condensation of erythroid progenitors. Megakaryocyte maturation results in 
polyploidization resulting in large nuclei unable to pass through pores effectively 
anchoring the MK. Anchorage is thought to allow extension of membrane projections 
into the blood where they are fragmented by blood shear stresses which ultimately 
produce platelets (Junt et al., 2007). 
 While trafficking of terminally differentiated hematopoietic lineages is necessary 
for their function, stem cells must be able to both self-renew and undergo asymmetric 
division in appropriate microenvironments (Knoblich, 2010). This differential 
segregation of cell fate determinants produces progenitors that expand symmetrically to 
generate tissue. Hematopoietic stem cells (HSCs, as a subset of CD34+ cells) exemplify 
these key properties of stem cells in that they are often quiescent in niches of the bone 
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marrow (BM), but they and/or their daughter cells polarize and divide asymmetrically in 
suitable niches to generate progenitors that further divide and specialize to terminally 
differentiated erythroid, MK, and white cell lineages. Many soluble factors regulating 
HSC maintenance and differentiation have been described (Trumpp et al., 2010), but 
physical aspects of hematopoiesis remain unclear. Myosin-II inhibition has been found to 
play a key role in the actomyosin forces imparting adhesion and matrix sensing in matrix 
modulated expansion of adult HSC/Ps (Holst et al., 2010). MII in the cell cortex is also 
known to drive cytokinesis and asymmetry of stem cell division in C. elegens is 
established by MII (Ou et al., 2010). Differentiation in embryogenesis indeed requires 
active MII (Conti et al., 2004), and while inhibition of MII in adherent embryonic stem 
cells (ESCs) increases survival in culture by preserving intercellular contacts (Chen et al., 
2010), inhibition can also lead to multinucleated cells  (Canman et al., 2003). 
Actomyosin forces stabilize the plasma membrane with an active cortical tension (Merkel 
et al., 2000), but these forces can drive cell rounding in cytokinesis (Sedzinski et al., 
2011) and can be dramatically altered in MSC differentiation (Engler et al., 2006). It has 
long been established that differentiated granulocytes soften to facilitate trafficking 
though the marrow (Lichtman, 1970), but until recently it has been unknown whether 
such processes are accompanied by changes in MII.  
 There are three isoforms of mammalian MII: A (MYH9), B (MYH10), and C 
(MYH14), each of which is regulated transcriptionally and posttranslationally. MIIA is 
found in most tissues (Ma et al., 2010) including blood (Maupin et al., 1994) and is 
essential to embryonic differentiation (Conti et al., 2004). MIIB is more highly polarized 
that MIIA, and can be found at the rear of migrating cells (Raab et al., 2012; Vicente-
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Manzanares et al., 2008). Additionally, MIIB has been shown to be important for MK 
differentiation (Lordier et al., 2012) and erythroid enucleation (Ubukawa et al., 2012), 
but functions in stem cells is generally unknown.  We begin our journey through the 
mechanosensitive properties of hematopoiesis and stress sensing with an investigation of 
HSC stiffness before transitioning into the lamins and the cell nucleus, moving outward 
to the cell cortex to reveal roles for MIIA and MIIB in adult hematopoiesis and finish 
with an investigation of how mechanical properties of the extracellular matrix can impact 
lamin expression.   
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2.2 MATERIALS AND METHODS 
Cell Culture  
Fresh purified bone marrow-derived human CD34+ cells and total mononuclear cells 
were obtained from either the Penn Xenograft Core Facility or AllCells (Emeryville, 
CA). Cells from at least five different donors were used in this study. Purity of the 
samples (>98%) was confirmed by flow cytometry with mono- clonal antibody against 
human CD34. All experiments with primary cells were performed in primary 
hematopoietic media (StemLine-II; Sigma) supplemented with 1x antibiotics and the 
following human recombinant cytokines: stem cell factor (SCF; 100 ng/mL) and Tpo 
(100 ng/mL). In some occasions, the media were also supplemented by fetal bovine 
serum (FBS) [10% (vol/vol)], dexamethasone (Sigma; 1 µM), 17β-estradiol (Sigma; 1 
µM), granulocyte-colony stimulating factor (G-CSF; 10 ng/mL), Epo (1 U/mL), and 
interleukin-3 (IL-3, 10 ng/ mL). All cytokines were purchased from R&D Systems. In 
some cases, after cells were cultured for 4 days, they were treated with different doses of 
cellular contractility inhibitors, including (±)-blebbistatin (EMD Biosciences) for 
indicated durations of up to 3 days. MEG01 and COS-1 cells were cultured in RPMI-
1640 and DMEM, respectively, supplemented with 10% FBS and 1% antibiotics. Cells 
were cultured at 37°C in 5% CO2. 
 
Antibody staining and flow cytometry  
Surface marker analysis for HSC/Ps was done on either a LSR II flow cytometer or 
FACSCalibur (Becton Dickinson). Fresh or cultured CD34+ - derived cells were stained 
in staining media (2% FBS in PBS) at room temperature for 1 hour (hr) with PE or APC-
	   30	  
Cy7 anti-CD34 (581, Invitrogen or Biolegend), PE-Cy7 anti-CD38 (HIT2, eBioscience), 
PECy5.5 anti-CD45RA (MEM-56, Invitrogen), APC anti-CD90 (5E10, BD Bioscience), 
washed and stained with Hoechst 33342 (Invitrogen) at 37°C for 30 minutes to stain 
nuclei, followed by washing with staining media with 7-AAD (Sigma) to exclude dead 
cells. Cells isolated from the bone marrow stained for 1 hr with APC anti-mouse CD47 
(miap301, AbD Serotec), FITC anti-human CD47 (BD Biosciences), and PE anti-human 
CD11b, PE anti-human CD19 (both from BD Biosciences), or PE anti-human 
Glycophorin A (Invitrogen). Platelets and Mks were analyzed by staining with PE anti-
mouse CD41 (eBioscience) and FITC anti-human CD41 (eBioscience) for 20 minutes 
(min), followed by analysis on FACSCalibur on log forward and side scatter scales. 
 
CFSE labeling 
CD34+-derived cells were labeled with CFSE (2.5 µM) in PBS/5% FBS for 3 min in dark 
at room temperature and washed once with PBS/5% FBS and once with HSC expansion 
media. The labeled cells were analyzed every day (d) for 3 days using multi-color flow 
cytometry with HSC/P markers. Given that cell division is unsynchronized, cell numbers 
from different CFSE peaks are normalized by dividing the cell numbers by division 
number to correct for the effect of cell expansion. The mean division number from each 
sample was calculated by fitting normalized CFSE data to the normal distribution curve 
and reporting its mean value. The cell decay rate was calculated as described previously 
(Gett and Hodgkin, 2000): Each peak represents a cohort of cells that entered their first 
division at the same time, and so one can calculate how many cells of each type 
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underwent each division with the decay in cell number versus division number reflecting 
proliferation, differentiation, and cell death. 
 
Electroporation of nucleic acid in cell culture 
Primary CD34+ cell culture and MEG01 cell line were transfected with DNA constructs 
or MIIB siRNA by electroporation (“nucleofection”) using the Nucleofector kits (Lonza) 
as described in the manual. Briefly, cultured cells were washed with PBS and 
resuspended with transfection solution containing 2 µg/mL DNA constructs or 3 µg/mL 
siRNA. They were then transferred into a cuvette and transfected with the Nucleofector 
II. The medium at 37°C was then added to transfected cells. Cells were incubated 
overnight and then the medium was exchanged to fresh on the next day.  
The siRNA sequences used for MIIB and MIIB knockdown are described previously 
(Raab et al., 2012; Shin et al., 2011). 
To silence the expression of lamin-B1, the retrovirus vector constructs containing shRNA 
were obtained from the laboratory of Robert Goldman (Northwestern University, 
Chicago) and prepared as described previously (P1). pSilencer constructs containing 
either scrambled or lamin-B1 shRNA sequences were transfected into HEK-293T cells, 
and virus-containing culture supernatants were collected at 24∼48 h following 
transfection in serum-free hematopoietic media. The culture supernatants containing virus 
were then incubated with CD34+-derived cells for shRNA transduction in the presence of 
5 µg/mL polybrene (Sigma) and incubated for 1 d. Virally transduced cells were selected 
by adding 1 µg/mL puromycin (Invitrogen) for 2 d and incubated in fresh medium for at 
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least 1 d before further analyses. Lamin-A was also down-regulated stably in a similar 
manner as lamin-B1 with human lamin-A shRNA (Sigma).  
For lamin-A promoter assays, we used a GFP construct driven by the human lamin-A 
promoter cloned by Genecopoeia. The promoter was derived from the 1,132-base pair 
upstream region and the first 385-base pair mRNA transcript region. Promoter activity 
was characterized with or without retinoic acid after transient transfection using LF2k 
(Invitrogen) per the manufacturer’s instructions. 
 
Cell sorting 
BM CD34+-derived cells at d 7 were stained with CD41-FITC at room temperature for 1 
hr, followed by with Annexin-V-PE (BD Biosciences) in the Annexin-V staining medium 
for 15min. Cells were then resuspended in 2% FBS/PBS with 7-AAD. Viable HSC/Ps 
and differentiated cells at d 7 culture were separated on the basis of CD34 surface 
expression by cell sorting performed on a FACS VantageTM machine (Becton 
Dickinson). Dead cells stained with 7-AAD and Annexin-V were excluded from sorting. 
Sorted cells were directly processed for microarray analysis. 
 
Colony forming assay 
1000-3000 CD34+-derived cells were seeded into methylcellulose containing media 
(MethoCult H4434, StemCell Technologies) supplemented with SCF, GM-CSF, IL-3, 
Epo. They were cultured for 14 days and colonies were scored at 10x magnification 
based on the published morphological criteria by StemCell Technoloigies. Colony 
forming content was normalized per 10,000 cells seeded. 
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Engraftment of CD34+ cells in NSG mice and limiting dilution analysis 
BM-derived CD34+ cells were cultured in SCF and Tpo (100 ng/ml each) for 4 days and 
treated under control conditions or blebbistatin (20 µM) for 3 days. The cells were 
injected intra-tibially into sublethally irradiated (250 rads) 6-10-week-old NSG mice 
within 24 hours after irradiation. Engraftment was assessed by analysis of blood or bone 
marrow using anti-mouse and anti-human CD47 antibodies using flow cytometry. The 
mice were sacrificed after 16 weeks post-transplantation. For secondary engraftment, 
50% of the bone marrow from femurs and tibias from each mouse was transplanted into 
one sublethally irradiated NSG mouse. 16 weeks after transplantation, blood and bone 
marrow were harvested from the mice and analyzed by flow cytometry. All animal 
experiments were done in accordance with institutional guidelines approved by the 
ethical committee from the University of Pennsylvania. The human repopulation HSC 
frequency was quantified by extreme limiting dilution analysis (ELDA) software (Hu and 
Smyth, 2009). 
 
Lentiviral transduction of CD34+ cells 
For MIIB knockdown experiment, fresh human BM CD34+ cells were transduced with 
lentiviral vector containing MIIB shRNA sequence previously verified (pLKO.1-puro, 
Sigma): 
5’CCGGGCCAACATTGAAACATACCTTCTCGAGAAGGTATGTTTCAATGTTGG
CTTTTTG-3’  
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Transduction was done on plate coated with 100 ng/ml retronectin (Lonza) in the 
presence of 5 µg/mL polybrene (Sigma). After 2 days of transduction, untransduced cells 
were selected by adding 1 µg/mL puromycin for 2 days, followed by transplantation. 
 
Inducible knockout mice, transplantation and engraftment 
Cre;MYH9loxP/loxP mice were produced by the laboratory of Catherine Léon and 
Christian Gachet (Université de Strasbourg) and provided by the laboratory of 
Christopher Hunter (University of Pennsylvania). 8-12 week-old gender-matched mice 
were used. For competitive repopulation, a total of 2 million donor BM cells from 
Cre;MYH9loxP/loxP (CD45.2) and genetically matched WT mice (CD45.1) were mixed 
1:1 and injected retro-orbitally into the lethally irradiated recipient WT mice (B6.SJL, 
CD45.1+). 8 weeks later, 20 mg/mL tamoxifen in sterilized corn oil (both from Sigma) 
was administered into the recipient mice 5 times for one week to induce Myh9 deletion. 
Chimerism was determined by flow cytometry analysis on PB at indicated time points, 
and the mice were sacrificed after 8 weeks of Myh9 deletion to perform BM and SP 
analysis. 
 
Micropipette aspiration  
Capillary tubes of 1.0 mm inner diameter (World Precision Instruments, Sarasota, FL) 
were pulled into micropipettes using a Flaming-Brown Micropipette Puller (Sutter 
Instrument, Novato, CA) and cut further using a deFonbrune-type microforge 
(Vibratome, St. Louis, MO). The average micropipette diameter was around 3 µm. 
Micropipettes were attached to a dual-stage water manometer with reservoirs of 
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adjustable height. Suction was applied by a syringe, and the corresponding pressure was 
measured by pressure transducer (Validyne, Northridge, CA) calibrated by a mercury U-
tube manometer. Images were acquired using a Nikon Eclipse TE300 inverted 
microscope using a 20x or 40x objective and a Cascade CCD camera (Roper Scientific). 
For experiments from Shin, et al., PNAS 2011, cells from BM CD34+ cultures in SCF 
and Tpo between 3 and 8 days were treated with 20 µM Bleb for 30 min-1 hr, followed 
by micropipette analysis. Pressures for different experiments ranged from 0.5 to 20 kPa. 
In some cases, cells were labeled with a very low dose (10 nM) of fluorescent BODIPY-
Taxol (Invitrogen) for 1 hr at 37°C to visualize the initial stage of microtubule 
polymerization during micropipette aspiration. 
For experiments from Shin, et al., PNAS 2013, primary cells or cell lines in suspension 
were subjected to micropipette analysis. Pressures for different experiments ranged from 
0.5 to 15 kPa.  
For experiments from Swift, et al., Science 2013, the average micropipette diameter was 
around 15 µm.  For untreated samples from mice, tissue was immediately aspirated. 
Collagenase treated samples were incubated at 37°C for 10 minutes in the presence of 0.1 
mg/mL collagenase (Sigma) and aspirated in the presence of enzyme. Pressures for 
different experiments ranged from 1 to 20 kPa. For aspiration of nuclei, cells were treated 
with 0.2 µg/mL Latrunculin A (Sigma) for 1 hr at 37°C, detached with trypsin/EDTA, 
centrifuged and resuspended in aspiration buffer of 135 mM NaCl, 5mM KCl, 5 mM 
HEPES, 1.8 mM CaCl2, 2 mM MgCl2, 2% BSA, 1:3000 propidium iodide (Molecular 
Probes). Nuclei were stained with Hoechst 33342 (Molecular Probes). Images were 
capture using a 60x oil objective.  
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For experiments from Shin, et al., Cell Stem Cell 2014, fresh BM CD34+ cells or 
transfected COS-1 cells in suspension were subjected to micropipette analysis. Pressures 
for different experiments ranged from 0.5 to 15 kPa.  
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2.3 RESULTS 
Myosin-II inhibition increases MK membrane fragmentability – (PNAS, 2011) 
To investigate the role of MII in membrane integrity under shear, cells were 
subjected to micropipette aspiration with stepwise decreases in pressure using pipettes 
similar in diameter to human capillaries (∼3 µm). The cell and its membrane shear and 
flow into the micropipette, resembling, in shape, elongated proplatelets. After just 30 min 
of blebbistatin, cells are approximately four-fold more compliant (Fig. 2.1A, right and 
Fig. 2.1B), and 40% of treated cells also rapidly fragment to average sizes similar to 
those of large human platelets (3∼4 µm). Platelets are now known to be generated by 
shearing of proplatelets (Thon et al., 2010), and no fragmentation was observed in 
untreated cells. Projection lengths up to the point of divergent fragmentation vary from 
10∼20 µm, which is similar to in vivo fragmented proplatelet lengths of ∼14 µm (Junt et 
al., 2007). Fragmentation stresses here correspond to effective membrane tensions of ∼1 
mN/m, which is 10-fold lower than cell membrane lysis tensions (Hategan et al., 2003). 
Platelets not only maintain membrane integrity but also exhibit characteristic structures, 
such as cortical, coil-like microtubules (MTs), and so we also aspirated primary MKs and 
MEG01 cells (an MK-like line) after labeling with a very low and cell-viable dose of 
fluorescent-Taxol (10 nM) (Guminski et al., 2001). Even at a 1,000-fold higher dose of 
Taxol, proplatelets are known to extend (Italiano et al., 1999). In slow aspirations here, 
MT-coils could be visualized extending into the projection tips at ∼0.7 µm/min (Fig. 
2.1C) and bundles of MTs appear more likely than individual MTs, all consistent 
previously reported rates and structures (Italiano et al., 1999). Although final structures 
are rate- and force-dependent as transition rates ∼ exp(force) (Hategan et al., 2003), the 
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basic findings here indicate both nonlytic fragmentation under shear and MK 
polyploidization could be promoted in part by MII inhibition, even with microtubule 
polymerization as reported (Italiano et al., 1999).  
 
Lamin A regulates trafficking and lineage maturation – (PNAS 2013) 
Transendothelial migration involves large deformation as nucleated cells pass through 
much smaller pores (Lichtman et al., 1989). Aspiration of a cell into a micropipette 
illustrates the requisite nuclear deformation (e.g., G/M cells, Fig. 2.2A). Our group’s 
previous aspiration experiments on a lung epithelial cell line showed that disruption of 
the cytoskeleton with or without lamin knockdown can reveal the contribution of lamins 
to nuclear properties (Pajerowski et al., 2007). This previous study prompted a similar 
approach here, but with care to use low stresses commensurate with those generated by 
cells during migration (Oakes et al., 2009). With G/M cells, lamin-A knockdown by 
∼50% (Fig. 2.2A) indeed softens the nucleus ∼two-fold (Fig. 2.2A). Further experiments 
using transwell migration showed an increase in trafficking for lamin-A knockdown cells 
at small pore area (Shin et al., 2013).   
 
Lamin Isoform Stoichiometry Predicts Nuclear Rheology – (PNAS 2013) 
Of the many studies of hematopoietic cell deformability (e.g., Lichtman 1970), nuclear 
deformability has not yet been directly characterized and compared across lineages. Our 
group has shown that fresh human CD34+ cells are highly deformable compared with 
solid-tissue cell types (Pajerowski et al., 2007), perhaps indicative of the stem 
cell/progenitor’s ability to traffic between marrow and circulation. The progressive 
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increase in aspirated length of a nucleus at a constant pressure (Fig. 2.2B) gives the 
nuclear compliance and often fits a power law J(t) = a·tb that is typical for polymer 
rheology (Pajerowski et al., 2007). The initial compliance is given by a, whereas b = 1 
indicates a simple fluid that flows and does not recover after release of stress, and b = 0 
indicates a simple elastic solid that will fully recover its shape. Lymphoid and myeloid 
nuclei show high initial compliance (a = 20 kPa−1) (Fig. 2.2B), as predicted from their 
low lamin levels and are roughly similar in this respect to fresh CD34+ cells (Pajerowski 
et al., 2007). T-cell nuclei are also more viscous (b = 0.22) than myeloid nuclei (b = 0.08) 
(Fig. 2.2B), consistent with a previous report that granulocytes do not permanently 
deform as they pass through marrow (Lichtman et al., 1989). In contrast, erythroid (Ery) 
progenitors generally show at least 10-fold lower initial nuclear compliance (Fig. 2.2B). 
Although ProEry (CD44+GPA-) nuclei exhibit viscoelastic behavior similar to that of T-
cell nuclei, late Ery (CD44-GPA+) nuclei are completely stiff and solid, consistent with 
their condensation during terminal differentiation. Megakaryocyte (MK) nuclei also have 
lower initial compliance than myeloid or lymphoid nuclei. Compared with MK 
progenitor (CD34-CD41+) nuclei (with b = 0.47), mature MK (CD41+CD42+) nuclei have 
20-fold higher compliance despite being more solid-like (b = 0.11) (Fig. 2.2B). The large 
size and complex shape of polyploid MK nuclei, rather than compliance itself, are 
therefore likely to limit MK traffickability. Consistent with this, lamin-A:B stoichiometry 
correlates strongly with local nuclear stiffness [reciprocal of compliance, 1/J(t), in Fig. 
3B] measured at different time points (Fig. 2.S1C), which is not the case for A+B 
intensity (Fig. 2.S1D). Given that B-type lamins localize to the lamina during erythroid 
differentiation (Krauss et al., 2005) and that nuclear stiffness increases with lamin A:B 
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(Fig. 2.2C), we hypothesized that down-regulation of B-type lamin(s) would effectively 
stiffen the nucleus during maturation. Typically, one expects that stiffness correlates 
positively with protein abundance, and so the prediction here is highly unusual for 
biopolymer physics. ProEry indeed shows decreased expression of B-type lamins 
compared with fresh CD34+ cells (Fig. 2.S1B), and nuclear stiffness of ProEry is high 
compared with circulating nucleated cells (Fig. 2.2C). To directly address the hypothesis, 
we knocked down lamin-B1, which is expressed at much higher levels than lamin-B2 in 
hematopoietic cells based on mass spectrometry analyses (data not shown). In erythroid 
precursors, partial knockdown of lamin-B1 by RNAi (∼50%) (Fig. 2.S1E) increases 
nuclear stiffness (Fig. 2.2D plot shows decreased compliance). Nuclear stiffening after 
lamin-B1 knock- down was also measured for a U251 glioma cell line in which the 
lamin-B1 isoform is only slightly more abundant and where knockdown-induced 
differentiation is unlikely (Fig. 2.S1F). Lamin- B1 down-regulation in erythroid lineages 
is thus sufficient to promote nuclear stiffening, which is likely to favor marrow retention 
of a cell (Fig. 2.S1A). A preliminary study using pharmacological perturbations of 
erythropoietic pathways suggests the association with nuclear rigidification (Fig. 2.S1G).  
 
Lamins Modulate Differentiation: Erythroid Lineage – (PNAS 2013) 
Recent studies of a few primary cells have shown significant modulation of 
differentiation by lamins. In particular, lamin-A overexpression in marrow-derived MSCs 
increases osteogenesis (Scaffidi and Misteli, 2008) whereas knockdown promotes 
adipogenesis (Naito et al., 2012). However, lamin knockout mice develop all tissue types 
before succumbing at or shortly after birth (Jahn et al., 2012; Kim et al., 2011), and so 
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most or all tissue lineages seem to develop to some extent, which implies lamins function 
as lineage maturation factors. Here, we manipulated lamin levels in those hematopoietic 
lineages with extreme expression, Ery and MK, to assess direct modulation of 
differentiation (Fig. 2.3A). Overexpression of lamin-A by ∼three-fold in CD34+ cells 
(Fig. 2.S2A) is close to the increased level measured during erythropoiesis (Fig. 2.S1B) 
and resulted in a significant shift toward blast forming unit-erythroid (BFU-E) from 
colony forming unit-granulocyte and macrophage (CFU-GM) (Fig. 2.3B), consistent with 
the map (Fig. 2.S1B). The multipotent CFU-granulocyte erythroid macrophage 
megakaryocyte (GEMM) was unaffected (Fig. 2.3B). B-type lamins decrease during 
erythroid development (Krauss et al., 2005; Zermati et al., 2001) (Fig. 2.S1B), and 
knockdown of lamin-B1 by RNAi in early hematopoietic progenitors indeed favors BFU-
E (Fig. 2.3C). In addition, lamin-B1 RNAi decreases CFU-GEMM in contrast to lamin-A 
overexpression, revealing lamin-B1 as more influential to the maintenance of multipotent 
progenitors. The results thus show that lamins regulate lineage specification induced by 
soluble factors. 
 
Lamins Modulate Differentiation: MK Lineage – (PNAS 2013) 
MKs normally show an increase in total lamin levels (Fig. 2.S1B), but also an increase in 
A:B ratio. Overexpression of lamin-A indeed increases the number of both early and late 
MK progenitors cultured from BM CD34+ cells based on surface markers (Fig. 2.3D). 
Furthermore, although lamin-B1 knockdown suppresses polyploid and 4n populations 
(Fig. 2.3E), overexpression of lamin-A enhances polyploidy (Fig. 2.S2B). Because 
Progeria patients reportedly have twofold more platelets in circulation (Merideth et al., 
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2008), we also tested the impact of the progerin mutant (Δ50) on MK polyploidy. 
Overexpression of progerin, which tends to drive lamin accumulation at the envelope 
(Dahl et al., 2006), does not greatly enhance the number of 8n MKs, but both wild-type 
and mutant overexpression increase high ploidy (≥16n) MKs (Fig. 2.S2B). The finding 
here that overexpression of both wild-type and progerin lamin-A gave the same 
phenotype is consistent with similar findings of increased osteogenesis in MSCs (Scaffidi 
and Misteli, 2008), suggesting a common mechanism of increased lamina assembly. 
Phosphorylation of lamin-A promotes disassembly and is high during cell division 
(Labbaye et al., 1994), and so we hypothesized that an S22A mutant that cannot be 
phosphorylated would limit nuclear division and again facilitate polyploidization. 
Overexpression of this mutant indeed shows a greater gain in 8n MKs than WT (Fig. 
2.S2B). Overall, the MK results suggest that, whereas lamina regulatory mechanisms 
might play a role during the formation of early polyploid MKs, the accumulation of 
lamin-A content per se appears sufficient to drive the formation of late polyploidy MKs 
through unknown mechanisms.  
 
Lamin-A Modulates Lineage Decisions – (PNAS 2013) 
Lamin-A knockdown with shRNA (∼75% efficiency) (Fig. 2.S2C) was performed to 
assess fate choices in the presence of a cytokine mixture that promotes multiple lineages 
(myeloid, erythroid, and MK). In such cultures, knockdown increases the total number of 
CFU-GM (Fig. 2.3F, Left) but decreases CFU-E and differentiated erythroid lineages 
without affecting BFU-E or the other differentiated lineages (Fig. 2.3F, Right). Together 
with the restriction of BFU-E by lamin-B1 (Fig. 2.3C), the results confirm predictions 
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from the lamin map (Fig. 2.S1B) that lamin-A and B1 play opposite roles in erythroid 
differentiation. 
 
Asymmetric Division Is Biophysically Regulated by MIIB – (CSC 2014) 
Large cortical tensions are generated in cells as they round up and divide during 
asymmetric division (Sedzinski et al., 2011). Because MYH10 correlates with a half-
dozen genes involved in asymmetric division of hematopoietic cells (Ting et al., 2012), 
confocal imaging and partial knockdown (Fig. 2.4Ai) were used to assess MIIB in 
asymmetric division of CD34+ cells (Fig. 2.4Aii), which occurs in ~30% of cells 
(consistent with Lordier et al., 2012). MIIB enriches toward the CD34hi daughter cell, 
concentrating near the cleavage furrow by ~3-fold (Fig. 2.4B), whereas CD34 appears 
segregated between cells but otherwise locally homogenous, consistent with lateral 
mobility of this membrane protein. The results suggest that high cortical tensions in the 
cleavage furrow have a similar effect on receptor-independent localization of MIIB as 
that of local stressing by a micropipette. 	   Partial knockdown of MIIB abolishes the 
asymmetry and also the segregation of CD34 (Figure 2.4B, bottom). Whereas asymmetric 
division of CD34+ cells results in 6-fold higher MIIB in the CD34+ daughter than in the 
CD34- daughter, knockdown decreases the MIIB level in CD34+ to that in CD34- and 
suppresses asymmetric division (Figure 2.4C). Prolonged cultures of MIIB knockdown 
cells increase the relative number of CD34+ progenitors with more CFU-GM (Figure 
2.4D), consistent with MIIB regulating asymmetric division when late CD34+ progenitor 
cells transition to CD34- cells and when CD34 molecularly segregates between daughter 
cells. Tracking of division using carboxyfluorescein diacetate succinimidyl ester (CFSE) 
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(Hawkins et al., 2007) shows that partial knockdown of MIIB increases the number of 
CD34+CD38- cells by 2-fold (Figure 2.4Ei) or for CD34+CD38+ cells by 1.5-fold (Figure 
2.4Eii), whereas CD34- numbers remain unaltered (Figure 2.4Eiii). On the other hand, 
partial MIIA knockdown (~30%) did not alter numbers of any subpopulations (Figure 
2.S3B). The data reveal MIIB as a major factor in asymmetric division and differentiation 
of CD34+ cells to CD34- cells.  
 
MIIA Dephosphorylates in Differentiation to a Mechanically Active State – (CSC 
2014) 
MIIA is often the dominant MII isoform and can influence MIIB (Raab et al., 2012), 
which implies that phosphoregulation of MIIA can in principle influence hematopoiesis 
(Figure 2.5A). We therefore examined regulation by niche factors of pS1943 in CD34+ 
cells and found the highest levels of pS1943 in uncultured CD34+ cells (Figure 2.5Bi; 
Figure 2.S13A), with levels systematically decreased upon differentiation with Tpo and 
Granulocyte-Colony Stimulating Factor (G-CSF), but not Stem Cell Factor (SCF) alone 
(Figure 2.5Bii). Transforming Growth Factor-β (TGF-β) promotes HSC hibernation 
(Yamazaki et al., 2011) and blocks the decrease in pS1943 with cytokines (Figure 2.5B). 
Remarkably, blebbistatin mimics TGF-β (Figure 2.5B). In contrast, very low pS1943 in 
myeloid CD33+ cells (Figure 2.S3A) and in the human monocytic cell line (THP-1) are 
consistent with rapid proliferation of THP-1 in suspension (which can be blocked by 
blebbistatin). Both CD34+ and CD34- cell numbers anti- correlate with the level of 
pS1943, and the half-maximal effect was observed at ~35% pS1943-MIIA (Figure 2.5B). 
MIIA is thus modulated by cytokines critical to pre-circulation differentiation.  
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 Fresh CD34+CD38- cells are softer than CD34+CD38+ (Figure 2.5Ci), and 
consistent with the high pS1943-MIIA in CD34+ cells. Cells transfected with a site-
specific MIIA phosphomimetic mutant (S1943D) fragment more often (from a weak 
cortex) and also divide more slowly compared to wild-type controls (Figures 2.5Cii and 
2.5Ciii). These functional results all indicate that high pS1943-MIIA impacts cell 
mechanics and limits cell division, and hence, differentiation.  
 
In Vivo Roles in HSC/Ps: MIIB Contributes to Differentiation, whereas MIIA 
Confers Survival – (CSC 2014) 
Based on our in vitro results, a major knockdown of MIIB in human cells grafted 
into BM should repress asymmetric division and lead to (1) an accumulation of human 
cells in marrow and (2) a suppression of circulating human blood cells. To test this 
hypothesis, fresh human CD34+ BM cells were transduced with shRNA-carrying 
lentivirus to knock down MIIB, which was followed by puromycin selection of 
transduced cells. Cells were injected directly into bone of NOD/SCID/IL-2Rγ-/- (NSG) 
mice to study BM retention both at 16 hr and at 20 weeks (Figure 2.6Ai); this same 
duration has been described by others (Notta et al., 2011) as providing ‘‘a stringent test of 
long-term repopulation’’ of human xenografts injected into the femurs of NSG mice for 
which ‘‘HSCs were operationally defined by lymphomyeloid engraftment that persisted 
for at least 20 weeks after transplant.’’ Standards for mouse HSCs differ from those of 
human (Doulatov et al., 2012), but 12–16 weeks is currently considered as ‘‘long-term 
engraftment’’ (Oguro et al., 2013). We injected directly into marrow rather than into 
blood to avoid any potential effect of knockdown on trafficking from blood to marrow. 
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Human cells in mice were identified by dual immunostaining for hCD45 and hCD47 
(Figure 2.S4A), since human RBC and platelets do not express hCD45 while hCD47 
confers immunocompatability to all human cells within NSG mice (Rodriguez et al., 
2013; Takenaka et al., 2007). Partial permanent MIIB knockdown (by ~40%) (Figure 
2.6Aii) leads to 3-fold greater retention of cells in marrow when they are assayed just 16 
hr after marrow injection (Figure 2.6Bi); this could reflect the fact that knockdown 
impairs migration through constraining micropores by 20% (p < 0.05; data not shown). 
Despite this initial retention advantage, the percentage of human PB cells in circulation at 
6 weeks after transplantation is 7-fold lower for the MIIB knockdown cells (Figure 
2.6Bii), and the difference is maintained after 20 weeks (Figures 2.6Ci and 2.6Cii). 
Sustained engraftment is evident in control mice with significant human cell numbers in 
marrow and four of five mice showing human cells in PB. In contrast, MIIB knockdown 
cells were 6-fold more abundant in marrow, but only one of five mice had human cells in 
circulation. MIIB is thus required to generate PB cells. Because MIIA is the dominant 
isoform in hematopoietic cells and is phosphoregulated distinctly in marrow cells versus 
PB cells, we characterized MIIA contributions to hematopoiesis by performing 
competitive transplants of BM from tamoxifen-inducible cre-Myh9 knockout mice. These 
conditional knockout cells (with surface marker CD45.2) were mixed 1:1 with cells from 
wild-type mice (CD45.1) and injected into sublethally irradiated recipient mice (CD45.1) 
(Figure 2.6Di). This knockout strategy with mouse cells instead of human cells proved 
necessary for understanding MIIA because our in vitro results for proliferation indicated 
no effect with partial knockdown of MIIA in contrast to major defects with MIIB partial 
knockdown (Figure 2.4A). At 8 weeks after transplantation of the mixed cells, the total 
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percentage of donor and competitor blood cells was ~50% each, and upon tamoxifen 
treatment, MIIA decreased as expected only in CD45.2 donor cells (Figure 2.6Dii). In 
PB, donor myeloid cells decreased rapidly compared to lymphoid cells (t1/2 = ~30–40 hr 
versus ~20–25 days) (Figure 2.6E), but these half-lives are within 2-fold of those 
reported for both myeloid (Basu et al., 2002; van Furth and Cohn, 1968) and lymphoid 
(Fulcher and Basten, 1997; Sprent and Basten, 1973) lineages in mouse blood. MIIA loss 
therefore does not greatly affect viability of terminally differentiated lymphoid cells, 
while blood cell production from progenitors is clearly suppressed. Consistent with this, 
we find in BM that Lin-Sca-1+c-Kit+ (LSK) CD150+ cells (which include progenitors or 
HSC/Ps; (Kiel et al., 2005)) are reduced 10-fold at just 8 weeks after Myh9 deletion (16 
weeks since transplant), with similar results for LSK in spleen and LS in blood (Figures 
2.6Fi, 2.6Fii, and 2.6Fiii, respectively). MIIA is thus required for sustained engraftment 
in vivo and hematopoiesis. An early apoptotic fraction (Annexin-V+ and 7-AAD-) of the 
LSK population also increased just 3 days after Myh9 deletion (Figure 2.6G), although 
the total LSK number remained unchanged at this time point (Figure 2.6F). Irreversible 
loss of MIIA therefore suppresses differentiated cell numbers in the long term as 
defective HSC/Ps progressively apoptose. 
 
Transient Inhibition of MII with Blebbistatin Spares Only Long-Term Multilineage 
Reconstituting Cells – (CSC 2014) 
Blebbistatin is a reversible inhibitor of all MII isoforms, and dose-response 
studies of CD34+ cultures show that it has a surprising but understandable effect: the 
diploid ‘‘HSC-enriched’’ population (as phenotypically defined per Majeti et al., 2007 
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and Novershtern et al., 2011) proves relatively stable to a 3-day treatment, which is long 
relative to the cell cycle, while the blebbistatin-treated multi-potent progenitors (MPP) 
and common potent progenitors (CPP) are depleted by 1.8-fold (±0.5) and 31-fold (±16), 
respectively. By suppressing only the progenitors and sparing the HSC-enriched 
population, the net effect is an enrichment of the latter among total CD34+ cells by up to 
16-fold (Figure 2.7Ai). Whole-genome transcript profiles indeed show that blebbistatin 
cultures correlate well with fresh HSC-enriched cells and MPP, but not CPP (data not 
shown), whereas control CD34+ cultures correlate with fresh CPPs. blebbistatin treatment 
beyond 3 days showed a progressive decrease in the HSC-enriched population, consistent 
with the conditional knockout studies above that suggest that MIIA is essential for 
hematopoiesis in vivo (Figures 2.6D–F). Functional tests of HSC enrichment by 
blebbistatin were conducted after washing out the drug and involved measuring the 
frequency of human cells in NSG mice after limiting dilution serial transplantations into 
multiple primary and secondary recipients (Figure 2.7B). A total duration of 32 weeks in 
primary plus secondary xenografts was chosen as sufficient to assess long-term 
multilineage engraftment of human HSCs in NSG mice (Notta et al., 2011). Our blood 
analyses 16 weeks after primary transplantation showed that positive engraftment 
required fewer CD34+ cells (~1 in 10,000) from blebbistatin-treated cultures compared to 
control cultures (Figure 2.7Bi; Figure 2.S4B). If long-term multilineage engraftment were 
due solely to progenitors (such as MPPs), then the fact that blebbistatin-treated cultures 
have relatively fewer progenitors (Figure 2.7A) would have required that more (not 
fewer) blebbistatin-treated CD34+ cells be injected for reconstitution. Both treated and 
control cultures also showed a similar percentage of human CD34+CD38- and 
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CD34+CD38+ populations in BM after transplantation (Figure 2.S4C), indicative of 
engraftment, and blebbistatin results also compare well to uncultured CD34+ cells in 
previous studies (Nishino et al., 2011). Sustained secondary engraftment provides an 
assay for cells with appropriate stem cell properties (Doulatov et al., 2012; Notta et al., 
2011; Oguro et al., 2013) and our secondary transplantation results show that blebbistatin 
maintains a higher fraction of the HSC-enriched population compared to untreated 
cultures (~5-fold once again). Both treated and control human CD34+ transplants 
produced a similar percentage of multilineage myeloid and lymphoid cells (Figure 
2.7Biii). MKs are unique among blood cells in being naturally polyploid and become 
more so in vitro with blebbistatin treatment, which also increases in vitro proplatelet 
formation (Shin et al., 2011). blebbistatin indeed enriches for mature polyploid MKs in 
culture by 10 fold (Figure 2.7Ci). For other lineages, the sensitivity of individual 
progenitor lineages to blebbistatin proves cytokine dependent (Figure 2.6A; Figure 
2.S4D). For SCF and Tpo CD34+-derived cells, the IC50 for CFU-GM is lower than that 
of BFU-E, with blebbistatin producing up to a 2-fold higher ratio of BFU-E to CFU-GM 
(Figure 2.7Cii). Erythroid lineages are thus preserved under non-Epo and submaximal 
MII inhibition. In contrast, when cells are cultured with Epo, both CFU-E and BFU-E 
numbers are reduced (Figure 2.7Ciii). Functional studies thus reveal that short-term 
reversible MII inhibition in combination with specific cytokines enriches for HSCs, 
mature MKs, and even erythroid progenitors.  
 
Matrix Determines Tissue Stiffness and Lamin-A Adjusts In Vivo – (Science 2013) 
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To address the relative affect of extracellular matrix and lamins on tissue stiffness, 
human-derived U251 glioblastoma tumors were grown in the brain and in subcutaneous 
flank sites of nude mice (Fig. 2.8A). In standard culture, these cells had a low A:B ratio 
similar to normal mouse brain (Fig. 2.8D). However, flank tumors of U251s had more 
matrix and were much stiffer than brain tumors, with scaling of collagen density versus 
matrix elasticity, E, appearing typical of normal adult tissue (Fig. 2.8B). Flank tumors of 
human-derived A549 lung cells (A:B ≈ 2.3) had similar E as U251 tumors and were only 
slightly stiffer than normal subcutaneous tissue, revealing a response independent of 
initial lamin levels (Fig. 2.8C). Collagenase treatment of fresh tumors reduced E by > 
50% in just 10 min, suggesting that collagen is a key determinant of tissue stiffness, 
unlike lamin-A. Consistent with this interpretation, human matrix or matrix-associated 
proteins were among the few proteins more than twofold higher in the flank compared 
with the soft brain site. Moreover, human lamin-A levels proved higher in flank versus 
brain sites (data not shown), whereas lamin-B1 and lamin-B2 were only slightly higher in 
brain. U251 cells thus adjust their lamin-A:B ratio by 1.5-fold, which fits remarkably 
well to the stiffness-dependent scaling of lamin-A:B found in normal tissues (Fig. 2.8E). 
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Figure 2.1 Myosin-II inhibition softens MK cortex and facilitates fragmentation – 
(PNAS 2011) 
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Fig. S2. (A) Complete micropipette aspiration data from: untreated (n = 14), 20 μM blebbistatin unfragmented (n = 10) and fragmented (n = 6) cells. Slopes
indicate compliance in units of (mN/m)!1. Untreated cells have median slope of 0.46 ± 0.05, and cells treated at 20 μM and unfragmented have a slope of 3.79 ±
0.84 (P < 0.0001). Median fragmentation threshold is "1 mN/m. (B) Primary MKs and MEG01 cells show cortical microtubule coil-like structures in micropipette
aspiration. Cells were labeled with a very low and cell-viable dose of fluorescent BODIPY-Taxol (10 nM), which binds specifically to microtubules and not to
soluble tubulin. Micropipette aspiration was followed by fluorescence imaging. Representative images are from at least five measurements per cell type. The
initial microtubule extension rate measured by lengths of the fluorescent signal over time under aspiration (<10 kPa) is "0.7 μm/min, consistent with previously
reported values. (Scale bars, 10 μm.)
Shin et al. www.pnas.org/cgi/content/short/1017474108 5 of 13
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Figure 2.1 Myosin-II inhibition softens MK cortex and facilitates fragmentation – 
(PNAS 2011) 
(A, left) Modeling MK maturation and platelet fragmentation in vitro by MII inhibition 
and micropipette aspiration on CD34+-derived cultures. (A, middle) Myosin inhibition 
increases membrane extension and fragmentation in micropipette aspiration. 
Representative fragmentation within seconds after 30 min of 20 µM blebbistatin 
treatment and aspiration ΔP = 1.4 kPa. (A, right) Aspiration length vs. effective cortical 
tension with median results shown. (B) Micropipette aspiration data from: untreated (n = 
14), 20 µM blebbistatin unfragmented (n = 10) and fragmented (n = 6) cells. Slopes 
indicate compliance in units of (mN/m)−1. Untreated cells have median slope of 0.46 ± 
0.05, and cells treated at 20 µM and unfragmented have a slope of 3.79 ± 0.84 (P < 
0.0001). Median fragmentation threshold is ∼1 mN/m. (C) Primary MKs and MEG01 
cells show cortical microtubule coil-like structures in micropipette aspiration. Cells were 
labeled with a very low and cell-viable dose of fluorescent BODIPY-Taxol (10 nM), 
which binds specifically to microtubules and not to soluble tubulin. Micropipette 
aspiration was followed by fluorescence imaging. Representative images are from at least 
five measurements per cell type. The initial microtubule extension rate measured by 
lengths of the fluorescent signal over time under aspiration (<10 kPa) is ∼0.7 µm/min, 
consistent with previously reported values. (Scale bars, 10 µm.)  
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Figure 2.2 Lamin ratios predict nuclear stiffness in hematopoietic lineages  – (PNAS 
2013) 
   
Fig. S3. 3D migration of hematopoietic lineages. (A) siRNA knockdown down-regulates lamin-A uniformly. Representative flow cytometry plot is shown. (B)
Data from migration assays were fitted as in Fig. 2B, where A = 100 and (B, Xc, m): (T cell: 0.03, 1.44, 5.51), (B cell: 0.01, 6.64, 0.95), (CD33+ hi, monocyte: 0.009,
5.00, 1.00), (CD33+ mid, granulocyte, 0.005, 5.00, 0.79). (C) Correlation analysis between half-maximal pore area (μm2) of migration (A1/2) and lamin A:B ratios,
where A1/2 = Xc + 1/B. See also Fig. 2B. The data were fitted with a power law, Y= 77.03X0.59, R2 = 0.6 for all data. (D, Left) Correlation analysis between A1/2
and lamin total intensity. (Right) Correlation analysis between migration sensitivity, Y = Δ (% Migrated)/Δ (Pore Area) between 3- and 5-μm pores, and lamin
total intensity. For all graphs, mean ± SEM of n = 3.
Shin et al. www.pnas.org/cgi/content/short/1304996110 5 of 11
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Figure 2.2 Lamin ratios predict nuclear stiffness in hematopoietic lineages – (PNAS 
2013) 
(A) Lamin-A confers nuclear stiffness, based on aspiration of G/M cells with or without 
knockdown with lamin-A siRNA (siLMNA). (Left) Quantitation of aspirated nuclear 
length (n = 3 donors, *P < 0.05). (Right) Representative image is for ΔP < 1 kPa at 60 s. 
(B) Nuclear compliance change versus time at constant pressure ΔP = 0.3–6 kPa. (Upper) 
A power law fit, J(t) (kPa−1) = a·tb (t = sec) for each blood cell type, where (b = 1 for 
fluids), (b = 0 for solids). (Lower) Values for (a, b) in each cell type are as follows: (T 
cell: 15.2, 0.2), (CD33+: 16.4, 0.1), (MkP ≥ 30s: 0.16, 0.5), (MK: 3.4, 0.1), (ProEry: 1.1, 
0.2), (LateEry: 0.3, 0). (C) High lamin-A:B correlates with stiff nuclei. (Upper) Images at 
2 min of nuclear aspiration at ΔP = 1–2 kPa. (Scale bar: 5 µm.) (Lower) Correlation 
between nuclear stiffness (at 2 min) and lamin-A:B fits J (at 2 min) = 0.23*(A:B – 
0.68)0.91 (R2 = 0.96). All results are mean ± SEM of n ≥ 5 for each cell type. (D) Lamin-
B1 knockdown stiffens nuclei in proerythroblasts, with no change in viable cell numbers 
(n = 10, P < 0.05). Nuclear compliance change with ΔP = 1–2 kPa where values for (a, b) 
in each sample are as follows: (scrambled: 12.8, 0.1), (shLMNB1: 9.4, 0.03). (Scale bars: 
5 µm.) 
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Figure 2.3 Lamins regulate erythroid and MK differentiation – (PNAS 2013) 
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Figure 2.3 Lamins regulate erythroid and MK differentiation – (PNAS 2013) 
(A) Scheme for in vitro differentiation. MEP, myeloid and erythroid progenitor; SCF, 
stem cell factor. (B and C) Colony-forming assays in methylcellulose medium show a 
shift to erythroid progenitors after (B) overexpression of GFP-lamin-A (∼40% 
transfection efficiency) or (C) knockdown of lamin-B1 (shLMNB1, ∼50% efficiency) in 
the presence of Epo for 3 d. *P < 0.05, GFP vs. GFP-lamin-A or scrambled vs. 
shLMNB1 (n = 3). (D and E) MK progenitor population enumerated by flow cytometry 
with CD41 and CD42b. (D) MK progenitors increase with lamin-A overexpression. 
CD41+CD42b−, early progenitor; CD41+CD42b+, late progenitor. *P < 0.05, GFP+ vs. 
GFP-lamin-A+ for each progenitor (n = 4). (E) Lamin-B1 knockdown decreases average 
MK ploidy. *P < 0.01, scrambled vs. shLMNB1 (n = 3). (F) Lamin-A is required for 
erythroid differentiation and restricts myeloid progenitor number. Cells were transduced 
with either scrambled or lamin-A shRNA (shLMNA) and cultured in the presence of Epo, 
IL-3 and Tpo. Functional progenitors (CFU-GM, BFU-E, CFU-GEMM) were quantified 
by colony-forming assay (Left) whereas differentiated subpopulations were quantified by 
flow cytometry as per (Hu et al., 2013) (Right), normalized by 104 initial cell number. 
CFU-E, CD34−CD36+IL-3R−; EarlyEry, CD44+GPA+; LateEry, CD44−GPA+; MkP, 
CD41+; Myeloid, CD33+. *P < 0.05, scrambled vs. shLMNA. 
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Figure 2.4 MIIB polarizes in and promotes asymmetric division of CD34+ to 
differentiated cells – (CSC 2014) 
   
Fresh CD34+CD38! are softer than CD34+CD38+ (Figure 4Ci),
and consistent with the high pS1943-MIIA in CD34+ cells, cells
transfected with a site-specific MIIA phosphomimetic mutant
(S1943D) fragment more often (from a weak cortex) and also
divide more slowly compared to wild-type controls (Figures
4Cii and 4Ciii). These functional results all indicate that high
pS1943-MIIA impacts cell mechanics and limits cell division,
and hence, differentiation. Transcriptional profiles reveal pertur-
bation of pathways that regulate MIIA phosphorylation in CD34+
cells by Blebb (Table S4). Matrix mechanics therefore have an
understandable effect on pS1943-MIIA as well (Figure 4Di):
soft FN-coated gels (20 mg/ml) maximize pS1943 in CD34+ cells
treated with cytokines compared to stiff matrix, while CD34!
cells appear unaffected (Figure 4Dii). This response to stiff matrix
is blocked with the phosphomimetic, deactivating S1943D-MIIA
(Figure 4Diii). Increased cell spreading as part of matrix engage-
ment on stiff substrate thus requires MIIB in CD34+ cells (Fig-
ure 2C), whereas differentiated cells use nonphosphorylated
MIIA. At the same FN density as above, the number of CD34+
CD38! is 4-fold higher on soft matrix relative to stiff matrix (but
Blebb eliminates the difference), whereas the number of
CD34+CD38+ remains constant (Figure 4E). CD34+CD38! cells
are thus sensitive to matrix elasticity, with sensitivity modulated
by MII.
In Vivo Roles in HSC/Ps: MIIB Contributes to
Differentiation, whereas MIIA Confers Survival
Based on our in vitro results, a major knockdown of MIIB in hu-
man cells grafted into BM should repress asymmetric division
and lead to (1) an accumulation of human cells in marrow
and (2) a suppression of circulating human blood cells. To test
this hypothesis, fresh human CD34+ BM cells were transduced
with shRNA-carrying lentivirus to knock down MIIB, which
was followed by puromycin selection of transduced cells. Cells
were injected directly into bone of NOD/SCID/IL-2Rg!/! (NSG)
mice to study BM retention both at 16 hr and at 20 weeks
(Figure 5Ai); this same duration has been described by others
(Notta et al., 2011) as providing ‘‘a stringent test of long-term
A
B
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Figure 3. MIIB Polarizes in and Promotes
Asymmetric Division of CD34+ to Differenti-
ated Cells
(A) Partial knockdown of MIIB decreases protein
by "40% in CD34+CD38! and CD34+CD38+. (Ai)
Mean Fluorescence Intensity (MFI) of MIIB protein
was measured by flow cytometry. (Aii) Hypotheti-
cal model for asymmetric segregation of CD34 and
MIIB in division shown for WT versus MIIB
knockdown.
(B) MIIB segregates asymmetrically in dividing
CD34+-derived cells unless MIIB is knocked down
(top). Bar = 5 mm. Intensities of MIIB and CD34
were measured (bottom) along the membrane
contour of dividing cells from ‘‘0’’ through the
cleavage furrow to the antipole, with distance
normalized by total length. A green arrow indicates
the difference in MIIB intensity between periphery
and cleavage furrow.
(C) MIIB membrane intensity bifurcates to CD34hi
and CD34lo daughters in dividing cell pairs (Ci),
unless MIIB is knocked down. Percentage of
asymmetrically dividing CD34+ cells is suppressed
with MIIB siRNA versus control (Cii). Greater than
forty cells per group.
(D) Colony forming assays after 3 days in methyl-
cellulose medium supplemented with cytokines.
(Di) A relationship among different progenitors in
terms of CD34 and MIIB expression. (Dii) CFU-GM
increases with MIIB knockdown.
(E) Absolute CD34+ cell numbers expand after
MIIB knockdown, with normalization to an initial
total of 10,000 cells (left), and CFSE tracking
shows an increase in mean division number per
time (right). Slopes for si-MIIB are as follows:
control, (0.02: 0.015) for CD34+CD38! (Ei)
and CD34+CD38+ (Eii), and (0.02: 0.02) for CD34!
(Eiii). For all graphs, *p < 0.05 between Control
( = Scrambled) versus MIIB siRNA for each data
point, mean ± SEM, and n R 3 donors.
See also Figure S2 and Table S3.
Cell Stem Cell
Myosin-II Regulates Adult Hematopoiesis
Cell Stem Cell 14, 81–93, January 2, 2014 ª2014 Elsevier Inc. 85
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Figure 2.4 MIIB polarizes in and promotes asymmetric division of CD34+ to 
differentiated cells – (CSC 2014) 
(A) Partial knockdown of MIIB decreases protein by ~40% in CD34+CD38- and 
CD34+CD38+. (Ai) Mean Fluorescence Intensity (MFI) of MIIB protein was measured by 
flow cytometry. (Aii) Hypothetical model for asymmetric segregation of CD34 and MIIB 
in division shown for WT versus MIIB knockdown. (B) MIIB segregates asymmetrically 
in dividing CD34+-derived cells unless MIIB is knocked down (top). Bar = 5 mm. 
Intensities of MIIB and CD34 were measured (bottom) along the membrane contour of 
dividing cells from ‘‘0’’ through the cleavage furrow to the antipole, with distance 
normalized by total length. A green arrow indicates the difference in MIIB intensity 
between periphery and cleavage furrow. (C) MIIB membrane intensity bifurcates to 
CD34hi and CD34lo daughters in dividing cell pairs (Ci), unless MIIB is knocked down. 
Percentage of asymmetrically dividing CD34+ cells is suppressed with MIIB siRNA 
versus control (Cii), n>40 cells/group. (D) Colony forming assays after 3 days in methyl- 
cellulose medium supplemented with cytokines. (Di) A relationship among different 
progenitors in terms of CD34 and MIIB expression. (Dii) CFU-GM increases with MIIB 
knockdown. (E) Absolute CD34+ cell numbers expand after MIIB knockdown, with 
normalization to an initial total of 10,000 cells (left), and CFSE tracking shows an 
increase in mean division number per time (right). Slopes for siMIIB are as follows: 
control, (0.02: 0.015) for CD34+CD38- (Ei) and CD34+CD38+ (Eii), and (0.02: 0.02) for 
CD34- (Eiii). For all graphs, *p < 0.05 between Control (= Scrambled) versus MIIB 
siRNA for each data point, mean ± SEM, and n≥3 donors. 
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Figure 2.5 Phosphorylation of MIIA regulates the biophysics of CD34+ 
differentiation – (CSC 2014) 
   
repopulation’’ of human xenografts injected into the femurs of
NSG mice for which ‘‘HSCs were operationally defined by lym-
phomyeloid engraftment that persisted for at least 20 weeks
after transplant.’’ Standards for mouse HSCs differ from those
of human (Doulatov et al., 2012), but 12–16 weeks is currently
considered as ‘‘long-term engraftment’’ (Oguro et al., 2013).
We injected directly into marrow rather than into blood to avoid
any potential effect of knockdown on trafficking from blood to
marrow. Human cells in mice were identified by dual immu-
nostaining for hCD45 and hCD47 (Figure S3A), since human
RBC and platelets do not express hCD45 while hCD47 confers
immunocompatability to all human cells within NSG mice
(Rodriguez et al., 2013; Takenaka et al., 2007). Partial perma-
nent MIIB knockdown (by !40%) (Figure 5Aii) leads to 3-fold
greater retention of cells in marrow when they are assayed
just 16 hr after marrow injection (Figure 5Bi); this could reflect
the fact that knockdown impairs migration through constraining
micropores by 20% (p < 0.05; Figure S2D). Despite this initial
retention advantage, the percentage of human peripheral blood
(PB) cells in circulation at 6 weeks after transplantation is 7-fold
lower for the MIIB knockdown cells (Figure 5Bii), and the differ-
ence is maintained after 20 weeks (Figures 5Ci and 5Cii).
Sustained engraftment is evident in control mice with significant
human cell numbers in marrow and four of five mice showing
human cells in PB. In contrast, MIIB knockdown cells were
6-fold more abundant in marrow, but only one of five mice
had human cells in circulation. MIIB is thus required to generate
PB cells.
Because MIIA is the dominant isoform in hematopoietic cells
and is phosphoregulated distinctly in marrow cells versus PB
cells, we characterized MIIA contributions to hematopoiesis
by performing competitive transplants of BM from tamoxifen-
inducible cre-Myh9 knockout mice. These conditional knockout
cells (with surfacemarker CD45.2) weremixed 1:1with cells from
A
B D
C E
Figure 4. Phosphorylation of MIIA Regu-
lates the Biophysics of CD34+ Differen-
tiation
(A) Dephosphorylation of MIIA at S1943 promotes
assembly and function.
(B) CD34+ differentiation with soluble factors
decreases pS1943. (Bi) Representative images
showing pS1943 expression in fresh CD34+ cells.
Bar = 5 mm. (Bii) pS1943 (normalized to MIIA) was
measured by flow cytometry [n = 3 donors, ± SEM;
fit to Log Y = aX + b (a,b): (CD34+: "0.05, 5.74; in
red), (CD34": "0.10, 6.74; in green)]. Minimum
pS1943 per MIIA was measured for THP-1 cells
(0.07 ± 0.01). All cells were treated with SCF and
indicated cytokines. pS1943% values were
normalized as described in Figure S1D (n = 3, ±
SEM). pS1943 percentage for SCF only = !40%.
(C) MIIA S1943D phosphomimetic decreases
both cortical stiffness and cytoskeletal stability.
Aspiration length L, normalized by pipette radius,
Rp (L/Rp), versus time for various cells with
(slope, intercept, effective viscosity h) were as
follows: (Ci) CD34+CD38" (5.7/min, 8.3, 3.2 Pa/s)
and CD34+CD38+ (2.2/min, 4.7, 8.5 Pa/s); (Cii)
MIIA-WT: (0.02/min, 0.5, 1,400 Pa/s), MIIA-
S1943D (0.70/min, 1.6, 40 Pa/s). n = 5, ±SEM. The
inset bar graph in (Cii) shows the fraction of
transfected COS-1 cells after MIIB knockdown
that undergo cell division (2n and 4n cells) as
calculated by subtracting the fraction of polyploid
cells (n = 3, ±SEM, *p < 0.05). (Ciii) Representative
images of aspiration of transfected COS-1 cells
(bar = 10 mm).
(D) CD34+CD38" cells sense matrix elasticity with
changes in pS1943-MIIA similar to cytokines (Di).
(Dii) Soft matrix maintains high pS1943 in CD34+.
*p < 0.05 (three donors, ±SEM). (Diii) pS1943
limits matrix sensing: cell area was normalized to
DNA to correct for ploidy of COS-1. *p < 0.05 for
GFP-S1943D 34 kPa versus GFP or GFP-MIIA
34 kPa (n R 20, ±SEM).
(E) CD34+ numbers on soft matrix (0.3 kPa)
scaled by stiff matrix (34 kPa) increase with
fibronectin (FN) density unless MII is inhibited.
For CD34+CD38", EC50 !22.4 mg/ml, *p < 0.05
(n R 3, ±SEM).
See also Table S4.
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Figure 2.5 Phosphorylation of MIIA regulates the biophysics of CD34+ 
differentiation – (CSC 2014) 
(A) Dephosphorylation of MIIA at S1943 promotes assembly and function. (B) CD34+ 
differentiation with soluble factors decreases pS1943. (Bi) Representative images 
showing pS1943 expression in fresh CD34+ cells. Bar = 5 mm. (Bii) pS1943 (normalized 
to MIIA) was measured by flow cytometry [n = 3 donors, ± SEM; fit to Log Y = aX + b 
(a,b): (CD34+: -0.05, 5.74; in red), (CD34-: -0.10, 6.74; in green)]. Minimum pS1943 per 
MIIA was measured for THP-1 cells (0.07 ± 0.01). All cells were treated with SCF and 
indicated cytokines. pS1943% values were normalized as described in Figure 2.S3A (n = 
3, ± SEM). pS1943 percentage for SCF only = ~40%. (C) MIIA S1943D 
phosphomimetic decreases both cortical stiffness and cytoskeletal stability. Aspiration 
length L, normalized by pipette radius, Rp (L/Rp), versus time for various cells with 
(slope, intercept, effective viscosity h) were as follows: (Ci) CD34+CD38- (5.7/min, 8.3, 
3.2 Pa/s) and CD34+CD38+ (2.2/min, 4.7, 8.5 Pa/s); (Cii) MIIA-WT: (0.02/min, 0.5, 
1,400 Pa/s), MIIA- S1943D (0.70/min, 1.6, 40 Pa/s). n = 5, ±SEM. The inset bar graph in 
(Cii) shows the fraction of transfected COS-1 cells after MIIB knockdown that undergo 
cell division (2n and 4n cells) as calculated by subtracting the fraction of polyploid cells 
(n = 3, ±SEM, *p < 0.05). (Ciii) Representative images of aspiration of transfected COS-
1 cells (bar = 10 mm, ±SEM).  
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Figure 2.6 MII isoforms regulate hematopoiesis in vivo – (CSC 2014) 
 
  
wild-type mice (CD45.1) and injected into sublethally irradiated
recipient mice (CD45.1) (Figure 5Di). This knockout strategy
with mouse cells instead of human cells proved necessary for
understanding MIIA because our in vitro results for proliferation
indicated no effect with partial knockdown of MIIA in contrast
to major defects with MIIB partial knockdown (Figure 3A). At
8 weeks after transplantation of the mixed cells, the total per-
centage of donor and competitor blood cells was !50% each,
and upon tamoxifen treatment, MIIA decreased as expected
only in CD45.2 donor cells (Figure 5Dii). In PB, donor myeloid
cells decreased rapidly compared to lymphoid cells (t1/2 =
!30–40 hr versus !20–25 days) (Figure 5E), but these half-lives
are within 2-fold of those reported for both myeloid (Basu et al.,
2002; van Furth andCohn, 1968) and lymphoid (Fulcher andBas-
ten, 1997; Sprent and Basten, 1973) lineages in mouse blood.
MIIA loss therefore does not greatly affect viability of terminally
differentiated lymphoid cells, while blood cell production from
progenitors is clearly suppressed. Consistent with this, we find
in BM that Lin" Sca-1+ c-Kit+ (LSK) CD150+ cells (which include
progenitors or HSC/Ps; Kiel et al., 2005) are reduced 10-fold at
just 8 weeks after Myh9 deletion (16 weeks since transplant),
with similar results for LSK in spleen and LS in blood (Figures
5Fi, 5Fii, and 5Fiii, respectively). MIIA is thus required for sus-
tained engraftment in vivo and hematopoiesis. An early
apoptotic fraction (Annexin-V+ and 7-AAD") of the LSK popula-
tion also increased just 3 days after Myh9 deletion (Figure 5G),
although the total LSK number remained unchanged at this
time point (Figure 5F). Irreversible loss of MIIA therefore sup-
presses differentiated cell numbers in the long term as defective
HSC/Ps progressively apoptose.
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Figure 5. MII Isoforms Regulate Hemato-
poiesis In Vivo
(A) Scheme for in vivo experiments to test MIIB
functions (Ai). (Aii) MIIB expression kinetics with
shRNA knockdown relative to control. t1/2 = 81 hr.
n = 5 mice for each group (±SEM for all graphs),
transplanted via an intratibial route with 5 3 103
BM CD34+ cells per sublethally irradiated mouse.
Transplantation occurred 4 days after lentiviral
transduction, with 2 days puromycin selection.
(B) MIIB knockdown increases short-term (16 hr)
retention in bone marrow (BM) (Bi), but decreases
short-term (6 week) generation of peripheral blood
(PB) (Bii). *p < 0.01 control (scrambled) versusMIIB
shRNA.
(C) MIIB knockdown increases long-term
(20 weeks) BM engraftment (Ci), but suppresses
PB generation (Cii). For PB generation, the number
of positively engrafted mice is shown (R0.1% total
nucleated cells).
(D) Scheme for in vivo experiment to test MIIA
functions (Di). BM cells from Cre:Myh9loxP/loxP
(CD45.2) and from WT competitor (CD45.1) were
transplanted at a 1:1 ratio into lethally irradiated
WT recipients. (Dii) Eight weeks after reconstitu-
tion, mice were treated with tamoxifen to delete
Myh9 as assayed by protein expression (*p < 0.01,
control versus tamoxifen, n R 3, ±SEM for all
graphs). Deletion occurred with t1/2 = 9.6 days. nR
8 mice for each group from two independent ex-
periments (±SEM for all graphs).
(E) PB lineages with deleted Myh9 are lost from
circulation with kinetics similar to clearance of WT
cells. The donor (top) and competitor (bottom)-
derived granulocyte (Gran, Gr-1+Mac-1+, larger
side scatter), monocyte (Mono, Gr-1+Mac-1+,
smaller side scatter), T cell (T, CD3+), and B cell (B,
B220+) lineages in PB were quantified at the indi-
cated time points after vehicle (left) or tamoxifen
(right) treatment. Decay half-lives for tamoxifen-
treated donor Gran, Mono, T, and B are 1.3, 1.7,
24.2, and 18.8 days, respectively
(F) Myh9 deletion decreases HSC/P subpopu-
lations across different hematopoietic organs in
the long term (8 weeks), but not in the short term
(3 days). Donor and competitor HSC/P cells were
quantified in BM (LSKCD150+, Fi), spleen (LSK, Fii),
and PB (LS, Fiii) (control versus treated, *p < 0.01).
(G) Myh9 deletion increases apoptosis of LSK.
Treatment was for 3 days (*p < 0.01).
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wild-type mice (CD45.1) and injected into sublethally irradiated
recipient mice (CD45.1) (Figure 5Di). This knockout strategy
with mouse cells instead of human cells proved necessary for
understanding MIIA because our in vitro results for proliferation
indicated no effect with partial knockdown of MIIA in contrast
to major defects with MIIB partial knockdown (Figure 3A). At
8 weeks after transplantation of the mixed cells, the total per-
centage of donor and competitor blood cells was !50% each,
and upon tamoxifen treatment, MIIA decreased as expected
only in CD45.2 donor cells (Figure 5Dii). In PB, donor myeloid
cells decreased rapidly compared to lymphoid cells (t1/2 =
!30–40 hr versus !20–25 days) (Figure 5E), but these half-lives
are within 2-fold of those reported for both myeloid (Basu et al.,
2002; van Furth andCohn, 1968) and lymphoid (Fulcher andBas-
ten, 1997; Sprent and Basten, 1973) lineages in mouse blood.
MIIA loss therefore does not greatly affect viability of terminally
differentiated lymphoid cells, while blood cell production from
progenitors is clearly suppressed. Consistent with this, we find
in BM that Lin" Sca-1+ c-Kit+ (LSK) CD150+ cells (which include
progenitors or HSC/Ps; Kiel et al., 2005) are reduced 10-fold at
just 8 weeks after Myh9 deletion (16 weeks since transplant),
with similar results for LSK in spleen and LS in blood (Figures
5Fi, 5Fii, and 5Fiii, respectively). MIIA is thus required for sus-
tained engraftment in vivo and hematopoiesis. An early
apoptotic fraction (Annexin-V+ and 7-AAD") of the LSK popula-
tion also increased just 3 days after Myh9 deletion (Figure 5G),
although the total LSK number remained unchanged at this
time point (Figure 5F). Irreversible loss of MIIA therefore sup-
presses differentiated cell numbers in the long term as defective
HSC/Ps progressively apoptose.
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Figure 5. MII Isoforms Regulate Hemato-
poiesis In Vivo
(A) Scheme for in vivo experiments to test MIIB
functions (Ai). (Aii) MIIB expression kinetics with
shRNA knockdown relative to control. t1/2 = 81 hr.
n = 5 mice for each group (±SEM for all graphs),
transplanted via an intratibial route with 5 3 103
BM CD34+ cells per sublethally irradiated mouse.
Transplantation occurred 4 days after lentiviral
transduction, with 2 days puromycin selection.
(B) MIIB knockdown increases short-term (16 hr)
retention in bone marrow (BM) (Bi), but decreases
short-term (6 week) generation of peripheral blood
(PB) (Bii). *p < 0.01 control (scrambled) versusMIIB
shRNA.
(C) MIIB knockdown increases long-term
(20 weeks) BM engraftment (Ci), but suppresses
PB generation (Cii). For PB generation, the number
of positively engrafted mice is shown (R0.1% total
nucleated cells).
(D) Scheme for in vivo experiment to test MIIA
functions (Di). BM cells from Cre:Myh9loxP/loxP
(CD45.2) and from WT competitor (CD45.1) were
transplanted at a 1:1 ratio into lethally irradiated
WT recipients. (Dii) Eight weeks after reconstitu-
tion, mice were treated with tamoxifen to delete
Myh9 as assayed by protein expression (*p < 0.01,
control versus tamoxifen, n R 3, ±SEM for all
graphs). Deletion occurred with t1/2 = 9.6 days. nR
8 mice for each group from two independent ex-
periments (±SEM for all graphs).
(E) PB lineages with deleted Myh9 are lost from
circulation with kinetics similar to clearance of WT
cells. The donor (top) and competitor (bottom)-
derived granulocyte (Gran, Gr-1+Mac-1+, larger
side scatter), monocyte (Mono, Gr-1+Mac-1+,
smaller side scatter), T cell (T, CD3+), and B cell (B,
B220+) lineages in PB were quantified at the indi-
cated time points after vehicle (left) or tamoxifen
(right) treatment. Decay half-lives for tamoxifen-
treated donor Gran, Mono, T, and B are 1.3, 1.7,
24.2, and 18.8 days, respectively
(F) Myh9 deletion decreases HSC/P subpopu-
lations across different hematopoietic organs in
the long term (8 weeks), but not in the short term
(3 days). Donor and competitor HSC/P cells were
quantified in BM (LSKCD150+, Fi), spleen (LSK, Fii),
and PB (LS, Fiii) (control versus treated, *p < 0.01).
(G) Myh9 deletion increases apoptosis of LSK.
Treatment was for 3 days (*p < 0.01).
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Figure 2.6 MII isoforms regulate hematopoiesis in vivo – (CSC 2014) 
(A) Scheme for in vivo experiments to test MIIB functions (Ai). (Aii) MIIB expression 
kinetics with shRNA knockdown relative to control. t1/2 = 81 hr. n = 5 mice for each 
group (±SEM for all graphs), transplanted via an intratibial route with 5x103 BM CD34+ 
cells per sublethally irradiated mouse. Transplantation occurred 4 days after lentiviral 
transduction, with 2 days puromycin selection. (B) MIIB knockdown increases 
immediate (16 hr) retention in bone marrow (BM) (Bi), but decreases short-term (6 week) 
generation of PB (Bii). *p < 0.01 control (scrambled) versus MIIB shRNA. (C) MIIB 
knockdown increases long-term (20 weeks) BM engraftment (Ci), but suppresses PB 
generation (Cii). For PB generation, the number of positively engrafted mice is shown 
(≥0.1% total nucleated cells). (D) Scheme for in vivo experiment to test MIIA functions 
(Di). BM cells from Cre:Myh9loxP/loxP (CD45.2) and from WT competitor (CD45.1) 
were transplanted at a 1:1 ratio into lethally irradiated WT recipients. (Dii) Eight weeks 
after reconstitution, mice were treated with tamoxifen to delete Myh9 as assayed by 
protein expression (*p < 0.01, control versus tamoxifen, n≥3, ±SEM for all graphs). 
Deletion occurred with t1/2 = 9.6 days. n≥8 mice for each group from two independent 
experiments (±SEM for all graphs). (E) PB lineages with deleted Myh9 are lost from 
circulation with kinetics similar to clearance of WT cells. The donor (top) and competitor 
(bottom)- derived granulocyte (Gran, Gr-1+Mac-1+, larger side scatter), monocyte (Mono, 
Gr-1+Mac-1+, smaller side scatter), T cell (T, CD3+), and B cell (B, B220+) lineages in 
PB were quantified at the indicated time points after vehicle (left) or tamoxifen (right) 
treatment. Decay half-lives for tamoxifen-treated donor Gran, Mono, T, and B are 1.3, 
1.7, 24.2, and 18.8 days, respectively (F) Myh9 deletion decreases HSC/P subpopulations 
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across different hematopoietic organs in the long term (8 weeks), but not in the short term 
(3 days). Donor and competitor HSC/P cells were quantified in BM (LSK-CD150+, Fi), 
spleen (LSK, Fii), and PB (LS, Fiii) (control versus treated, *p < 0.01). (G) Myh9 
deletion increases apoptosis of LSK. Treatment was for 3 days (*p < 0.01). 
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Figure 2.7 MII inhibition maintains HSC enriched population with long-term 
multilineage reconstitution potential – (CSC 2014) 
   
Transient Inhibition of MII with Blebbistatin Spares
Only Long-Term Multilineage Reconstituting Cells
Blebbistatin is a reversible inhibitor of all MII isoforms, and
dose-response studies of CD34+ cultures show that it has a sur-
prising but understandable effect: the diploid ‘‘HSC-enriched’’
population (as phenotypically defined per Majeti et al., 2007
and Novershtern et al., 2011) proves relatively stable to a 3-
day treatment, which is long relative to the cell cycle, while the
Blebb-treated MPP and CPP are depleted by 1.8-fold (±0.5)
and 31-fold (±16), respectively. By suppressing only the progen-
itors and sparing the HSC-enriched population, the net effect is
an enrichment of the latter among total CD34+ cells by up to 16-
fold (Figure 6Ai). Whole-genome transcript profiles indeed show
that Blebb cultures correlate well with fresh HSC-enriched cells
and MPP, but not CPP (Figure 6Aii, Table S4, and Table S5),
whereas control CD34+ cultures correlate with fresh CPPs.
Blebb treatment beyond 3 days showed a progressive decrease
in the HSC-enriched population, consistent with the conditional
knockout studies above that suggest that MIIA is essential for
hematopoiesis in vivo (Figures 5D–5F).
Functional tests of HSC enrichment by Blebb were conducted
after washing out the drug and involvedmeasuring the frequency
of human cells in NSGmice after limiting dilution serial transplan-
tations into multiple primary and secondary recipients (Fig-
ure 6B). A total duration of 32 weeks in primary plus secondary
xenografts was chosen as sufficient to assess long-term
A
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B Figure 6. MII Inhibition Maintains HSC-
Enriched Population with Long-Term
Multilineage Reconstitution Potential
(A) Scheme for in vitro experiments (top). (Ai)
Representative flow cytometry contour plots for
CD34+ subpopulations, with dose-dependence of
2n cells showing 15.6- ± 4.1-fold enrichment at
20 mM Blebb. Absolute cell numbers were scaled
to 104 initial cells and fit to dose-response curves:
CPP and MPP IC50 = 10.5 mM; HSC-enriched
numbers = 646 ± 77 (nR 5 donors, ±SEM). These
IC50 values are within !2-fold of the inhibition
constant Ki for pure MII (Kovács et al., 2004). (Aii)
Blebb-treated CD34+ cells show a gene ex-
pression profile similar to fresh CD34+CD38" for
hematopoietic genes (Table S4 and Table S5).
Values are derived from two experiments.
(B) Limiting dilution serial transplant analyses
show functional HSCs after myosin inhibition
after 16 weeks (long-term). (Top) Scheme for
in vivo experiments. (Bi) Limiting dilution primary
transplant. The number of transplanted CD34+
cells versus the percentage of unsuccessful
engraftment determines the frequency of re-
populating cells (n = 26 recipients per group from
three independent experiments; p < 0.0005). (Bii)
Secondary transplantation of BM from primary
transplant demonstrates the maintenance of
higher HSC frequency with Blebb compared
to control (n R 13 recipients per group, p < 0.01)
(See Figure S3B). Transplantation with Blebb-
exposed CD34+-derived cells shows similar
multilineage engraftment in the NSG mice
compared to control cells, including myeloid
(CD33+), lymphoid (CD19+) (Biii) (±SEM), and
erythroid (GPA+) (Biv). Bar = 5 mm.
(C) Kinetics of human-CD41+ platelets in circula-
tion were measured after transplantation of
human CD34+-derived cells and normalized by
the initial number of CD41+ cells transplanted.
Areas under curves show significant differences
between drug-treated and control. p < 0.05 in
both phase I and phase II from at least nine re-
cipients in three experiments (±SEM).
(D) Effects of Blebb on progenitors. (Di) Enrichment
of polyploidMKs by Blebb (n = 4). y axis represents
the ratios between polyploid MKs and 2n + 4n MKs. EC50 = 7.5 mM; Hill coefficient = 7.0. (Dii) Enrichment of BFU-E relative to CFU-GM in the absence of Epo,
evaluated by colony forming assays. The maximum ratio was observed at 12.5 mM. IC50 = 10 mM, Hillslope = 5.0 (n = 3, ±SEM). (Diii) Sensitivity of erythroid
progenitors to Blebb in the presence of Epo. BFU-E = CD34+IL-3R+CD36"; CFU-E = CD34"IL-3R"CD36+. Absolute values were normalized to 104 initial cell
input and fit to dose-response curves. IC50, Hill coefficient for CFU-E, 2n: 8.7 mM, "4.4 and 4n: 12.9 mM, "6.3; BFU-E, 2n: 10.9 mM, "9.7, 4n: 13 mM, 28, and
Poly R 8n: 0.2 mM, 2.0. (n = 2, ±SEM).
See also Figure S3, Table S4, and Table S5.
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Blebbistatin is a reversible inhibitor of all MII isoforms, and
dose-response studies of CD34+ cultures show that it has a sur-
prising but understandable effect: the diploid ‘‘HSC-enriched’’
population (as phenotypically defined per Majeti et al., 2007
and Novershtern et al., 2011) proves relatively stable to a 3-
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and MPP, but not CPP (Figure 6Aii, Table S4, and Table S5),
whereas control CD34+ cultures correlate with fresh CPPs.
Blebb treatment beyond 3 days showed a progressive decrease
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knockout studies above that suggest that MIIA is essential for
hematopoiesis in vivo (Figures 5D–5F).
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(A) Scheme for in vitro experiments (top). (Ai)
Representative flow cytometry contour plots for
CD34+ subpopulations, with dose-dependence of
2n cells showing 15.6- ± 4.1-fold enrichment at
20 mM Blebb. Absolute cell numbers were scaled
to 104 initial cells and fit to dose-response curves:
CPP and MPP IC50 = 10.5 mM; HSC-enriched
numbers = 646 ± 77 (nR 5 donors, ±SEM). These
IC50 values are within !2-fold of the inhibition
constant Ki for pure MII (Kovács et al., 2004). (Aii)
Blebb-treated CD34+ cells show a gene ex-
pression profile similar to fresh CD34+CD38" for
hematopoietic genes (Table S4 and Table S5).
Values are derived from two experiments.
(B) Limiting dilution serial transplant analys s
show functional HSCs after myosin inhibition
after 16 weeks (long-term). (Top) Scheme for
in vivo experiments. (Bi) Limiting dilution primary
transplant. The number of transplanted CD34+
cells versus the percentage of unsuccessful
engraftment determines the frequency of re-
populating cells (n = 26 recipients per group fr m
three independent experiments; p < 0.0005). (Bii)
Secondary transplantation of BM from pri ary
transplant demonstrates the maintenance of
higher HSC frequency with Blebb compared
to control (n R 13 recipients per group, p < 0.01)
(See Figure S3B). Transplantation with Blebb-
exposed CD34+-derived cells shows similar
multilineage engraftment in the NSG mice
compared to control cells, including myeloid
(CD33+), lymphoid (CD19+) (Biii) (±SEM), nd
erythroid (GPA+) (Biv). Bar = 5 mm.
(C) Kinetics of human-CD41+ platelets in circula-
tion were measured after transplantation of
human CD34+-derived cells and normalized by
the initial number of CD41+ cells transplanted.
Areas under curves show significant differences
between drug-treated and control. p < 0.05 in
both phase I and phase II from at least nine re-
cipients in three experiments (±SEM).
(D) Effects of Blebb on progenitors. (Di) Enrichment
of polyploidMKs by Blebb (n = 4). y axis represents
the ratios between polyploid MKs and 2n + 4n MKs. EC50 = 7.5 mM; Hill coefficient = 7.0. (Dii) Enrichment of BFU-E relative to CFU-GM in the absence of Epo,
evaluated by colony forming assays. The maximum ratio was observed at 12.5 mM. IC50 = 10 mM, Hillslope = 5.0 (n = 3, ±SEM). (Diii) Sensitivity of erythroid
progenitors to Blebb in the presence of Epo. BFU-E = CD34+IL-3R+CD36"; CFU-E = CD34"IL-3R"CD36+. Absolute values were normalized to 104 initial cell
input and fit to dose-response curves. IC50, Hill coefficient for CFU-E, 2n: 8.7 mM, "4.4 and 4n: 12.9 mM, "6.3; BFU-E, 2n: 10.9 mM, "9.7, 4n: 13 mM, 28, and
Poly R 8n: 0.2 mM, 2.0. (n = 2, ±SEM).
See also Figure S3, Table S4, and Table S5.
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Figure 2.7 MII inhibition maintains HSC enriched population with long-term 
multilineage reconstitution potential – (CSC 2014) 
(A) Scheme for in vitro experiments (top). (Ai) Representative flow cytometry contour 
plots for CD34+ subpopulations, with dose-dependence of 2n cells showing 15.6- ± 4.1-
fold enrichment at 20 mM blebbistatin. Absolute cell numbers were scaled to 104 initial 
cells and fit to dose-response curves: CPP and MPP IC50 = 10.5 mM; HSC-enriched 
numbers = 646 ± 77 (n≥5 donors, ±SEM). These IC50 values are within ~2-fold of the 
inhibition constant Ki for pure MII (Kovacs et al., 2004) (B) Limiting dilution serial 
transplant analyses show functional HSCs after MII inhibition after 16 weeks (long-
term). (Top) Scheme for in vivo experiments. (Bi) Limiting dilution primary transplant. 
The number of transplanted CD34+ cells versus the percentage of unsuccessful 
engraftment determines the frequency of repopulating cells (n = 26 recipients per group 
from three independent experiments; p < 0.0005). (Bii) Secondary transplantation of BM 
from primary transplant demonstrates the maintenance of higher HSC frequency with 
blebbistatin compared to control (n ≥ 13 recipients per group, p < 0.01). Transplantation 
with blebbistatin- exposed CD34+-derived cells shows similar multilineage engraftment 
in the NSG mice compared to control cells, including myeloid CD (CD33+), lymphoid 
(CD19+) (Biii) (±SEM), and erythroid (GPA+) (Biv). Bar = 5 mm. (C) Kinetics of 
human-CD41+ platelets in circulation were measured after transplantation of human 
CD34+-derived cells and normalized by the initial number of CD41+ cells transplanted. 
Areas under curves show significant differences between drug-treated and control. p < 
0.05 in both phase I and phase II from at least nine recipients in three experiments 
(±SEM). (C) Effects of blebbistatin on progenitors. (Ci) Enrichment of polyploidy MKs 
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by blebbistatin (n = 4). y axis represents the ratios between polyploid MKs and 2n + 4n 
MKs. EC50 = 7.5 mM; Hill coefficient = 7.0. (Cii) Enrichment of BFU-E relative to 
CFU-GM in the absence of Epo, evaluated by colony forming assays. The maximum 
ratio was observed at 12.5 mM. IC50 =10 mM, Hillslope = 5.0 (n = 3, ±SEM). (Ciii) 
Sensitivity of erythroid progenitors to blebbistatin in the presence of Epo. BFU-E = 
CD34+IL-3R+CD36-; CFU-E = CD34-IL-3R-CD36+. Absolute values were normalized to 
104 initial cell input and fit to dose-response curves. IC50, Hill coefficient for CFU-E, 2n: 
8.7 mM, -4.4 and 4n: 12.9 mM, -6.3; BFU-E, 2n: 10.9 mM, -9.7, 4n: 13 mM, 28, and 
Poly≥8n: 0.2 mM, 2.0. (n = 2, ±SEM).  
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Figure 2.8 Lamin-A and collagen levels scale with tissue stiffness, but collagen 
determines stiffness while lamin-A responds to tissue stiffness – (Science 2013) 
    
E 
with E and also showed transcripts scaling with
E in both man and mouse (fig. S2). Collagen-1 is
the most abundant protein in animals, and its two
fiber-coassembling isoforms both gave collagen-
1 ~ E 1.5 (Fig. 1G). Gels made with purified
collagen-1 scale as ~ E 0.5 (35), but a different
exponent for tissue seems consistent with addi-
tional matrix or cell components contributing
to tissue mechanics. Indeed, collagen-3, -5, -6, -11,
Fig. 1. Lamin-A and collagen levels scale with tissue stiffness, but col-
lagen determines stiffness while lamin-A responds. (A) Tissue deformation
under force is quantified by E and transfers stresses through the extracellular
matrix and the cytoskeleton into the nucleus. (B and C) The proteomes of
adult mouse tissues were profiled to determine whether scaling of mechan-
ical properties with biopolymer concentration exists across tissues. (D) Quan-
titative proteomics of multiple human and mouse tissues and cells revealed
scaling with E of the absolute ratio or stoichiometry of lamin-A to lamin-B
through MS quantification of a pan-lamin peptide. Differences in ratios are
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brain and flank scale with E as observed for adult mouse tissues. (J ) Stiffness
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S3A), but splitting the two splice-forms shows that lamin-A scales more dramatically, with E 1.0, 
whereas lamin-C scales as E 0.5.  Lamin-A is suppressed in the brain by microRNA MIR-9 (109) and an 
analysis of MIR-9s in tissue microarrays confirms abundant expression in brain but without any 
systematic relation to E. 
  
Fig. S6. Proteomic profiling of U251 xenograft tumors and mechanical properties of tumors.  
Xenografts were harvested after 4 wks, solubilized, and prepared for quantitative, label-free mass 
spectrometry. (A) About 20 - 30% of peptides from the tryptic digests were uniquely human, with 
quantitation done for almost 200 human proteins. Mouse collagens were quantified from uniquely 
mouse derived peptides. (B) Human cells in the brain express lower ECM proteins and lower lamin-A 
than human cells in the flank (p  0.05; n = 3), consistent with brain being softer than flank per Fig. 1D. 
Lamin-B2 is essentially constant, and lamin-B1 changes much less than lamin-A, consistent with Fig. 
1F. Only about 5% of quantifiable proteins indeed differ between the two in vivo sites by more than 2-
fold. The difference between the flank tumor and cultured cells is more pronounced, with 40% of 
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Figure 2.8 Lamin-A and collagen levels scale with tissue stiffness, but collagen 
determines stiffness while lamin-A responds to tissue stiffness – (Science 2013) 
(A) Human glioblastoma cells U251Luc (expressing luciferase for imaging) were 
xenografted into mouse brain and flank, and 4-week-old tumors were profiled by MS 
proteomics. (B) Mouse-derived collagens in U251 grown in mouse brain and flank scale 
with E as observed for adult mouse tissues. (C) Stiffness of flank tumors made with high 
(A549) or low (U251) lamin-A:B cells was similar to the stiffness of the subcutaneous 
site (subQ). Tumors were 50% softer after only a brief treatment with collagenase 
(col’ase). (D) Quantitative proteomics of multiple human and mouse tissues and cells 
revealed scaling with E of the absolute ratio or stoichiometry of lamin-A to lamin-B 
through MS quantification of a pan-lamin peptide. Differences in ratios are significant 
with brain << liver < fat < heart, lung, and muscle << skull << femur and cartilage, where 
< indicates P ≤ 0.05 and << indicates P ≤ 0.01. Nuclei with abundant lamin-A are stiff 
(20). Cultured cells showed the same trend as their primary source tissue. HSCP, human 
hematopoietic stem cell progenitors from marrow; U251, human glioblastoma cells from 
brain; A549, human adenocarcinoma epithelial cells from lung; C2C12, mouse myoblast 
cells from muscle; MSC, osteo-prone human mesenchymal stem cells from mar- row. (E) 
Lamin composition and stiffness of the tumors fit adult tissue scaling. All points are 
significantly different where indicated (n ≥ 3 MS measurements).  
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2.4 DISCUSSION 
 The epigenetic changes of lineage specification are likely affected by the nuclear 
lamina, which might selectively, if indirectly, interact with different chromatin regions 
during differentiation (Peric-Hupkes et al., 2010). Here, we show roles of the lamins in 
deformability-based sorting as well as lineage induction of blood cells. This 
characterization of lamin expression stoichiometry in freshly isolated hematopoietic cells 
from human marrow and blood demonstrates that absolute lamin A:B ratios correlate 
with nuclear stiffness (Fig. 2.3B). Although prior studies suggest that lamin-A is “below 
the detection limit” in terminally differentiated myeloid and lymphoid cells (Gerner and 
Sauermann, 1999), another study suggested that it is restricted to the late stage of 
lymphoid development but not earlier stages (Olins et al., 2008). Some studies suggest 
that B-type lamins are constitutive (Guilly et al., 1990; Röber et al., 1990) whereas other 
studies indicate that they are down-regulated in primary neutrophils (Olins et al., 2008). 
One study also acknowledges that, whereas blood granulocytes have much lower levels 
of both lamin-A and -B than the granulocytic HL-60 cell line, both lamins are detectable 
by confocal microscopy with distinct polymorphonuclear morphology (Olins et al., 
2008). Our efforts to take a standardized approach with MS- IF show that A- and B-type 
lamins are generally present across different blood-cell types and at different levels. 
Although our data support some prior studies that total lamin expression is significantly 
decreased in both lymphoid and myeloid lineages upon differentiation from progenitors 
(CD34+CD38+), lamin A: B ratios are increased to ∼1 (Fig. 2.S1B) and correlate with the 
known distribution of these lineages in marrow versus blood. 
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 Because most small openings between endothelial cells in marrow sinusoids are 
filled by marrow cells in situ (Lichtman et al., 1989), nuclear stiffness seems a reasonable 
limiting factor. Although it was previously appreciated that granulocytes are highly 
traffickable due to their unique polymorphonuclear morphology, our study reveals that T 
cells may be even more amenable to trafficking than granulocytes due to (i) lower lamin 
A:B ratio (Fig. 2.S1B), (ii) lower marrow:blood cell ratio (data not shown), (iii) lower 
nuclear stiffness (Fig. 2.2C), and (iv) lower half-maximal pore area for migration (data 
not shown). In contrast, although MK nuclei remain deformable (Fig. 2.2B), their size 
and complex morphology generally limit MK migration through small pores. Intact MKs 
could therefore be occasionally observed in circulation, but further chromatin 
condensation after exhaustive platelet generation would tend to inhibit traffickability 
(Lichtman et al., 1989). Flow cytometry analyses of what crosses the micropore filters in 
our MK experiments indeed show that many more small-cell fragments (e.g., platelet-like 
particles) traffic across than cells (data not shown), consistent with the platelet generating 
scheme in Fig. 2.S1A. 
 Our results indicate that lamin-A:B stoichiometry defines nuclear stiffness, 
indicating separable roles as distinct polymers in defining viscoelasticity of nuclei. Given 
that decreasing lamin-A softens nuclei (Pajerowski et al., 2007) (Fig. 2.2A) and that 
migration sensitivity to pore size increases as the relative amount of lamin-A increases 
(data not shown), lamin-A dictates time-dependent deformability, which is indicative of a 
viscous fluid. On the other hand, lamin-B1 confers nuclear elasticity and resilience (Fig. 
2.2D) so that its decrease during erythropoiesis produces a nucleus that is slow to recover 
and effectively stiffer. These results are consistent with previous measurements by 
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fluorescence correlation spectroscopy (Shimi et al., 2008) showing lamin-A is more 
mobile than B-type lamins. 
 Asymmetric division provides a means to maintain stemness while generating the 
many differentiated cells required for a tissue with high turnover such as blood (105 
nucleated cells/s). However, it has been unclear as to how two interconnected daughter 
cells physically sort components to become distinct. While asymmetry of stem cell 
division in C. elegans is driven by its one isoform of MII (Ou et al., 2010), the 
mammalian homolog, MIIA, is expressed in many cells other than stem cells and unlike 
MIIB, MIIA polarizes very weakly if at all (Raab et al., 2012; Vicente-Manzanares et al., 
2008). Compared to any other hematopoietic lineage, CD34+ cells express the most MIIB 
relative to MIIA. MIIB polarizes strongly to regions of high cell tension or curvature 
where it can physically break the symmetry of cytokinesis (Sedzinski et al., 2011). It is 
therefore almost predictable that MIIB in CD34+ cells will polarize near a cleavage 
furrow and define the MIIBhi daughter cell in asymmetric division (Figure 2.4). Since 
MIIB is localized near the membrane and is known to link to membrane proteins (Clark 
et al., 2006), MIIBhi could also help sort cell surface proteins such as CD34 and thereby 
correlate with CD34hi as seen. Depletion of MIIB from the CD34lo daughter cell is also 
propagated as a key aspect of the MII isoform switch that defines and delineates 
hematopoiesis. How MYH10 is ultimately repressed in differentiation requires further 
study: RUNX1 down-regulates MYH10 during MK differentiation (Lordier et al., 2012), 
but RUNX1 does not anticorrelate in general with MYH10 and is not required for normal 
functions once HSCs are formed from vascular endothelial cells during embryonic 
development (Chen et al., 2009). Nevertheless, asymmetric processes are hinted at by a 
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number of polarizable proteins in our early CD34+ cells, including Cdc42, which 
polarizes in correlation with HSC aging (Florian et al., 2012). Generic polarization of a 
protein in hematopoietic cells seems predictive of a role in asymmetric division 
(Beckmann et al., 2007), but MIIB’s role in physically breaking the symmetry of 
cytokinesis seems unique and motivates deeper study of biophysical factors that feed 
back into transcription programs and perhaps even regulate cancer stem cell 
differentiation (Cicalese et al., 2009). 
Motile cells that are sufficiently adherent can generate enough traction forces to 
pull themselves apart even in the absence of MII, whereas cells in suspension or daughter 
cells that cannot crawl away with sufficient force (to break the intercellular bridge) tend 
to become polyploidy (Zang et al., 1997). HSC/Ps grow well as suspension cells that do 
not adhere and spread strongly on substrates compared to other solid tissue cell types, and 
they only possess a thin cortical cytoskeleton; cytokinesis defects are thus likely to favor 
polyploidy in these cell types. In a blood cancer line that only expresses MIIA, partial 
knockdown of MIIA indeed increases polyploidy in vitro as does blebbistatin and the 
cancer cells survive (Shin et al., 2011). In healthy human and mouse primary cells, 
however, such a process of endomitosis is usually seen only for MKs (among blood cells 
at least), which implies that other cell types are either never tetraploid or apoptose if they 
become so. Irreversible ablation in vivo of MIIA in primary blood cells indeed enhances 
apoptosis and depletes most dividing blood cell types (Figures 2.6D–G). This seems 
consistent with cell death in blebbistatin treatments being downstream of MII inhibition. 
Although the specificity of this drug has been questioned (Shu et al., 2005), the reversible 
3-day treatment here with blebbistatin of primary CD34+ cells in vitro increases ploidy of 
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viable MKs and enhances apoptosis of progenitors with slower dividing stem/progenitor 
cells dying only with more sustained drug treatments. Our findings ultimately reveal not 
only a biophysical hierarchy of actomyosin forces in adult hematopoiesis but also some 
utility in controlling those forces to enrich for stem cells.  
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Figure 2.S1. Lamin map of human hematopoiesis and correlation analysis between 
nuclear stiffness and lamins – (PNAS 2013)  
Fig. S4. Correlation analysis between nuclear stiffness and lamins. (A) Correlation between nuclear stiffness and lamin A:B ratio at 60, 120, and 300 s after
aspiration under constant pressure. The graph was fitted with a power law, Y = (0.13!0.27)(X-0.6)(0.85!1.1), R2 " 0.9. Mean ± SEM of n " 5 for each cell type. (B)
Correlation analysis between nuclear stiffness and lamin total intensity at 120 s after aspiration. The graph was fitted with a power law, Y = 0.05(X-0.32)0.55,
R2 " 0.8 for T cell, CD33+, CD34+, and MK-II, whereas Y = 5.50X#1.80, R2 " 0.9 for LateEry, ProEry, MK-I and MK-II. (C) Lamin-B shRNA down-regulates lamin-B
without affecting lamin-A (n = 3 donors, P < 0.05). (D) Nuclear stiffening of U251 cells after lamin B1 knockdown. Nuclear compliance change with time under
constant pressure ΔP $ 3 kPa over time with a power law fit, J(t) (kPa#1) = A·tB (t = sec), where (A, B):): (scrambled (scr): 2.05, 0.13), (shLMNB1: 1.43, 0.13), n = 5,
P < 0.05, scrambled vs. shLMNB1 at each time point, paired t test.
Shin et al. www.pnas.org/cgi/content/short/1304996110 6 of 11
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Fig. S5. Perturbation of physiological pathways can phenocopy the stiffening of nuclei with lamin-B down-regulation. Many other proteins change during
erythropoiesis, and we hypothesized that, if we pharmacologically perturbed important erythropoietic pathways, then we should be able to phenocopy lamin-
B changes as intrinsic to a common erythropoietic program. To first identify candidate targets, we performed quantitative mass spectrometry analyses of
erythroid cells both without and with lamin-B1 RNAi treatment, which promotes BFU-Es. (A) HSP90 protein down-regulated during late erythropoiesis based
on mass spectometry profiling of erythropoietic cells at five distinct stages of differentiation (1), consistent with a role for HSP90 in hematopoietic differ-
entiation (2). (Inset) HSP90 phosphorylation levels at Ser226 and Ser255 (involved in drug resistance of cancer cells) (3) are up-regulated by lamin-B1 knock-
down only in the presence of Epo. (B) Histone acetylation of H2A.X at Lys120 is decreased by lamin-B1 knockdown. (C) HSP90 and histone acetyltransferase
inhibitors stiffen nuclei in erythropoiesis. GPA+ erythroblasts were treated with the HSP90 inhibitor 17-AAG (60 nM) or with the histone acetyltransferase
inhibitor anacardic acid (A.A., 20 μM) for 1 d, followed by micropipette aspiration of nuclei. Although GPA+/hi cells generally have stiffer nuclei than GPAlo
(ProEry), all nuclei largely flow irreversibly at constant pressure. Both drugs phenocopy the stiffening of erythroblast and the decrease in lamin-B. Nuclear
compliance change with the power law fit (a, b): (DMSO: 4.1, 0.14), (17-AAG 60 nM: 1.9, 0.09), [Anacardic Acid (A.A.) 10 μM: 1.9, 0.05] P < 0.05 (n = 5), DMSO vs.
17-AAG or A.A. for each time point in paired t test. (Inset) Graph shows down-regulation of lamin-B with both 17-AAG and A.A. One-way ANOVA *P < 0.05,
Mean ± SD. (Scale bars: 3 μm.)
1. Hu J, et al. (2013) Isolation and functional characterization of human erythroblasts at distinct stages: Implications for understanding of normal and disordered erythropoiesis in vivo.
Blood 121(16):3246–3253.
2. Grebenová D, et al. (2006) The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells Mol Dis 37(3):210–217.
3. Kurokawa M, Zhao C, Reya T, Kornbluth S (2008) Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol
28(17):5494–5506.
Shin et al. www.pnas.org/cgi/content/short/1304996110 7 of 11
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Figure 2.S1. Lamin map of human hematopoiesis and correlation analysis between 
nuclear stiffness and lamins – (PNAS 2013) 
(A) Hematopoietic cells are mostly in marrow or blood, and only a fraction of cells 
transmigrate through the endothelium with or without their nucleus. EryP, erythroid 
progenitors; GM, granulocytes and monocytes; HSCP, hematopoietic stem cell and pro- 
genitors; Lym, lymphocytes; MK, megakaryocytes; RBC, red blood cells; WBC, white 
blood cells. (B) Lamin-A relative to B-type lamins, transformed to a measurable A:B 
ratio versus calibrated sum intensity A+B (a.u.); on log scales, these are the respective 
difference and sum of chemical potentials for A and B. Mean fluorescent intensity of 
lamin for each subpopulation from flow cytometry was calibrated to an absolute ratio 
from MS analyses of a standard A549 cell line (lamin-A:B = 2.3). The dashed line 
schematically illustrates the semipermeable barrier between bone marrow (BM) and PB, 
and the net probability of partitioning based on lamin expression can be estimated from 
the upper half and lower half probabilities: PTOT = PUH PLH = 0.00006. Measurements are 
mean ± SEM of n ≥ 3,with error bars omitted if <5% of mean. BMG, BM granulocytes 
(CD33mid); BM M, BM monocytes (CD33hi); CD34+CD38-, early progenitors; 
CD34+CD38+, common progenitors; LateEry, late erythroblasts (CD44-GPA+); MK, 
polyploid MKs (average 16N); MKP, MK progenitors (CD34-CD41+); MSC, 
mesenchymal stromal cells; PB G/M, PB granulocytes/monocytes; Plt, platelets; ProEry, 
proerythroblasts (CD44+GPA-); RBC, red blood cells; T, B, lymphoids. Representative 
MSC results from one donor are shown because the variation in A:B ratios between 
donors and cultured cells was minimal. (C) Correlation between nuclear stiffness and 
lamin A:B ratio at 60, 120, and 300 s after aspiration under constant pressure. The graph 
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was fitted with a power law, Y = (0.13∼0.27)*(X-0.6)(0.85∼1.1), R2 ≥ 0.9. Mean ± SEM of n 
≥ 5 for each cell type. (D) Correlation analysis between nuclear stiffness and lamin total 
intensity at 120 s after aspiration. The graph was fitted with a power law, Y = 0.05*(X-
0.32)0.55, R2 ≥ 0.8 for T cell, CD33+, CD34+, and MK-II, whereas Y = 5.50X−1.80, R2 ≥ 
0.9 for LateEry, ProEry, MK-I and MK-II. (E) Lamin-B shRNA down-regulates lamin-B 
without affecting lamin-A (n = 3 donors, P < 0.05). (F) Nuclear stiffening of U251 cells 
after lamin B1 knockdown. Nuclear compliance change with time under constant 
pressure ΔP ≤ 3 kPa over time with a power law fit, J(t) (kPa−1) = A·tB (t = sec), where 
(A, B):): (scrambled (scr): 2.05, 0.13), (shLMNB1: 1.43, 0.13), n = 5, P < 0.05, 
scrambled vs. shLMNB1 at each time point, paired t test. (G) HSP90 and histone 
acetyltransferase inhibitors stiffen nuclei in erythropoiesis. GPA+ erythroblasts were 
treated with the HSP90 inhibitor 17-AAG (60 nM) or with the histone acetyltransferase 
inhibitor anacardic acid (A.A., 20 µM) for 1 d, followed by micropipette aspiration of 
nuclei. Although GPA+/hi cells generally have stiffer nuclei than GPAlo (ProEry), all 
nuclei largely flow irreversibly at constant pressure. Both drugs phenocopy the stiffening 
of erythroblast and the decrease in lamin-B. Nuclear compliance change with the power 
law fit (a, b): (DMSO: 4.1, 0.14), (17-AAG 60 nM: 1.9, 0.09), [Anacardic Acid (A.A.) 10 
µM: 1.9, 0.05] P < 0.05 (n = 5), DMSO vs. 17-AAG or A.A. for each time point in paired 
t test. (Inset) Graph shows down-regulation of lamin-B with both 17-AAG and A.A. One-
way ANOVA *P < 0.05, Mean ± SD. (Scale bars: 3 µm.) 
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Figure 2.S2. Perturbation of lamin-A expression MK polyploidy and colony forming 
capacity – (PNAS 2013) 
 
  
Fig. S6. (A) GFP–lamin-A overexpression increases lamin-A by 2.5-fold compared with GFP control (n = 3 donors, P < 0.05, mean ± SEM). (B) Lamin-A enhances
MK polyploidization. Overexpression of GFP, wild-type (WT), Progerin mutant (Δ50), and phospho-deficient (S22A) mutant of lamin-A in MEG01 cells. **P <
0.05, GFP vs. S22A 8n. *P < 0.05, GFP vs. WT, Δ50 or S22A (n = 4). (C) Lamin-A shRNA down-regulates lamin-A selectively by 75% whereas lamin-B remains
unchanged (n = 3 donors, P < 0.05, mean ± SEM). (D) Retinoic acid increases the mean size of CFU-GM. (E) Retinoic acid increases the number of CFU-GM
whereas it decreases that of BFU-E (n = 2 donors, P < 0.05, mean ± SEM).
Fig. S7. Migration of nucleated MKs and platelet fragments through pores. (A) Illustration of nucleated MKs and platelets (plt) migrating through 3-μm pores
under SDF-1 gradient. (B) Size calibration between forward scatter values from flow cytometry and known diameter of beads and MEG01 cells (measured by
light microscopy), assuming that each cell or fragment is circular. Mean ± SEM, n = 3. (C) Migration of CD41+7-AAD! fragments and nucleated cells from
MEG01 through 3- and 8-μm pores. Cytoplasm diameter was extrapolated as in B assuming that each fragment or nucleated cell is circular. Exponential decay
fit, half-life: 3-μm pore = 0.3 μm, 8-μm pore = 4.6 μm. R2 > 0.98, mean ± SEM, n = 3.
Shin et al. www.pnas.org/cgi/content/short/1304996110 8 of 11
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Figure 2.S2. Perturbation of lamin-A expression MK polyploidy and colony forming 
capacity – (PNAS 2013) 
(A) GFP–lamin-A overexpression increases lamin-A by 2.5-fold compared with GFP 
control (n = 3 donors, P < 0.05, mean ± SEM). (B) Lamin-A enhances MK 
polyploidization. Overexpression of GFP, wild-type (WT), Progerin mutant (Δ50), and 
phospho-deficient (S22A) mutant of lamin-A in MEG01 cells. **P < 0.05, GFP vs. S22A 
8n. *P < 0.05, GFP vs. WT, Δ50 or S22A (n = 4). (C) Lamin-A shRNA down-regulates 
lamin-A selectively by 75% whereas lamin-B remains unchanged (n = 3 donors, P < 0.05, 
mean ± SEM). (D) Retinoic acid increases the mean size of CFU-GM. (E) Retinoic acid 
increases the number of CFU-GM whereas it decreases that of BFU-E (n = 2 donors, P < 
0.05, mean ± SEM).  
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Figure 2.S3.  Myosin-IIA phosphorylation contour and CD34+ quantification 
following Myosin-IIA knockdown – (CSC 2014) 
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Figure 2.S3.  Myosin-IIA phosphorylation contour and CD34+ quantification 
following Myosin-IIA knockdown – (CSC 2014) 
(A) % pS1943-MIIA versus total MIIA map (n ≥ 3 donors, ± SEM). (B) CD34+ cell 
numbers do not change after partial MIIA knockdown (30%), evaluated by CFSE 
tracking as in Fig. 2.4E (n = 2 donors, ± SEM). 
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Figure 2.S4. Details of primary and secondary transplants following blebbistatin 
treatment – (CSC 2014) 
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Figure 2.S4. Details of primary and secondary transplants following blebbistatin 
treatment – (CSC 2014) 
(A) Representative plot showing that most hCD45+ cells from BM are hCD47+ (~97%) in 
NSG mice 16-wk after transplantation of human CD34+ cells. (B) (Top) Summary of 
primary and secondary NSG transplantation data. (Bottom) Estimation of human SRC 
frequency in NSG mice by extreme limiting dilution analysis (ELDA) (Hu and Smyth, 
2009). (C) Quantification of human BM CD34+CD38+, CD34+CD38-CD133-, and 
CD34+CD38-CD133+ subpopulations from NSG mice xenografted with human CD34+ 
cells, showing no difference between control and blebbistatin-exposed. (D) Colony 
forming assays demonstrate reduced progenitor numbers by MII inhibition. CFU-GM 
IC50 = ~10.5 µM, Hill coefficient = -6; BFU-E IC50 = 18.6 µM, Hill coefficient = -20 (n 
≥ 3 donors, ± SEM). Note that BFU-E and CFU-GEMM numbers are not changed under 
~15 µM, while CFU-GM number is significantly reduced. 
 
 
 
   
	   83	  
CHAPTER 3: REGULATION OF MYOSIN IIA ACTIVITY IS CRITICAL FOR 
NORMAL THROMBOPOIESIS AND THE MECHANISMS OF MYH9-RD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter appeared as the manuscript currently submitted to Blood and in revision – 
Myosin-IIA repression favors fragmentation to pre/pro-platelets, but its activation by 
shear facilitates division to platelets and fails in macro-thrombocytopenia. Spinler KR, 
Shin JW, Lambert MP, and Discher DE.  
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Dr. Jae-Won Shin contributed to experiment design. Dr. Michele Lambert provided 
access to MYH9-RD patient samples and contributed hematological insight. 
ABSTRACT 
 The ploidy of cultured megakaryocytes and the generation of pre/pro-platelets 
from megakaryocytes are both increased by pharmacological inhibition of MII, but 
mutations in non-muscle myosin-IIA (MIIA) cause MYH9-related diseases (MYH9-RD) 
that adversely affect platelets. In bone marrow, megakaryocytes extend projections into 
the microcirculation where shear facilitates fragmentation to large pre/pro-platelets, 
suggesting that fluid stresses and MII activity might couple in platelet biogenesis. Here, 
in bulk shear, platelet-like-particles generated from megakaryocytes are maximized at a 
shear stress typical of that in the microcirculation and after treatment with the MII 
inhibitor blebbistatin. MIIA activity in static megakaryocytes is naturally repressed 
through phosphorylation at S1943, but shear decreases phosphorylation, consistent with 
MIIA activation and localization to platelet cortex. Micropipette aspiration of single 
megakaryocytes shows MII inhibition facilitates generation of CD41+ fragments similar 
in size to pre/pro-platelets, and MYH9-RD mutants phenocopy MII inhibition in a 
dominant negative effect. Blood from a MYH9-RD patient with prototypical macro-
thrombocytopenia shows diffuse MIIA in large platelets, while normal pre/pro-platelets 
treated with blebbistatin exhibit diffuse MIIA and fail to divide to small platelets. The 
findings explain the large platelets in MYH9-RD but underscore a near-normal 
thrombocrit in terms of platelet mass. Myosin-II regulation thus controls platelet size and 
number.     
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3.1 INTRODUCTION 
 Intravital imaging of mouse bone marrow has shown that polyploid MKs extend 
large and flexible proplatelet projections across the fenestrated endothelium into the 
bloodstream where proplatelets are fragmented by fluid shear (Junt et al., 2007). In vitro 
studies of mouse MKs have also shown proplatelet extensions can be increased 2~3 fold 
in length with inhibition of MII by the drug blebbistatin (Chen et al., 2007; Eckly et al., 
2010). We showed human MKs treated with the same drug for 3 days increased both MK 
ploidy and proplatelet numbers, yielding up to 4-fold more functional platelets in vivo 
and in vitro (Shin et al., 2011). Drug washout proved essential in the latter studies 
because normal platelets rely on the A-type isoform, MIIA, to contract wounds and clots 
(Lam et al., 2011; Maupin et al., 1994). Myosin-II normally contributes to cytokinesis, 
membrane rigidity, and contraction of matrix, and so its transient inhibition explains both 
high ploidy MKs and increased proplatelets (Franke et al., 2005). These pharmacological 
findings and the fact that MIIA is expressed throughout hematopoiesis (Shin et al., 2014) 
lead us to hypothesize that normal MK-platelet physiology also involves an initial 
suppression of MIIA activity. This hypothesis brings into focus the cell function(s) that 
are dysregulated when MIIA (MYH9) is mutated in MYH9-Related Diseases (MYH9-RD).  
Patients who had previously been diagnosed with May-Hegglin anomaly, Epstein 
syndrome, or Fechtner syndrome all have autosomal dominant MYH9-RD mutations (Seri 
et al., 2003) with large platelets in reduced numbers (macrothrombocytopenia) and 
leukocyte inclusions at birth as well as increasing risks with age of developing 
nephropathy, deafness and cataracts (Balduini et al., 2011). 
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Myosin-II inclusions suggest dysfunctional protein (Balduini et al., 2011; Eckly et al., 
2009; Godwin and Ginsburg, 1974; Kelley et al., 2000; Pecci et al., 2005; Savoia et al., 
2010; Seri et al., 2000). However, mice with MK-specific MIIA knockout show a higher 
percentage of MKs with proplatelet buds and larger proplatelets even though there are up 
to 70% fewer platelets in PB (Eckly et al., 2009). Similar phenotypes are evident in mice 
expressing MYH9-RD mutations D1424N or E1841K that occur in the filament forming 
tail of MIIA (Zhang et al., 2012). These mutations among others impede filament 
assembly (Franke et al., 2005), which is necessary for MII contractility. Why such 
mutants are not phenocopied by blebbistatin inhibition of MII seems paradoxical, 
especially if our hypothesis is correct that normal MK-platelet physiology initially 
suppresses MIIA. Here we resolve this apparent paradox with evidence of transient 
physiological suppression of MIIA in normal MKs. The important effects of shear 
fragmentation in bulk are clarified first followed by biophysical, pharmacological, and 
mutagenesis studies of single cells and platelets. Together with comparisons to MYH9-
RD patient samples, we ultimately provide evidence that in normal MKs, MIIA is down-
regulated by reversible phosphorylation of MIIA until shear fragmentation to 
proplatelets. Subsequently, MIIA is normally activated for cleavage of proplatelets to 
small, contractile-competent platelets – but MYH9-RD proplatelets cannot complete the 
final cleavage.   
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3.2 MATERIALS AND METHODS 
All blood from patients and controls was collected after informed consent with Internal 
Revue Board (IRB) approval at the Children’s Hospital of Philadelphia and the 
University of Pennsylvania. This study was conducted in accordance with the Declaration 
of Helsinki. 
 
Materials 
For washing or antibody staining of cells, Phosphate Buffered Saline (PBS) without Ca2+ 
or Mg2+ (Invitrogen) was supplemented with 1% bovine serum albumin (BSA) (Sigma-
Aldrich). For cell culture, RPMI-1640, penicillin-streptomycin, and fetal bovine serum 
(FBS) were all purchased from Invitrogen. For Western analysis, protease inhibitor 
mixture was purchased from Sigma. For flow cytometry, 7-Amino-actinomycin D (7-
AAD) was purchased from Sigma and Hoeschst 33342 was purchased from Invitrogen. 
The (±)-blebbistatin was purchased from EMD Biosciences. Prostaglandin E1 was 
purchased from Sigma. 
 
Antibodies 
Primary antibodies used for flow cytometry, Western blotting, and imaging include anti-
human CD41-PE or –APC (eBioscience), anti-Annexin V-PE (BD Biosciences), non-
muscle myosin-II (MIIA) (Sigma), phosphorylated S1943 MIIA (pS1943 MIIA) (Cell 
Signaling), β-actin (Santa Cruz). Secondary antibodies include donkey anti-rabbit Alexa 
488 (Invitrogen), donkey anti-rabbit Alexa 647 (Invitrogen), and anti-mouse or anti-
rabbit HRP-conjugated IgG (GE Healthcare). 
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Cell Culture and Transient Transfection 
MEG-01 cells were obtained from ATCC and maintained in RPMI-1640 supplemented 
with 10% FBS and 1% antibiotics. Cells were transfected using an Amaxa Nucleofector 
kit according to the manufacturer’s instructions (Lonza). Briefly, 106 cells were 
resuspended in the nucleofector solution and supplement provided in the kit. DNA was 
added and the sample was placed in the Nucleofector Device and run on the preset 
program X-005. Cells were then incubated at room temperature for no more than five 
minutes followed by addition of 1 mL of pre-warmed RPMI-1640 medium and transfer to 
6 well plates containing 1 mL of pre-warmed RPMI-1640 per well. Medium was 
exchanged two times 24 hours after nucleofection. Transfected cells were viable for 2-3 
days as confirmed by exclusion of 7AAD staining. Transfection efficiency was ~5% to 
~10% for GFP-tagged MIIA constructs (WT, S1943D, S1943A, S1114P, D1424N, 
E1841K). 
For experiments using primary cells, CD34+ bone marrow derived cells were obtained 
from the University of Pennsylvania Stem Cell and Xenograft Core. Cells were cultured 
for 3-4 days in the presence of SCF and Tpo (R&D Systems) in Stem Span SFEM II 
(Stem Cell Technologies) supplemented with 1% antibiotics. After this brief cytokine 
culture, cells were used as described throughout for MEG-01.  
 
Rheometry and Platelet-Like-Particle Generation 
MEG-01 cells treated with DMSO or 20 µM blebbistatin (72 hrs) were washed, 
resuspended in Ca2+-free Tyrode’s + 1:1000 PGE1, and loaded onto a rheometer (Bohlin-
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Gemini). After 15 minutes of shear, samples were collected, labeled per Table S1, and 
analyzed by flow cytometry (LSR-II; BD Biosciences). 
 
Functional Characterization of MEG-01 Derived Platelet-Like-Particles (PLPs) 
PLP activity was determined by collagen-I stimulation (100 µg/mL). Sheared samples as 
described above were labeled per Table 3.S1 and analyzed by flow cytometry. 
 
Micropipette Aspiration 
For fragmentation studies, MEG-01 cells were treated +/- 20µM blebbistatin for 72 hrs 
followed, washed, and stained per Table 3.S1. For mutagenesis studies, transiently 
nucleofected MEG-01 cells were assayed within 48 hours of nucleofection. For cells 
treated with blebbistatin, cells were incubated at 37°C with 20 µM blebbistatin for 4 
5min, washed, and stained, per Table 3.S1. Capillary tubes of 1.0mm I.D. (World 
Precision Instruments) were pulled into micropipettes using a Flaming-Brown 
Micropipette Puller (Sutter Instrument) and cut further using a deFonbrune-type 
microforge (Vibratome) (<D>~3µm). A micropipette was attached to a dual-stage water 
manometer with reservoirs of adjustable height. Suction was applied by syringe, and the 
corresponding pressure was measured by a pressure transducer (Validyne) calibrated by a 
mercury U-tube manometer. Pressures for different experiments ranged from 0.5 to 20 
kPa. Images were acquired using a Nikon Eclipse TE300 inverted microscope using a 
40x objective and a Cascade CCD camera (Roper Scientific). Further image analysis was 
done using ImageJ (National Institutes of Health).  
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Proplatelet Enrichment, Treatment, and Imaging 
Human PB was obtained by venipuncture collected into 10% (v/v) AJ buffer (85 mM 
sodium citrate, 69 mM citric acid, 20 mg/ml glucose). Proplatelet fractions were enriched 
and treated as previously described (Thon et al., 2010, 2012). Briefly, PB samples were 
centrifuged for 20 min at 180g. Buffy and PRP was transferred to a new tube and spun 
for 15 min at 180g. Buffy and PRP was transferred to a new tube and spun for 15 min at 
1000g. The pellet was resuspended in Tyrode’s Buffer and treated for 1-6 hrs with 
DMSO, 10 µM blebbistatin, or 5 µM nocodazole at 37°C. After treatment, samples were 
seeded onto poly-L-lysine (1µg/ml) coated coverslips, allowed to adhere for 15 min at 
RT, and fixed with 4% paraformaldehyde. Antibody incubation was done per Table 3.S1. 
 
Proplatelet Flow Cytometry 
Human PB collected as described above was immediately fixed with 4% 
paraformaldehyde and RBCs lysed with 2 volume equivalents RBC Lysis Buffer (Sigma) 
for 10 minutes at 37°C. For drug treatment, whole blood was treated with DMSO, 10µM 
blebbistatin, or 5 µM nocodazole at 37°C before fixation/lysis. Fixed and lysed samples 
were washed twice, resuspended in Tyrode’s buffer for and antibody incubated per Table 
3.S1 and run on a BD LSRII.  
 
MYH9-RD Transfection and Immunofluorescence 
A549 cells were used as they are easily transfected and adherent, which simplifies 
imaging. Cells were seeded on 18 mm2 circular microscope cover slips in a 6 well plate 
and allowed to adhere overnight in F-12 growth media (Life Technologies) supplemented 
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with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. MYH9-RD 
constructs were introduced via transfection using Lipofectamine 2000 (Life 
Technologies) as per the manufactures protocol. Briefly, media was removed from cells 
and replaced with 800 µL Opti-MEM (Life Technologies) per well. Two cocktails were 
prepared for each reaction. Cocktail A consisted of 7 µL Lipofectamine 2000 + 93 µL 
Opti-MEM. Cocktail B consisted of 3 µg DNA + Opti-MEM to bring total volume to 100 
µL. A and B were combined and after 5 mins were added dropwise to each well. Cells 
were incubated for ~5 hours at 37°, 5% CO2 after which media was replaced with F-12 
growth media and allowed to incubate overnight. 
The following protocol was followed for visualizing MYH9-RD induced MII aggregates 
as well as MII expression in MYH9-RD patient platelets. Cells were briefly fixed with 4% 
paraformaldehyde followed by three PBS washes. Next, cells were permeabilized with 
0.5% Triton X-100 then blocked using 3% BSA + 0.05% Tween-20. Either total MII or 
pS1943 MII primary antibody was added at 1:100 by dilution with blocking buffer and 
incubated for 5-6 hours at room temperature. Cells were washed three times with PBS 
and either Alexa 488 or Alexa 647 secondary antibody was added at 1:400 diluted with 
PBS. For patient platelet experiments, CD47-APC was added at 1:100. After incubation 
at room temperature for 60 minutes, cells were washed twice followed by addition of 
Hoescht 33342 1:10,000, incubation at room temperature for 5 minutes, and another two 
PBS washes. Cover slips were then mounted on slides using ProLong Gold Antifade 
Reagent (Life Technologies), sealed with nail polish, and cured for 24 hours before 
imaging. Images were acquired using an Olympus IX71 inverted microscope with a 
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300W Xenon lamp illumination using 40x, 60x, or 150x objectives with or without 1.6x 
multiplication. Further image analysis was done using ImageJ. 
 
Western Blotting 
In general, cells were washed with ice-cold PBS and lysed on ice with lysis buffer (150 
mM sodium chloride, 1% Nonidet P-40, 1% protease inhibitor mixture, 1 mM activated 
sodium orthovanadate, 50 mM Tris at pH 8.0) for 30 mins. Whole lysates were separated 
on 3%-8% sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) gels 
(NuPAGE 3-8% Tris-Acetate, Invitrogen). The proteins were then transferred to a 
polyvinylidene fluoride (PVDF) membrane with an iBlot Gel Transfer Device 
(Invitrogen), followed by blocking with 5% nonfat dry milk solution for 1 hr. Incubation 
with primary antibodies was done at 4°C overnight with 1:1000 β-actin or 1:1000 HSP90, 
and 1:1000 MIIA or pS1943 MIIA antibodies. After washing, the membrane was 
incubated with 1:2500 anti-rabbit and 1:2500 anti-mouse HRP-conjugated IgG antibodies 
at room temperature for 1 hr. The blot was developed with ChromoSensor (GenScript) 
for 5 mins, followed by digital scanning to perform densitometry analysis by ImageJ. 
 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 4. Unless otherwise noted, 
all statistical comparisons were made by unpaired two-tailed Student t test and were 
considered significant if P < 0.05.  
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3.3 RESULTS 
Optimal shear stress for platelet-like-particle generation is maximized by MII 
inhibition 
As an initial cell type to explore MII’s role in platelet generation, we used the human 
megakaryocytic cell line MEG-01 which has been used by others as a model for both 
human MK and platelet generation (O’Brien et al., 2008; Takeuchi et al., 1998). A cone-
and-plate rheometer mimics in vitro the shear stress applied to MK projections in vivo 
(Fig. 3.1A), with a narrow gap size (60 µm) and controlled temperature (37ºC). 
Compared to unsheared MKs, an optimal shear stress of ~2 Pascal (Pa) generates up to 2-
fold more CD41+ PLPs (platelet-like particles), and MKs pretreated for 3 days with 
blebbistatin to increase MEG-01 ploidy (Fig. 3.S1) produce >4-fold more PLPs (Fig. 
3.1B).  The optimal shear coincides with arterial vessel shear stress (1.5 – 3.0 Pa) 
(Schubert et al., 2000), and higher shear stresses suppress fragmentation to CD41+ PLPs. 
Importantly, shear and blebbistatin have similar effects on primary human MKs. Bone 
marrow derived CD34+ cells were cultured for 3-4 days in the presence of SCF and Tpo 
to direct differentiation towards MKs, and an additional 3 days of culture with 
blebbistatin promoted polyploidy and MK maturation per our recent studies (Shin et al., 
2011). Shearing the treated cells indeed results in ~5-fold more CD41+ PLPs relative to 
static untreated culture (Fig. 3.1C).  
 To assay PLP functionality, collagen-I activated aggregation was measured. 
Sheared cell suspensions were stimulated with 100 µg/mL collagen-I in the presence of 1 
mM CaCl2 followed by flow cytometry analyses (Fig. 3.1D). Activation was determined 
for the Annexin-V+, 7-AAD-, CD41+ aggregated population with aggregation revealed by 
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high side scatter as reported by others (O’Brien et al., 2008). In the absence of collagen-I, 
activated aggregation was always low (<2%) but was also 2-3 fold higher at the highest 
shear compared to static or optimal shear. Such shear activation (Lu et al., 2013) might 
also underlie the decrease in PLP numbers at high shear (Fig. 3.1B) – as examined in a 
related context in the next section. Collagen-I stimulation of MEG-01 derived PLPs 
shows ~12% activated PLPs from static, untreated cultures and ~12-20% activated PLPs 
from blebbistatin treated, sheared cultures (Fig. 3.1D). Neither shear stress nor 
blebbistatin impacts fragment activation. Stimulation of primary human MK derived 
PLPs shows ~70% activation regardless of MII inhibition, and this level of activation is 
observed for either static or 2 Pa sheared samples (Fig. 2.1E).  
 Scaling the absolute number of MEG-01 derived PLPs generated (Fig. 3.1B) by 
the activation results (Fig. 3.1D) provides a more accurate accounting of functional PLPs 
(Fig. 3.1F). An optimum at 2 Pa shear emerges for 20 µM blebbistatin, with an ~8-fold 
increase in functional PLPs compared to those from static, untreated MEG-01 cultures. 
Whether the optimum results from loss of functionality at high shear or else high shear 
affecting fragmentation itself is addressed by investigating the MK’s response to shear 
stress. 
 
Myosin-IIA heavy chain is stress activated  
Contractility of platelets is important to wound closure (Lam et al., 2011), and we have 
found recently that primary hematopoietic stem cells maintain a high level of MIIA 
phosphorylated on S1943 (pS1943) that tends to deactivate MIIA (Fig. 3.2A, sketch) and 
this phosphorylation generally decreases through differentiation (Shin et al., 2011). 
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Dephosphorylation is known to shift the equilibrium from soluble, cytoplasmic dimers 
toward assembled bipolar filaments (Alberts et al., 2007) that interact with actin filaments 
in contributing to cell division, membrane rigidity, and strong adhesion to rigid matrices.  
Our previous studies also showed late MKs relative to fresh platelets have ~3-fold higher 
pS1943 per MIIA (Shin et al., 2011). Here, increasing shear stress on MEG-01 cells (per 
Fig. 3.1A) decreases pS1943 per MIIA in a physically reasonable exponential form to 
~3-fold lower levels relative to static culture (Fig. 3.2A, plot). Shear activation of 
pS1943 by dephosphorylation as measured by single cell flow cytometry (Fig. 3.2A) 
decays to a minimum by ~4-6 Pa, as confirmed by immunoblot (Fig. 3.2A, inset), which 
might explain the decrease in PLP generation at shear stresses >2 Pa.  Importantly, fresh 
human platelets exhibit the same low level of pS1943 (Fig. 3.2A star & Fig. 3.S2). 
Mature MKs in bone marrow are certainly shielded from fluid shear and should in 
principle maintain a high level of pS1943 to enhance polyploidization (mimicked in vitro 
by blebbistatin) and to suppress cortical rigidity during proplatelet extension and 
fragmentation (Fig. 3.2B). Prolonged exposure to shear stress would deplete pS1943 and 
thereby remove the block on MIIA activity to obtain a contractile phenotype only in 
circulating platelets.  Such a post-translational activation would be consistent with 
previous interpretations of the MIIA gene in mice, Myh9, as a negative regulator of 
platelet generation (Chen et al., 2007), for which complete knockout causes defects in 
proplatelets and MK viability (Eckly et al., 2010). 
One prediction of the shear stress activation model is that wild-type MII should 
localize at the appropriate place and time with stress, and so micropipette aspiration was 
used to apply local stresses to proplatelet-like projections of MEG-01 cells while imaging 
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GFP-MIIA constructs (Fig. 3.3A, sketch). WT MIIA indeed accumulates over minutes 
toward the highly stressed tip of the membrane projection (Fig. 3.3A, upper image), 
consistent with a mechanosensitive response seen first for dictyostelium MII (Ren et al., 
2009). Intravital imaging (Junt et al., 2007) has suggested MKs extend proplatelet 
pseudopods into blood in <15 min with fragmentation in ~30 min, although in vivo 
stresses are unknown. A phospho-mimetic S1943D mutant of MIIA proves unresponsive 
as it distributes uniformly along the aspirated length, and a non-phosphorylatable S1943A 
mutant remains more in the cell body and is depleted along the aspirated length (Fig. 
3.S3). Treating the nucleofected cells with blebbistatin for 30 min prior to aspiration 
suppresses the mechanosensitive response of WT as well as S1943A’s decay along the 
aspirated projection, producing a more uniform S1943D phenotype for all. Projections of 
aspirated membrane for the S1943D mutant and for blebbistatin treated cells were also 
softer in distending more under high aspiration stress than for WT or S1943A (Fig. 3.S3). 
The results thus suggest a high level of pS1943 favors proplatelet extension to facilitate 
fragmentation into the bloodstream (per Fig. 3.2B) while also ensuring that the resulting 
platelet population has relatively homogeneous MII levels among fragmented 
proplatelets.  
Consistent with phosphorylation-induced repression of MII during platelet 
biogenesis, micropipettes with diameters similar to small human capillaries (~3 µm) 
show that blebbistatin facilitates generation of CD41+ fragments (Fig. 3.3A, right 
micrograph) in greater numbers than without inhibition (Fig. 3B).  Larger diameter 
micropipettes also cause fragmentation, but blebbistatin always provides higher yields.  
Fragment sizes decrease with decreasing micropipette diameter but do not depend on MII 
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inhibition (Fig. 3.3C, 3.S4). The composition of similarly induced erythrocyte membrane 
fragments agrees well with that of microvesicles generated in processes such as 
reticulocyte maturation to discocytes, suggesting physiological relevance (Knowles et al., 
1997). Here, CD41+ fragments are similar in size to normal human preplatelets (Fig. 
3.3C, 3.S4 shaded regions), and we showed previously that membrane projections and 
fragments in micropipette aspiration have taxol-staining microtubules (Shin et al., 2011) 
similar to those seen in MK proplatelets and platelets (Italiano et al., 1999). The results 
thus indicate that down-regulation of MII activity facilitates formation and fragmentation 
of MK projections, but size of CD41+ fragments depends on capillary diameter.  
 
MYH9-RD mutants are not activated by stress  
Mutations in the tail of MIIA can cause MYH9-RD, with mutants S1114P, D1424N, and 
E1841K studied here all blocking myofilament assembly (Balduini et al., 2011) even 
when mixed with WT MIIA, suggesting dominant negative phenotypes (Franke et al., 
2005). Patients expressing the E1841K mutation have macro-thrombocytopenia with 
normal platelet aggregation but no change in platelet shape (Canobbio et al., 2005). Here, 
PB samples from a patient with a D1424N mutation showed macro-thrombocytopenia 
with increased platelet size and a reduced platelet count of 21.8 fL and 90,000/µL, 
respectively. Immunofluorescence imaging of MIIA and pS1943 in platelets that were 
allowed to spread on glass coverslips  (Fig. 3.4A) shows an absence of normal peripheral 
MIIA localization in patient platelets (Fig. 3.4B). In contrast, pS1943 distribution 
remains diffuse in both normal and patient platelets, consistent with the imaging of the 
synthetic S1943D mutant. MIIA density is also decreased in patient platelets compared to 
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normals (Fig. 3.4C), which is consistent with previous studies of MYH9-RD showing up 
to 50% deficiency in total MIIA (Deutsch et al., 2003);  in contrast, pS1943 densities are 
similar for normal and patient (Fig. 3.4D). The diffuseness of the patient’s total MIIA is 
thus consistent with a significant fraction of MIIA being inactive.   
Mean projected areas of platelets are larger for the patient as expected, with an 
increase from 6.9 µm2 for normals to 19 µm2 for D1424N patient, which is about half the 
size of mature RBCs (Fig. 3.4E). Platelet perimeters and calculated circularity (Thon et 
al., 2010) for normals show a mixture of high circularity, small perimeter normal platelets 
with dumbbell-shaped, large perimeter proplatelets and high circularity, large perimeter 
preplatelets (Fig. 3.4F). Platelets from the MYH9-RD patient were predominately high 
circularity and large perimeter, corresponding to preplatelets (Fig. 3.4F), consistent with 
previously noted effects of EDTA anticoagulant on repressing the dumbbell-shaped 
proplatelets (Thon et al., 2012). Past observations of a cleavage furrow (Schwertz et al., 
2010) and a “snapping” back of the membrane following proplatelet fission (Thon et al., 
2010) thus suggest a role for active MII similar to that in cytokinesis of MK progenitors 
(Shin et al., 2011).   
A plot of normal peripheral thrombocrits from platelet count and size data of 
Thompson et al (Thompson and Jakubowski, 1988) shows that our D1424N patient has a 
peripheral thrombocrit in the normal range (Fig. 3.4G). Mouse models with the D1424N 
mutation have approximately two-fold more MKs in the marrow than normal mice 
(Zhang et al., 2012), and if such compensation also occurred in humans, the patient 
thrombocrit per MK approaches a linear fit of the normal data. These findings support a 
hypothesis for MYH9-RD defects in terminal platelet processing (Fig. 3.4H), consistent 
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with normal biogenesis of platelets in which pS1943 deactivates MIIA in earlier steps 
(Fig. 3.2B). Thus, in normal platelet generation, large pre/pro-platelets sheared from the 
pS1943-rich processes that are extended by MKs can reversibly convert between 
proplatelets and preplatelets, but the pinching and subsequent fission to properly sized 
platelets is driven by MIIA. The conclusion that pre-/pro-platelets in MYH9-RD patients 
can be readily generated but cannot undergo fission helps to explain the increased MPV 
and decreased platelet count with reasonable maintenance of peripheral thrombocrit. Two 
key aspects of this model are examined next: 1) MYH9-RD mutants act as dominant 
negatives in stress-induced membrane fragmentation, and 2) normal MII activity is 
ultimately needed for cyto-fission to platelets.  
  
MYH9-RD mutants exert dominant negative effect in fragmentation of projections 
In micropipette aspiration of MEG-01 cells expressing MYH9-RD mutants as GFP 
fusions, the fluorescence on the aspirated projection appeared nearly flat and time-
independent as did blebbistatin-treated cells expressing the wild-type GFP-MIIA (Fig. 
3.5A). Fragments generated per cell were likewise similar for MYH9-RD mutants and for 
blebbistatin treated MEG-01’s (non-transfected), and all were significantly higher than 
DMSO treated control while they were zero for wild-type GFP-MIIA expressing cells 
(Fig. 3.5B). The transfected cell results thus reveal a dominant negative effect of MYH9-
RD on fragmentation since the constructs are overexpressed to mimic the stoichiometry 
of a heterozygous state (with immunostaining of total MIIA being 60% higher in GFP 
expressing cells than non-expressing cells, Fig. 3.S5). Consistent with past reports for 
granulocytes (Deutsch et al., 2003; Pecci et al., 2005; Savoia et al., 2010) and and in 
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contrast to wild-type GFP-MIIA that appeared cortical (Fig. 3.3A), the MYH9-RD 
mutants expressed in MEG-01 cells showed more GFP aggregates against a diffuse GFP 
signal – which we quantified in well-spread cells (Fig. S5). Additionally, in micropipette 
aspiration of MEG-01’s, the mutants did not affect fragment size (Fig. 3.S4), consistent 
with the above noted lack of size difference between fragments from blebbistatin treated 
and control cells (Fig. 3.3C). Cells overexpressing MYH9-RD mutants were slightly 
larger than cells overexpressing WT MIIA despite similar GFP intensities (Fig. 3.5C); 
however, DMSO control treated MEG-01’s were larger than transfected cells, while 
blebbistatin treated cells were the largest (Fig. 3.5C), consistent with their higher ploidy 
(Fig. 3.1A, 3.S1). Since MK size relates to maturity (Mattia et al., 2002) (ploidy, 
proplatelet extension, and platelet release), overexpression of normal MIIA tends to 
suppress size/maturity whereas MYH9-RD mutants slightly increase MK size/maturity 
and disproportionately increase fragmentability (vs DMSO, Fig. 3.5B).  
 
Myosin-IIA activity is critical to pre-/pro-platelet fission to platelets 
To determine whether normal MIIA activity is necessary for final fission to platelets, 
which seems defective in MYH9-RD, PB from healthy anonymous donors collected into 
buffer was enriched for proplatelets as described by others (Thon et al., 2012). Cultures at 
37°C were treated for 1 or 6 hrs with blebbistatin or nocodazole to respectively inhibit 
MII or depolymerize microtubules. Immunostaining for MIIA reveals that the normal 
peripheral distribution is made diffuse by blebbistatin but not by nocodazole (Fig. 
3.6A,B). Additionally, MIIA localizes to the cleavage furrow of proplatelets, and 
immunostaining for the other hematopoietic isoform (Shin et al., 2014), MIIB, indicated a 
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relative intensity of MIIA:MIIB ~ 250 that confirms MIIA as the relevant isoform. 
Quantitation of circularity and perimeter per recent studies (Thon et al., 2012) suggests 
small perimeter platelet populations always dominate, but both drug treatments enrich for 
the large discoidal preplatelet populations compared with DMSO controls (Fig. 3.6C).  
Relative to the barbell-shaped proplatelets, the preplatelets shift from ~1:3 for DMSO 
control cultures to ~40:1 for blebbistatin treatment and ~8:1 for nocodazole treatment 
(Fig. 3.6C). No significant difference between 1 and 6 hrs suggests that the transition 
takes 10’s of min or less, which is consistent with the mechano-activation kinetics of 
MIIA (Fig. 3.S3) and also with cytokinesis in mitosis (Shin et al., 2011). While both 
MIIA and microtubule activity drive these conversions, inhibition of MIIA alone 
generates large platelets with diffuse MIIA that appear similar to MYH9-RD platelets 
(compare Fig. 3.6A,B with Fig. 3.4A).  
Flow cytometry was done on whole blood samples after treating for 1 hr with 
DMSO, blebbistatin, or nocodazole. Samples were fixed following drug treatment, and 
RBCs lysed prior to incubation with antibodies. Populations were determined from 
scatter of normal human platelets and calibration beads, and platelets were gated as 
CD41+, Hoechst-, GPA-. In agreement with immunofluorescence, drug treatment 
compared to control showed a significant increase in the ratio of preplatelets to 
proplatelets resulting from an increase in preplatelets at the expense of proplatelets (Fig. 
3.6D). 
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Figure 3.1 Shear stress and pharmacological inhibition of myosin synergistically 
enhance platelet-like-particle generation in vitro 
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Figure 3.1 Shear stress and pharmacological inhibition of myosin synergistically 
enhance platelet-like-particle generation in vitro 
(A) Myosin inhibition scheme and schematic of cone and plate rheometer. MEG-01 cells 
were cultured for 3 days with 20 µM blebbistatin (IC50 ≈ 5 µM). PLP generation is 
assayed on the third day of culture. Cell suspensions placed on the rheometer are 
subjected to controlled temperature, shear stress, stress duration, and gap size. Samples 
collected from the rheometer are analyzed by flow cytometry to quantify PLP (R1) and 
nucleated cell (R2) fractions. (B) Quantitation of PLP generation following cone and 
plate imparted shear stress (n=6, ±SEM, *, +, # P<0.05, **, ++ P<0.005. + significant 
from DMSO culture, # significant from blebbistatin culture, * significant from previous 
shear stress condition). The data is fit with a combination of a one phase exponential 
decay and a one site-specific binding model. DMSO fit: y=[2+4.0*exp(-
0.62*x)]*[0.10+(0.66/(0.65+x))], R2=0.97). Bleb fit: y=[2+4.0*exp(-
0.62*x)]*[0.26+(1.5x/(0.94+x))], R2=0.98). (C) Primary human CD34+ bone marrow 
derived cells were cultured for 3-4 days in the presence of SCF and Tpo to drive 
differentiation towards MKs followed by an additional 3 days of culture in the presence 
of 15 µM blebbistatin to promote polyploidy and MK maturation. PLP generation is 
quantified following cone and plate rheometry. Values are relative to unsheared, 
untreated cell culture (n=3, ±SEM, * P<0.05). (D) MEG-01 cell suspension stimulated by 
100 µg/mL collagen-I and 1 mM CaCl2. Activation determined by shift in side scatter and 
Annexin-V+CD41+. Stimulation activates up to ~12% of unsheared PLPs, and ~12-20% 
of shear generated PLPs (n=3, ±SEM). (E) Primary human MKs stimulated with 
collagen, similar to in panel D, following cone and plate imparted shear stress (n=2, 
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±SEM). (F) Considering the increased number of PLPs generated from shear panel B, 
shear results in an ~8x net increase in functional PLPs compared to unsheared, untreated 
MEG-01 from culture (n=5, ±SEM, *, + P<0.05. # significant from untreated condition, * 
significant from previous shear stress condition). 
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Figure 3.2 Shear stress modulates megakaryocyte myosin activity 
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Figure 3.2 Shear stress modulates megakaryocyte myosin activity 
(A) Cartoon of the location of S1943, the site examined in this work and implicated in 
MII filament formation. S1943 phosphorylation leads to MIIA inhibition and less 
contractile cells. Quantification of MEG-01 pS1943 shows shear dependence. After 
shear, cells are collected, fixed, permeabilized, and stained for analysis by flow 
cytometry (n=4, ±SEM). The fit is: y=0.046+0.093*exp(-1.32x) (R2=0.98, *P<0.05). The 
star is quantification resulting from flow cytometry of resting fresh human platelets. (A, 
inset) Western blot shows agreement with flow data. Namely, phosphorylation of non-
muscle MIIA S1943 decreases in a shear stress dependent manner. Original blot was 
cropped to economize figure size. No further manipulation was performed. (B) High 
ploidy mature megakaryocytes transmigrate to the perivascular niche where they extend 
membrane extensions into the vasculature. These extensions are then fragmented by shear 
imparted by the blood flow. While these initial fragments may be large in size and 
heterogeneous in size distribution additional exposure to blood flow fragments these 
further to normal sized human platelets. This process is dependent on MII activity, which 
is sensitive to shear stress through phosphorylation of S1943. 
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Figure 3.3 Myosin IIA inhibition is necessary to generate fragments similar in size to 
normal human platelets from in vitro micropipette aspiration 
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Figure 3.3 Myosin IIA inhibition is necessary to generate fragments similar in size to 
normal human platelets from in vitro micropipette aspiration 
(A) MEG-01 cells are nucleofected with GFP-MIIA or else labeled with fluorescent anti-
CD41. Representative fluorescent images of GFP-MIIA or else CD41-PE labeled MEG-
01 undergoing fragmentation induced by micropipette aspiration (scale bar = 5 µm). 
Intensity of cell body has been adjusted to aid in visualization of aspirated fragment. True 
intensity of the CD41 labeled MEG-01 is plotted below micrograph. (B) Blebbistatin 
treatment increases the number of fragments per cell as well as permission of 
fragmentation at smaller radius pipettes. Shaded region indicates range of reported 
normal human platelet size. Linear fit of DMSO: y=0.57x-0.8, R2=0.99, n=2, ±SEM. 20 
µM blebbistatin: n>15, ±SEM. Statistical significance determined between DMSO and 20 
µM blebbistatin for a given Rp, *P<0.05. (C) Fragment area is not affected by 
blebbistatin; however, blebbistatin treatment facilitates fragmentation of smaller 
fragments from smaller radius pipettes. Linear fit of 20 µM blebbistatin: y=138x-187 
(R2=0.99, n<40, ±SEM). DMSO: n>6, ±SEM. Pink shaded region denotes calculated 
range of area from reported normal human platelet diameters. Gray shaded region 
denotes estimations from reported preplatelet diameters (Thon et al., 2012). 
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Figure 3.4 Characterization of abnormalities in MYH9-RD patient platelets 
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Figure 3.4 Characterization of abnormalities in MYH9-RD patient platelets 
(A) Peripheral blood was obtained from a patient expressing the c.4270G>A (D1424N) 
MYH9-RD mutation was collected in EDTA. Buffy coat was incubated with CD41-APC, 
total or pS1943 MIIA antibodies, and Hoescht 33342. Platelets were identified as 
CD41+Hoescht- expression (scale bar = 5 µm). (B) Peripheral MIIA is disrupted in 
platelets containing the MYH9-RD mutation. Intensity line scans were made along 
perpendicular major and minor axes as shown in (A). Myosin distribution is quantified by 
the ratio of average peripheral intensity to average center intensity. Total MIIA is 
peripheral in normal platelets while diffuse in mutant platelets while phospho-MIIA is 
diffuse in both cases. MYH9-RD mutation results in a decrease in total MIIA (C) but not 
pS1943 MIIA expression (D). (E) Patient platelets show an increase in projected area. (F) 
MYH9-RD mutation has a dramatic effect on observed platelet shape. (Normal: n=83; 
D1424: n=78; RBC: n=32).  Red blood cells from a normal donor were used as an 
internal calibration control for size and shape in E and F. (G) Thrombocrit values 
calculated from MPV and platelet count data published in Thompson Blood 1988 show a 
weak dependence on MPV (Linear Regression: Thrombocrit = -0.01 * MPV + 0.33, 
R2=0.12, n=49) (Thompson and Jakubowski, 1988). The red diamond is the value for the 
D1424N patient used throughout this paper. Assuming a compensatory mechanism of 
increased MK number as demonstrated in mouse, (Zhang et al., 2012) the MYH9-RD 
patients thrombocrit could fit the trend of normal thrombocrit. (H) Proposed model of 
platelet generation accounting for MYH9-RD induced macrothrombocytopenia. MK 
shedding of preplatelets is an analogous process to erythroblast enucleation. The 
circulating reticulocyte becomes a terminal RBC through the aid of hydrodynamic shear 
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force, however the absence of MIIA prevents further fission events. Similarly, the blood 
shear forces assist the transition from preplatelet to proplatelet, but the presence of MIIA 
allows for cleavage furrow formation and fission resulting in normal platelets. MYH9-RD 
mutations abrogate normal MIIA activity preventing cleavage furrow formation and 
platelet fission. This results in an increase in circulating preplatelets and the phenotypic 
large platelets.   
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Figure 3.5 Myosin localization and MK fragmentation altered by MYH9-RD 
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Figure 3.5 Myosin localization and MK fragmentation altered by MYH9-RD 
GFP-MIIA mutation associated with MYH9-RD, S1114P, D1424N, or E1841K 
specifically, were introduced into MEG-01 cells. (A) Upon application of stress, GFP-
MIIA is seen evenly distributed throughout the aspirated length in a manner similar to 
either S1943D MIIA or blebbistatin treated cells (gray dotted line). S1114P: (y=1.7*10-
4x+0.84, R2=0.26, n=6, ±SEM). E1841K: (y=1.1*10-4x+0.81, R2=0.27, n=10, ±SEM). 
Representative fluorescent micrographs showing uniform GFP distribution from a GFP-
E1841K MIIA and fragment shedding from a GFP-S1114P mutant (scale bar = 5 µm).  
(B) These cells showed an enhanced propensity to produce fragments similar to that of 
blebbistatin treatment (n>8, ±SEM, *P<0.05, significant from untransfected-DMSO). (C) 
Quantification of MEG-01 size for each of the cell types used for micropipette aspiration. 
The MYH9-RD mutant cells, which produced fragments, show a higher distribution of 
larger cells compared to the phospho-mutants that did not fragment. 
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Figure 3.6 Myosin IIA activity controls conversion to proplatelets and cleavage of 
normal platelets 
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Figure 3.6 Myosin IIA activity controls conversion to proplatelets and cleavage of 
normal platelets 
Proplatelet-enriched fractions from PB collected in AJ buffer were incubated with 
DMSO, 10 µM blebbistatin, or 5 µM nocodazole for 6 hours at 37°C. (A) Representative 
images of cultures after drug treatment. (B) High magnification (240x) of culture 
presented in (A) to demonstrate MIIA distribution and morphology after each treatment. 
Line scans and surface plots demonstrate MII localization at the periphery observed for 
DMSO and nocodazole treatment is disrupted by blebbistatin treatment. Staining for 
MIIB was done in parallel using the same secondary antibody, which indicated 
intensity/area, on average, MIIA:MIIB=250 (N=25 across 5 fields of view each isoform). 
(C) Quantification of immunofluorescence of 6 hr treated proplatelet-enriched fractions 
shows a shift toward preplatelets at the expense of proplatelets following blebbistatin or 
nocodazole incubation. 1 hr treatments were done in parallel. Population breakdown 
enumerated in black font, mean±SEM population projected area in red font.  Gates are set 
based on previously published values (Thon et al., 2012). (D) Representative flow 
cytometry scatter plots. Platelet populations were determined based on scatter, then gated 
on CD41+, Hoescht-, GPA-. Results of flow cytometry analyses. 
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3.4 DISCUSSION 
The results here first suggest that normal MKs suppress MIIA activity via tail 
phosphorylation (pS1943) to increase ploidy and to be sufficiently pliable to fragment 
readily under shear as is relevant to pre-/pro-platelet generation (Fig. 3.2B). Secondly, the 
results suggest that MYH9-RD mutations (at least in the tail) likewise favor pliability and 
fragmentation, but the re-activation of MIIA that normally occurs in human platelets is 
insufficient for MYH9-RD pre-/pro-platelets.  For normal pre-/pro-platelets, this re-
activation drives fission to small and abundant normal platelets but MYH9-RD pre-/pro-
platelets do not (Fig. 3.4H).  Evidently, flow stresses are optimized (Fig. 3.1) for initial 
fragmentation of MK projections in vivo (Junt et al., 2007), but flow stresses do not 
fragment pre-/pro-platelets, which is a process made efficient in normals by MIIA-
mediated cyto-fission. 
The results thus provide a novel outside-in regulatory mechanism for 
thrombopoiesis. While MIIA activity has already been established as a negative regulator 
of platelet generation (Chen et al., 2007), MIIA exhibits more regulated activity. 
Specifically, shear stress provides the external cue that impacts MII activity by reducing 
MIIA phosphorylation at S1943. Exposure to high stress activates MIIA locally (Fig. 
3.S3), which leads to a tensed and stiff cell that is much less likely to fragment in 
micropipette aspiration (Fig. 3B, 5B). Inhibition of MIIA softens the membrane to favor 
fragmentation to sizes similar to normal human pre-/pro-platelets (Fig. 3.3B). Altogether 
the results suggest kinetics that strikes a balance between MK fragmentation and MK 
contractility. If MK proplatelet processes were to grow abnormally long and spend too 
much time extended into the vasculature prior to fragmentation, then the proplatelets will 
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likely have heterogeneous protein distributions (especially mechanosenstive MII) and 
therefore have variable function.  
Previous work demonstrated that microtubule stabilization or destabilization by 
taxol or nocodazole respectively favors proplatelets or preplatelets (Thon et al., 2012). 
However, tubulin expression is not affected by the MYH9-RD mutation D1424N 
(Deutsch et al., 2003). The formation of a cleavage furrow and the lack of proplatelets in 
this MYH9-RD mutant sample suggest roles for MIIA in facilitating pre-/pro-platelet 
transition as well as cytofission. Combined with the noted fragmentability of the MEG-01 
cells expressing the MYH9-RD mutants, macrothrombocytopenia is understandable in 
spite of the reasonable PB thrombocrit (Fig. 3.4G). Eckly et al. likewise reported in 
lineage-specific Myh9 knockout mice a higher percentage of MKs that extend 
proplatelets which were also larger than normal MKs despite a cytopenia in the knockout 
mice (Eckly et al., 2009). Furthermore, Zhang et al.’s transgenic mice expressing 
D1424N or E1841K mutations exhibit macrothrombocytopenia and a slight elevation in 
peripheral thrombocrit (Zhang et al., 2012). Our results support these data and provide 
credence to a model wherein switchable MIIA activity is critical to normal platelet 
biogenesis.    
 In summary, this seems the first study to demonstrate a regulated synergy 
between MIIA activity and shear stress in platelet generation in both normal and MYH9-
RD. Importantly, shear stress enhances MIIA activity by reduction of phosphorylation of 
S1943. The detailed outside-in signal has yet to be elucidated, but MK fragment size and 
fragment number are clearly enhanced by repressing MII activity. Subsequently, MIIA 
activity is critical to the transition from preplatelet to proplatelet with cleavage furrow 
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ingression and cytofission to platelets. This process is necessary for production of normal 
sized platelets and is disrupted by either pharmacological inhibition with blebbistatin or 
MYH9-RD mutation. Previous work on MK lines (Apostolidis et al., 2012) has also 
shown MYH9 to be downstream of the p53 that seems normally repressed to permit 
ploidy; indeed, p53 knockdown downregulates MYH9, ACTA2, and FLNA all of which 
are cytoskeletal contributors to actomyosin forces. Platelet size abnormalities might thus 
result from p53 defects.  Myosin-II activity in early MKs with and without MYH9-RD 
mutation could also be very different, as suggested by studies of MK adhesion forces 
(Chen et al., 2013) and from the fact that MIIB is high normally in early MKs but 
dysregulated in some diseases (Bluteau et al., 2012; Shin et al., 2014). Furthering our 
work with pharmacological MII inhibition using blebbistatin, perhaps an intravital 
microscopy study of Myh9 conditional knockout mice could further elucidate the critical 
role of MIIA in proplatelet fission in vivo. The present results suggest a spatio-temporal 
mechanism of platelet production, which ties together mechano-responsive MK 
contractility and fragmentation, and most strikingly, preplatelet to proplatelet conversion 
followed by proplatelet fission. 
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Table 3.S1. List of antibodies used in Chapter 3 Methods 
 
  
Experiment Buffer Antibody
Dye/4
Conjugate
Time4(min)/4
Temp4(°C) Dilution Manufacturer
! 7!AAD 60'/'20 1:1000 Sigma
! Hoescht'33342 60'/'37 1:2500 Invitrogen
anti!hu'CD41 APC 60'/'37 1:20 Biolegend
pS1943'MIIA ! 120'/'20 1:100 Cell'Signaling
anti!hu'MIIA ! 120'/'20 1:100 Cell'Signaling
donkey'anti!rb' Alexa'488 60'/'20 1:400 Invitrogen
! 7!AAD 60'/'20 1:1000 Sigma
anti!hu'CD41 APC 60'/'37 1:20 Biolegend
Annexin'V PE 60'/'20 1:10 BD'Biosciences
! Hoescht'33342 45'/'37 1:1000 Invitrogen
anti!hu'CD41 PE 45'/'37 1:10 eBioscience
pS1943'MIIA ! 4'/'~16 1:100 Cell'Signaling
anti!hu'MIIA ! 4'/'~16 1:100 Cell'Signaling
anti!hu'MIIB ! 4'/'~16 1:100 Sigma
donkey'anti!rb' Alexa'488 60'/'20 1:400 Invitrogen
anti!hu'CD41 APC 60'/'20 1:100 Biolegend
! Hoescht'33342 5'/'20 1:10000 Invitrogen
anti!hu'CD41 APC 45'/'20 1:20 Biolegend
Glycophorin'A PE 45'/'20 1:20 Biolegend
! Hoescht'33342 45'/'20 1:2500 Invitrogen
Tyrode's'+'
PGE1'
(1:1000)
Rheometry'
&'PLP'
Generation
1%'BSA
Micropipette'
Aspiration
3%'BSA'+'
0.05%'
Tween!20
Proplatelet'
Imaging
Tyrode's'
Proplatelet'
Flow'
Cytometry
Tyrode's'+'PGE1'
(1:1000)'+'Ca
2+'
(1mM)
Functional'
Characterization'
of'MEG!01'
Derived'PLPs
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Table 3.S1. List of antibodies used in Chapter 3 Methods 
Description of antibodies and incubation protocols employed for the noted experiments. 
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Figure 3.S1. Pharmacological inhibition of myosin increases megakaryocyte ploidy 
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Figure 3.S1. Pharmacological inhibition of myosin increases megakaryocyte ploidy 
(A) Increased ploidy of MEG-01 cells by blebbistatin treatment. Cells were treated with 
DMSO, 20 µM, or 50 µM blebbistatin for 72 hrs followed by staining with Hoescht 
33342 and analysis by flow cytometry. Raw data (left) is characterized by the histogram 
(right). Blebbistatin results in ~3 fold increase in 4n cells and >20 fold increase in higher 
ploidy (≥8n) cells (n=15, *P<0.005). Since MII activities affect cytokinesis, we proposed 
a scheme in which MII inhibition by blebbistatin would increase higher ploidy MKs. 
When MEG-01 cells were treated with blebbistatin for 72 hours we observed 4N and ≥8N 
populations increased at the expense of the 2N population without effecting total MK 
numbers in a dose dependent manner as seen by flow cytometry (Figure S1A). 
Quantitatively, 4N populations increased ~3-fold while 8N populations increased >20 
fold (Figure 3.S1B). These results are in agreement with those we previously shown with 
blebbistatin treatment of CD34+ derived cultures (Shin, 2011). 
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Figure 3.S2. Phosphorylation of resting fresh human platelets 
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Figure 3.S2. Phosphorylation of resting fresh human platelets 
(A) Fresh human platelets were analyzed with flow cytometry and gated on CD41 for 
either total MIIA (left), or pS1943 MIIA (middle). The histogram illustrates the resultant 
distribution of total MIIA or pS1943 MIIA and the mean of each distribution is captured 
by the vertical lines (A, right). (B) Individual events were analyzed. Bins were created to 
include equal number of events per bin. The linear fit of total MIIA: y=2.4x+19, R2=0.99. 
Linear fit of pS1943 MIIA: y=0.2x-0.9, R2=0.99. (C) The ratio of pS1943 to total MIIA 
was calculated by dividing the linear fits from panel B. The fit: y=[0.1x/(8+x)]-0.05, 
R2=0.99, <pS1943/MIIA> = 0.06.  
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Figure 3.S3. MIIA activity impacts localization and MEG-01 membrane stiffness 
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Figure 3.S3. MIIA activity impacts localization and MEG-01 membrane stiffness 
(A) Representative fluorescent micrographs of nucleofected MEG-01 cells during 
micropipette aspiration. All scale bars = 10 µm.  GFP-WT MIIA shows accumulation at 
the tip, GFP-S1943D MIIA shows uniform distribution along the aspirated length, GFP-
S1943A MIIA shows depletion at the tip.  (B) Treatment with blebbistatin recovers a 
uniform distribution regardless of construct (n>10, ±SEM, *P<0.05, statistical 
significance determined between ±blebbistatin for a given construct at a given time 
point). (C) MEG-01 membrane stiffness is affected by introduction of GFP tagged MIIA 
constructs by nucleofection. Cells phosphomimetic introduced with the phosphomimetic 
S1943D mutant show a similar membrane softening as is seen by pharmacological 
treatment of untransfected cells with blebbistatin (D) (N>25 cells, ±SEM).  
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Figure 3.S4. Effect of MYH9-RD on fragmentation size 
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Figure 3.S4. Effect of MYH9-RD on fragmentation size 
(A) Fragment volume is not affected by blebbistatin; however, blebbistatin treatment 
facilitates fragmentation of smaller fragments from smaller radius pipettes. Pink shaded 
region denotes calculated range of volume from reported normal human platelet 
diameters. Gray shaded region denotes calculated range of volume from reported 
preplatelet diameters (Thon et al., 2012). Both shaded regions calculated using reported 
diameters and assuming ellipsoid shape. Linear fit of 20 µM Blebbistatin: y=84x-68 
(R2=0.9956, n<40, ±SEM). DMSO: n>6, ±SEM. (B) Fragmentation of MEG-01 cells 
following introduction of either S1114P or E1841K GFP-MIIA. MYH9-RD mutation 
does not significantly impact either fragment area (B) nor fragment volume (C) compared 
to DMSO treated MEG-01 (dashed line) (N≥10, ±SEM). 
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Figure 3.S5. Visualization of MYH9-RD induced myosin aggregates 
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Figure 3.S5. Visualization of MYH9-RD induced myosin aggregates 
(A) Nucleofection was used to introduce GFP-MIIA constructs in A549 cells. These cells 
were used for imaging instead of spherical MEG-01 because the highly adherent A549 
cells are generally well spread and thus easier to focus on all aggregates for quantitation. 
Immunofluorescence reveals abnormal MII aggregates that are enriched in exogenous 
MII compared to surrounding cytoplasm (scale bar = 10 µm). (B) Total MIIA 
overexpression in GFP+ is ~1.7x relative to GFP- cells (N=15, ±SEM). (C) Quantitation 
of cells displaying MII aggregates (N≥30, *P<0.05). (D) Exogenous MII is seen to 
accumulate in aggregates compared to the surrounding cytoplasm while total MII 
(exogenous + endogenous) is similarly present in both aggregates and cytoplasm (N≥65, 
±SEM, *P<0.05). 
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CHAPTER 4: IgG TREATMENT TO STIMULATE PHAGOCYTOSIS OF 
CD47LOW SOLID TUMORS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter represents work included in the manuscript – Selective phagocytosis of 
CD47low human cells in solid tumors following systemic injection of anti-human IgGs. 
(Spinler KR, Tewari M, Athirasala A, Nair P, and Discher DE. 2014, in preparation).  
 
 
Manorama Tewari  and Avathamsa Athirasala both contributed to cell line generation. 
Praful Nair generated paclitaxel loaded polymer worms and assayed in vitro cytotoxicity.   
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ABSTRACT 
 CD47 is expressed to varying extent on all viable human cells and interacts with 
phagocytes to provide a “don’t eat me” signal that is now being explored in numerous 
cancer contexts. We studied human-CD47 (hCD47) knockdown cells that stably express 
tdTomato in solid tumor xenografts in NSG mice. NSG macrophages are known to 
recognize hCD47 as ‘self’.  While partial knockdown had no effect on tumor growth, 
deep knockdown increased growth except when knockdown cells were grafted as mosaic 
tumors with a minor fraction of wildtype GFP+ tumor cells. All tumors containing 
knockdown cells shrunk significantly after systemic injection of IgG that was broadly 
generated against human molecules. Importantly, IgG treatments selectively cleared 
knockdown cells based on flow cytometry analyses of excised tumors. When treatment 
was stopped, tumors re-grew unless treated again. Shrinkage proved similar in kinetics 
and extent to that achieved with paclitaxel chemotherapy, and co-administration of IgG 
and drug showed little to no synergy. Injected antibody did not cause significant anemia, 
thrombocytopenia, nor weight loss, and levels of hCD47 on tumor periphery or core 
subpopulations were unaffected. While injected IgG was detected on both human and 
mouse cells from the tumors – including macrophages – circulating cells were not 
opsonized. Importantly, a significant fraction of the IgG+ macrophages from hCD47-
knockdown tumors were also tdTomato+, consistent with phagocytosis of tumor cells or 
fragments. Besides implications for therapy, the results suggest a selective pressure 
against hCD47low cells that could account for the oft-reported upregulation of hCD47 in 
cancer.  
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3.1 INTRODUCTION 
 CD47 is a cell surface glycoprotein that was originally described as a highly 
expressed ovarian carcinoma antigen (OA3) (Campbell et al., 1992). It is now known to 
interact with SIRPα on phagocytes to provide a “don’t eat me” signal and thus act as a 
“marker of self” (Oldenborg, 2000). The CD47-SIRPα interaction leads to tyrosine 
phosphatase activation and inhibition of MII accumulation at the phagocytic synapse 
(Tsai and Discher, 2008). Red blood cells (RBCs) from CD47 knockout mice injected 
into control mice are cleared within hours by macrophages compared to weeks for normal 
RBCs (Oldenborg, 2000). Conversely, we have recently demonstrated that a minimal 
peptide designed from human CD47 delays phagocytic-mediated clearance from murine 
circulation when attached to a range of nanosized particles (Rodriguez et al., 2013). 
Macrophages from non-obese diabetic/severe combined immunodeficient (NOD/SCID) 
mouse strains express a SIRPα variant that is capable of cross-reacting with human 
CD47. This cross-reactivity explains the success of human hematopoietic grafts in such 
mice compared to other strains (Strowig et al., 2011; Takenaka et al., 2007). While CD47 
is nearly ubiquitously expressed on human cells (Reinhold et al., 1995), it has shown to 
be expressed at elevated levels in circulating stem cells (Jaiswal et al., 2009), liquid 
(Chao et al., 2010a, 2011a; Majeti et al., 2009), and solid tumors (Willingham et al., 
2012). In fact, increased CD47 mRNA expression has shown a correlation with a poor 
clinical prognosis in patients with acute myeloid leukemia (AML), non-Hodgkin’s 
lymphoma (NHL) (Chao et al., 2010a; Majeti et al., 2009), ovarian cancer, gliomas, and 
glioblastomas (Willingham et al., 2012). 
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Targeting the CD47-SIRPα pathway has currently been an active area of research. 
Murine models of leukemias (Chao et al., 2010a, 2011a; Majeti et al., 2009), myeloma 
(Kikuchi et al., 2005), and breast cancer (Manna and Frazier, 2004) have been 
successfully treated with anti-CD47 antibody. Since CD47 is expressed on nearly all 
cells, any treatment that involves an anti-CD47 antibody will not only opsonize cancer 
cells, but normal cells as well. Despite the potential for adverse side effects, mice 
engrafted with AML leukemic stem cells and treated with anti-CD47 (B6H12) antibody 
showed selective elimination of AML cells while sparing normal stem cells and did not 
show any abnormality in blood counts other than a slight neutropenia (Majeti et al., 
2009). Other CD47 targeting strategies have used liposome-protamine-hyaluronic acid 
(LPH) nanoparticles loaded with siRNA against CD47  (LPH(CD47)) to inhibit tumor 
growth and metastasis without hematopoietic toxicity (Wang et al., 2013). Use of 
liposomal clodronate to deplete macrophages resulted in significant diminishing of 
treatment efficacy implicating phagocytosis by macrophages as the process of tumor 
clearance in each of the preceding methods (Majeti et al., 2009; Wang et al., 2013). The 
selectivity of CD47-SIRPα interaction led to the observation that cancer cells express 
calreticulin (CRT), a pro-phagocytic signal (Gardai et al., 2005), while normal cells do 
not (Chao et al., 2010b). Thus, it seems that in addition to blocking the “don’t eat me” 
signal by disrupting the CD47-SIRPα interaction, an “eat me” signal is also needed to 
stimulate macrophages to eat. Others have approached the CD47-SIRPα interaction from 
the opposite end, by engineering a high-affinity SIRPα variant to out compete native 
SIRPα for CD47 binding (Weiskopf et al., 2013). 
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Recent advances in clinical cancer treatment have seen the development of new 
treatment strategies centered on co-administration of traditional chemotherapeutic drugs 
with cancer specific-monoclonal antibodies. The efficacy of treatment of hematopoietic 
malignancies have particularly been improved (Dougan and Dranoff, 2009) including the 
addition of the anti-CD20 antibody (rituximab) to chemotherapy to improve long-term 
prognosis of B cell lymphomas (Molina, 2008), NHL (Coiffier et al., 2002; Hallek et al., 
2010), and chronic lymphocytic leukemia (CLL) (Wendtner et al., 2004). The 
improvement in efficacy of treatment is a result of tumor opsonized antibody engagement 
of the Fc-receptor (FcR) of NK cells (Clynes et al., 2000) or macrophages (Minard-Colin 
et al., 2008) in a process known as antibody-dependent cell-mediated cytotoxicity 
(ADCC). A recent study using an inducible mouse model of B cell lymphoma has 
demonstrated that treatment with the anti-CD52 antibody, alemtuzumab, is efficacious 
only when administrated as the full length antibody and not as a F(ab’)2 fragment which 
lacks its Fc portion (Pallasch et al., 2014). This study confirms that alemtuzumab, in 
particular, and immunotherapeutic monoclonal antibodies in general, exert an antitumor 
activity not by binding to the cancer cell, but by recruiting effector cells that possess the 
FcR.  
These chemo-immunotherapy strategies have also been combined with CD47 
therapy to block a negative phagocytic signal while simultaneously delivering a 
prophagocytic signal. A combination of anti-CD47 antibody plus rituximab has shown 
synergistic elimination in NHL xenografts in mice (Chao et al., 2010a). The anti-
Her2/Neu antibody trastuzumab has been used in combination with a high affinity SIRPα 
variant to show dramatic shrinking of human breast tumors xenografts in mice (Weiskopf 
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et al., 2013). Additionally, CD47 blocking plus administration of macrophage stimulating 
cytokines, M-CSF and GM-CSF, has shown anti-tumor activity in a variety of tumor 
settings (Hernandez-Ilizaliturri et al., 2005; Sanda et al., 1992; Stockmeyer et al., 1997; 
Valerius et al., 1993). Finally, co-administration of anti-CD47 strategies with chemo-
radiation therapy has shown to increase infiltrating macrophages at tumor sites (Funada et 
al., 2003; Le et al., 2007; Welsh et al., 2005). 
Our recent work using a minimal peptide designed from human CD47 
demonstrating the abrogation of phagocytosis has led to the current investigation. Here 
we solid tumor model displaying a stable, near complete knockdown of CD47. 
Xenografts of CD47 kd tumors in NSG mice show responsiveness to treatment with 
polyclonal antibodies while tumors displaying normal CD47 levels do not respond to 
treatment. We also demonstrate that antibody treatment stimulates macrophage clearance 
of low CD47 expressing cells, but treatment does not significantly alter CD47 expression 
of tumor cells. Furthermore, combined treatment with antibody and paclitaxel shows 
similar tumor shrinking.    
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4.2 MATERIALS AND METHODS 
 
Materials For washing or antibody staining of cells, PBS without Ca2+ or Mg2+ 
(Invitrogen) was supplemented with 2% FBS (Invitrogen). For cell culture, Ham’s F-12 
growth media, penicillin-streptomycin, and FBS were all purchased from Invitrogen. For 
flow cytometry, 7-Amino-actinomycin D (7-AAD) was purchased from Sigma and 
Hoeschst 33342 was purchased from Invitrogen.  
 
Antibodies Primary antibodies used for flow cytometry, and imaging include anti-
human CD41-FITC (Biolegend), CD47(B6H12)-APC (Biolegend), CD47(B6H12)-
AF647 (BD Pharmingen), CD235a-PE (Biolegend). Primary anti-mouse F4/80-APC/Cy7 
(Biolegend), CD11b-PE/Cy7 (Biolegend).  Secondary antibodies include donkey anti-
rabbit Alexa 488 (Invitrogen), or donkey anti-rabbit Alexa 647 (Invitrogen). 
 
Development of Human CD47-KD Cell Lines A549 cells originally obtained from 
ATCC were previously made to stably express tdTomato (Harada et al., 2014) and 
cultured in Ham’s F-12 growth media supplemented with 10% FBS and 1% penicillin-
streptomycin. Stable CD47-KD cell lines were established using a standard transduction 
protocol. Briefly, human CD47 short-hairpin RNA (shRNA) lentiviral transduction 
particles (#NM_00177) were purchased from Sigma. tdTomato-A549 cells were 
transduced with viral particles and stable clones were generated by puromycin selection. 
The CD47 knockdown efficiency was determined by antibody staining (B6H12) using 
flow cytometry. Two stable A549 cell lines were selected based on CD47 knockdown 
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efficiency. The KD+ cell line (#TRCN0000007837) was further refined by successive 
rounds of flow sorting to establish a 90% CD47 knockdown (CD47 KD++). The WT Scr 
cell line (#TRCN0000007835) was chosen as it displayed a level of CD47 expression 
similar to that of untransduced cells and was thus effectively used as a WT Scramble 
control. WT Scr cells were further transduced with green fluorescent protein (GFP)-
lentiviral particles to obtain a genetically engineered cell line stably expressing GFP 
(wildtype (WT) GFP (Scr)). GFP expressing cells were selected using flow sorting to 
obtain a highly pure population of GFP+ WT Scr cells.  
 
Immunofluorescence A549 cells were seeded on 18 mm2 circular microscope cover 
slips in a 6 well plate and allowed to adhere overnight in F-12 growth media 
supplemented with 10% FBS and 1% antibiotics. Cells were briefly fixed with 4% 
paraformaldehyde for 5 min at RT followed by three PBS washes. Next, cells were 
blocked using 3% BSA + 0.05% Tween-20 followed by antibody incubation in blocking 
buffer. Primary antibodies were used at 1:100 and incubated for 1 hr at RT. After 
incubation, cells were washed three times with PBS. All donkey secondary antibodies 
(Alexa Fluor 488 and 647) were stained for 1 hr at RT at 1:400 dilution in PBS. Hoescht 
33342 was used to stain DNA at 1 µg/mL for 5 minutes at RT. Cover slips were washed a 
final three times with PBS before mounting on slides using ProLong Gold Antifade 
Reagent (Life Technologies), sealed with nail polish, and cured for 24 hours before 
imaging Images were acquired using an Olympus IX71 inverted microscope with a 300W 
Xenon lamp illumination using 40x, 60x, or 150x objectives with or without 1.6x 
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multiplication. Further image analysis was done using ImageJ (National Institutes of 
Health).  
 
Flow Cytometry of In Vitro Cultured Cells A549 cells were dissociated using 10 mM 
EDTA in PBS, washed, and resuspended in 2% FBS in PBS. Antibody (B6H12-AF647 
1:50) incubation was done at RT for 1 hr followed by washing and resuspension in 2% 
FBS. Samples were run on a BD LSRII.  
 
Establishment of A549 tumors In Vivo CD47 knockdown and control cells were 
dissociated from tissue culture flasks using 10 mM EDTA in PBS. 106 cells per injection 
were suspended in 100 µL ice cold PBS and 25% Matrigel (BD) and injected 
subcutaneously in the flank of non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice with null expression of interleukin-2 receptor gamma chain (NSG 
mice). Mice were obtained from the University of Pennsylvania Stem Cell and Xenograft 
Core. All animal experiments were planned and performed according to IACUC 
protocols. 
 
In Vivo Tumor Imaging Mice were anesthetized via inhalation of isoflurane at 3 L/min 
and maintained at 1.5 L/min. Imaging was acquired using a Perkin Elmer IVIS Spectrum 
with excitation and emission filters set at 535 nm and 580 nm respectively optimized for 
tdTomato imaging. Images of each face of the sagittal were taken to capture both left and 
right flanks.  
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Antibody Treatment Mice were warmed under heat lamp prior to tail vein injection to 
dilate vein. Rabbit anti-human red blood cell (anti-hRBC) (Rockland Immunochemicals) 
was reconstituted per manufacturers direction and further diluted using sterile PBS. Mice 
were injected with 600 µg / animal (~20 mg/kg) twice a week. Anti-human IgG (H+L) 
(Sigma Aldrich) was injected at 8 µg / animal (~0.3 mg/kg) daily for one week.  
 
Generation of Drug Loaded Polymer Worms Polyethyleneoxide (PEO) -
Polybenzylcaprolactone (PBCL) diblock copolymer was obtained from Alberta Research 
Chemicals Inc. (ARCI), Edmonton, AB, Canada. Aggregates were formed in water by 
solvent evaporation of the copolymer dissolved in chloroform with the final 
concentration of polymer in water being 30 mg/ml. The aggregates were mixed with PKH 
26 hydrophobic red dye, and morphology confirmed by imaging using an Olympus IX71 
microscope with a 60x objective (oil, 1.25 NA) and Cascade CCD camera (Photometrics, 
Tuscon, AZ). Paclitaxel dissolved in methanol, and was added to the aggregates at a 
concentration of 30 µg of drug per mg of polymer in dispersion. The mixture was stirred 
overnight, and the unincorporated drug was removed by dialyzing using a Slide-A-Lyzer 
Dialysis cassette with a Molecular Weight Cut-Off (MWCO) of 3000 (Thermo 
Scientific). The dialyzed mixture was centrifuged at 2000 rpm for 8 minutes prior to 
injection. The drug loading was measured via Shimadzu prominence HPLC (High 
Performance Liquid Chromatography) with Pinnacle DBC18 Column (4.6x150 mm, 5 
µm particles). In vitro cytotoxicity was assayed as described in Cai et al., 2007. 
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Ex Vivo Tumor Flow Cytometry Analysis On the day of analysis mice belonging to the 
treatment cohort were injected with the standard antibody dose as described above. Mice 
were euthanized 1.5-2 hours following injection by cervical dislocation. Tumors and 
spleens were removed, placed in 20% FBS, and tumor core and periphery tissue was 
segregated. Tumor tissue was cut into 1-3 mm pieces, transferred to 15 mL centrifuge 
tubes and spun to remove media. Tissue was then resuspended in 3 mL warm Dispase 
(STEMCELL Technologies) supplemented with 3 mg/mL Collagenase (Sigma) and 200 
uL of 1 mg/mL DNAse I (Roche). Samples were pipetted for 1-3 minutes until cloudy, 
but not stringy. Dissociation was quenched by addition of 10 mL room temperature PBS 
and suspension was filtered using a 70 µm cell strainer. Filtrate was spun, supernatant 
discarded, and pellet resuspended in 2% FBS for antibody incubation. Spleens were 
prepared by mechanical dissociation, filtration, and RBC lysis using Red Cell Lysing 
Buffer (Sigma). Lysed samples were washed and resuspended in 2% FBS for antibody 
incubation.  
 Prior to antibody incubation samples were blocked with Fc Block (BD 
Pharmingen) (1:500) for at least 5 min at room temperature (RT). CD47-AF647 (1:25), 
donkey anti-rabbit AF488 or AF700 (1:400), F4/80 APC-Cy7 (3:50), CD11b PE-Cy7 
(1:25), and Hoescht 33342 (1:1250) were incubated at RT for 1 hr. After incubation, cells 
were washed and resuspended in 2% FBS.  
 Additionally, RBC samples were prepared each day flow cytometry was done as 
an internal calibration and normalization standard.   
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4.3 RESULTS 
Antibody Stimulated Tumor Shrinking is Dependent on CD47 Expression 
We previously established a human lung cancer cell line expressing the fluorescent 
protein, tdTomato (Harada et al., 2014). Transduction and antibiotic selection resulted in 
both a stable “scramble” tdTomato-A549 (WT Scr) cell line and a stable CD47 
knockdown tdTomato-A549 (CD47 KD) cell line. Approximately 60% knockdown was 
confirmed by immunofluorescence (Fig. 4.S1A, right). Both WT Scr and CD47 KD were 
used in a preliminary in vivo study in which subcutaneous xenograft tumors were grown 
on each flank of NSG mice. Tumor progression was monitored in this and all subsequent 
in vivo studies by live animal imaging to detect tdTomato fluorescence. No significant 
difference in tumor growth rate was observed between WT Scr and CD47 KD (Fig. 
4.S1B). Motivated by recent work showing tumor shrinking by blocking the CD47-
SIRPα interaction by injection of a high affinity SIRPα variant in combination with a 
chemotherapeutic antibody (Weiskopf 2014) and the well established use of Rho(D) 
antibodies in suppression of isoimmunization, we hypothesized that any opsonizing 
antibody could be used in combination with CD47-SIRPα disruption. Indeed, when mice 
bearing CD47 KD xenograft tumors are treated with anti-human IgG antibody, tumors 
shrink to ~60% of the size at treatment initiation by 7 days (Fig. 4.S1C). We further 
enriched our CD47 KD cell line by 2 rounds of cell sorting to purify for CD47 
knockdown cells (CD47 KD+) and confirmed by flow cytometry (Fig. 4.S2C). 
Subcutaneous xenograft tumors grown on the flank of NSG mice show no significant 
difference in growth rate between WT Scr and CD47 KD+ (Fig. 4.1A). To show that 
antibody-mediated tumor shrinking of CD47 knockdown tumors is truly independent of 
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one particular antibody, we treated mice with an anti-human RBC antibody (Ab) that is 
the purified IgG fraction from antiserum. Ab binding to A549’s was confirmed by 
immunofluorescence (Fig. 4.1C). Nearly 50% reduction in tumor size was observed after 
4 weeks of biweekly treatment (Fig. 4.1B). The highest dosage of Ab is equivalent to 
~20% of serum IgG levels in fully immunocopetent C57BL/6 mice (Klein-Schneegans et 
al., 1989) and ~150% of serum IgG levels reported for humanized NSG mice (Rajesh et 
al., 2010) (Table 4.1). When antibody treatment is discontinued, tumors continue 
growing at a similar rate as observed prior to treatment and independent of CD47 
expression (Fig. 4.1A, B). Surprisingly, after this period of uninterrupted regrowth, 
reapplication of antibody is again capable of shrinking CD47 KD+ tumors (Fig. 4.1B) 
with similar apparent kinetics as the first round of treatment.  
Although the CD47 KD+ had been cell sorted it still contained a small 
subpopulation of cells expressing normal levels of CD47. To determine that it is truly the 
low CD47 cells that are being cleared, we furthered enriched the CD47 KD+ cell line by 
additional cell sorting (CD47 KD++) and also transfected the WT Scr cell line with GFP 
(GFP WT Scr). Flow cytometry confirmed GFP expression and CD47 KD++ knockdown 
of 93% (Fig. 4.S5B). Despite multiple rounds of cell sorting, the CD47 KD++ cell line 
still contained a minor population expressing normal CD47 levels, but this was 
determined to be minor (~10%) and distinct (by flow cytometry) from the CD47-low 
“true CD47 knockdown” majority. NSG mice were split into the following 3 cohorts: 1) 
WT GFP Scr, 2) CD47 KD++, 3) Mosaic (WT GFP Scr/CD47 KD++ injected 1:3). The 
mosaic tumors were subsequently determined to be comprised of a 1:2.7 ratio of WT 
GFP Scr : CD47 KD++ by flow cytometry (Fig. 4.1E and 4.S5B). Xenografts were again 
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grown subcutaneously on each flank. CD47 KD++ tumors showed an enhanced growth 
rate compared to tumors containing WT CD47 expression levels (Fig. 4.1D) perhaps 
consistent with previous observation of the loss of thrombospondin-1 signaling through 
CD47 increasing stemness (Kaur et al., 2013). Mosaic tumors treated with Ab showed a 
slightly enhanced responsiveness as CD47 KD+ reached a 40% reduction in tumor size by 
10 days following biweekly dosing (Fig. 4.1E). Tumors excised from euthanized mice at 
the termination of treatment show an inversion of GFP+ : GFP- ratio (Fig. 4.1F). The 
initial ratio of 1:2.7 was not significantly changed in untreated mosaic tumors while the 
antibody treated mosaic tumor ratio was 3.3:1 indicating that tumor shrinking was due to 
selective clearance of GFP- CD47 KD++ cells.  
 
Antibody Treatment Is Not Accompanied by Adverse Hematologic Side Effects 
Several previous studies disrupting the CD47- SIRPα interaction in mice by treatment 
with anti-CD47 antibody (see Willingham 2012) or a high affinity SIRPα variant-human 
IgG fusion (Weiskopf 2013) showed significant loss of RBCs and development of 
chronic anemia. Animals treated with Ab do not show a loss of weight, as is common 
with chemotherapeutic strategies, and in fact most treated animals gained weight 
throughout the study (Fig. 4.2A, 4.S2F). Contrary to these other similar approaches, our 
treatment strategy does not significantly affect PB cells. Platelet counts remain relatively 
unchanged, however, there is a slight insignificant reduction in hematocrit following 
antibody treatment (Fig. 4.2B). These trends in cell number reduction are mirrored by the 
tendency of antibody opsonization of RBCs and platelets (Fig. 4.2C). In vitro binding of 
Ab to mouse RBCs (mRBC), human RBCs (hRBCs), or MEG-01 (a human 
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megakaryocytic cell line) showed that the affinity of antibody for mRBC is ~300 µM 
(Fig. 4.S2A,B), which is ~10-4 weaker than for human cells. Despite this dramatically 
reduced affinity, local concentrations of Ab at the injection site could briefly approximate 
the affinity for mRBC, thereby opsonizing a fraction of mRBC that could explain the 
slight reduction in observed hematocrit.  
 
Antibody Treatment as Efficacious as Chemotherapy in CD47 Knockdown Tumors  
Recent clinical advances using a combination therapy comprised of a highly specific 
monoclonal antibody, such as rituximab, with chemotherapy (see for example Coiiffier 
2002 or Hallek 2010) motivated the addition of the front-line chemotherapeutic paclitaxel 
with Ab treatment. Our group has shown that paclitaxel (Tax) loaded polymer 
filomicelles are capable of shrinking A549 and U251 xenograft tumors in the flank of 
mice (Baumann et al., 2013; Christian et al., 2009). Leveraging our polymer expertise, 
we generated Tax loaded filomicelles capable of killing A549 cell in vitro regardless of 
CD47 expression (Fig. 4.3B) as also evident by similar Hill Coefficients for each cell 
type (Fig. 4.S3A). Cytotoxicity was quantified using the MTT assay described in Cai et 
al (Cai et al., 2007). As expected, CD47 KD++ tumors responded to either Ab alone or Ab 
+ Tax while normal CD47 tumors responded to combination treatment only (Fig. 4.3A, 
4.S3D). Tumor shrinking by Tax displayed similar rate and magnitude of shrinking as we 
previously reported (Christian et al., 2009). While the addition of chemotherapy to 
antibody treatment was not synergistic, there was a slight additive effect, but this 
additional response was not significantly different than Ab treatment alone. HPLC 
quantification of Tax concentration in filomicelles revealed that the average Tax dose 
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delivered was ~4.4 mg/kg (Fig. 4.S3B). Addition of Tax to the antibody treatment 
resulted in further reduction in hematocrit and a slight elevation in thrombocrit (Fig. 
4.3C) without significantly altering antibody binding (Fig. 4.3D). None of the mice from 
any treatment arm experience weight loss during the treatment period (Fig. 4.S3C), but a 
slight reduction in CD11b+ leukocytes was observed upon application of Tax (Fig. 4.3E). 
These results indicate that similar tumor shrinking can be achieved by CD47-SIRPα 
disruption and antibody rather than a chemotherapeutic approach. 
 
Antibody Treatment Shrinks Tumors by Macrophage Phagocytosis of CD47 
Knockdown Cells 
At the completion of each treatment regimen, mice were euthanized, xenograft tumors 
removed, and when possible, core and periphery tumor tissue kept separated, and 
analyzed by flow cytometry (Fig. 4.4A). Flow cytometry of tumor tissue showed similar 
CD47 expression levels regardless of antibody treatment (Fig. 4.4B). GFP expression in 
the mosaic tumors helped in determining a more granular view of CD47 expression and 
this strategy again revealed similar CD47 levels between untreated and Ab treated within 
a specific population. A closer examination of the CD47 surface density on the A549 
tumor cells, reveals that each knockdown cell type displayed <200 molecules/µm2 at the 
time of tumor inoculation (Table 4.2). Even these values are likely conservative 
overestimates resulting from an underestimate of A549 surface area determined by 
imaging well spread cells.   Periphery and core tumor tissue were similarly opsonized and 
this level of opsonization was matched in mouse stromal cells (Fig. 4.4D). Likewise, 
mature macrophages in tumor core and periphery showed bound Ab, however the level of 
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Ab binding to macrophage was much higher than in either tumor or stromal tissue, and 
macrophages of the periphery had slightly more bound Ab than those of the core. Tissue 
from mice used in the mosaic tumor studies recapitulated the trends in Ab binding 
showing similar levels in tumor xenograft and mouse stroma accompanied by a higher 
level in tumor and splenic macrophages. Additionally, Ab likewise bound macrophages 
in the PB. These data provide evidence of a direct interaction of the antibody with 
macrophages and that macrophages in the circulation retain and/or bind antibody. 
Analysis of total macrophage numbers as a percent of total mouse cells within a given 
tissue reveal significantly higher numbers of mature macrophages and that neither 
subpopulation significantly changes by antibody treatment (Fig. 4.4F, left). Addition of 
Tax to antibody treatment showed similar macrophage numbers in CD47 KD++ and 
spleen (Fig. 4.4F, right) compared to CD47 KD+ and mosaic studies. However, the 
number of mature macrophages found in WT Scr tumors is elevated with Tax perhaps a 
response to chemotherapeutic induced tumor apoptosis. 
We next wanted to see whether Ab binding to macrophage was providing a 
phagocytic stimulus. To do this, macrophages were analyzed by flow cytometry using a 
modified gating scheme (Fig. 4.S4A) that has been previously published (Rose et al., 
2012). This method allows discrimination between immature (CD11b+F4/80intermediate) 
and mature (CD11b+F4/80hi) macrophages. In general, the immature macrophage 
subpopulation had much less Ab bound and was very infrequently tdTomato+ (Fig. 
4.S4D, E, 4.S5D, E). Mature macrophages from untreated mice were infrequently 
tdTomato+, but mature macrophages from treated animals showed a drastic increase in 
tdTomato, treatment antibody, or both (Fig. 4.5A). Macrophages that were tdTomato- 
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from the CD47 KD+ study were equally Ab bound regardless of tissue source (Fig. 4.5B, 
right), however, tdTomato+ macrophages showed a marked increase when bound to 
antibody and such macrophages were more frequent from CD47 KD+ tumors (Fig. 4.5B, 
left; compare bars 2 & 4 with 8 & 10). Similar trends were seen from mosaic tumors. 
Specifically, treatment with antibody resulted in an increase in tdTomato+ in antibody 
bound macrophages (Fig. 4.5C). Addition of Tax to the antibody showed similar Ab 
binding to macrophage in the tdTomato- fraction (Fig. 4.5D, right; compare with Fig. 5B, 
right filled bars) and antibody treatment alone recapitulated the tdTomato+ Ab bound 
percentages seen in the CD47 KD+  study (compare Fig. 5D left, bars with black outline 
vs. Fig. 5B left, solid bars). Interestingly, supplementing antibody treatment with Tax 
resulted in an increase in tdTomato+ Ab bound macrophages compared to antibody alone 
for WT Scr and CD47 KD++ tumors (Fig. 4.5D, left; compare black outlined bars with 
bars without outline). The likely cause of such an increase may be due in part to an 
increase in CRT expression on chemotherapy induced apoptotic cells, which would 
provide an additional “eat me” signal. Such an increase has been reported in leukemic 
cells as soon as 72 hours following cyclophosphamide treatment (Pallasch et al., 2014) 
and shown to be sufficient to induce phagocytosis (Gardai et al., 2005). These results 
provide a mechanism of antibody mediated tumor clearance whereby disruption of the 
CD47-SIRPα, in this case by CD47 knockdown, provides a removal of the normally 
present “don’t eat me” signal, while antibody opsonization provides a phagocytic 
stimulation to mature macrophages effectively delivering an “eat me” signal. 
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Figure 4.1 In Vivo tumor growth and Ab treatment 
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Figure 4.1 In Vivo tumor growth and Ab treatment 
(A) In vivo growth curve of CD47 KD+ “deep knockdown” during 2 periods of no 
treatment. (WT Scr: n=4 mice, 8 tumors; CD47 KD+: n=6 mice, 12 tumors. Mean ± 
SEM). Slope of linear fit = 1.02 mm2/d corresponding to tumor growth rate (R2=0.99). 
(A, inset) Representative fluorescent overlays of untreated (left) and Ab-treated (right) 
mice at the end of the treatment period. (B) Tumor response to 200 and 600 µg Ab / 
mouse followed by removal of antibody and subsequent re-administration. (WT Scr ± 
Ab, CD47 KD+ - antibody: n=2 mice, 4 tumors; CD47 KD+ + antibody: n=4 mice, 8 
tumors. Mean ± SEM). (C) Immunofluorescence confirms Ab binding (left) to A549 in 
vitro compared to secondary antibody only control (right) (scale bar = 10 µm). Images 
have been adjusted to allow visualization of cells in control image. Bar graph below the 
images reflects true fluorescence of each unaltered image.  (D) CD47 KD+ cells were 
further sorted to generate CD47 KD++, an ultra-deep knockdown. Xenotransplants in 
NSG mouse flanks show a slight growth advantage for CD47 KD++ (linear fit slope = 
1.56 mm2/d, R2=0.99) compared to tumors comprised of WT GFP Scr either in part or in 
whole (linear fit slope = 1.02 mm2/d, R2=0.98). (WT GFP Scr: n=2 mice, 4 tumors; CD47 
KD++: n=2 mice, 4 tumors; Mosaic: n=6 mice, 12 tumors. ± SEM). (D, inset) Flow 
cytometry of cells used in xenotransplants. (gray=isotype; black=CD47 KD++; green 
dashed outline=WT GFP Scr; green fill=Mosaic) (E) Treatment of tumors shown in (A) 
with 600 µg Ab / mouse twice a week. Solid lines are corresponding linear fits with 
R2>0.97. Dashed line is fit of average of final three points each of which are insignificant 
from d 15. (* P<0.05, compared to previous data point, within a treatment arm. (WT GFP 
Scr, KD++, and Mosaic - antibody: n=2 mice, 4 tumors; CD47 KD+: n=2 mice, 4 tumors; 
Mosaic + antibody: n=4 mice, 8 tumors. Mean ± SEM). (F) Ratio of GFP-:GFP+ as 
determined by flow cytometry following removal of tumors from sacrificed mice. 
(Xenograft d0: n=9, 3 independent experiments done in triplicate; Untreated: n=4 tumors; 
Ab Treated: n=8 tumors. Mean ± SEM). Xenograft d0 was measured using cells reserved 
during xenotransplantation and subsequently measured by flow cytometry.  
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Table 4.1. Relative IgG Supplementation 
 
 
 
  
Total&IgG Inject&0.6&mg&IgG&Ab
mg/mL Blood&(mL)1 mg&IgG %&of&IgG
C57BL/62 1.5 2.4 3.6 17%
Humanized&NSG3 0.165 2.4 0.4 154%
300&ug&Rhogam
mg/mL L mg&IgG %&of&IgG
Hu&IgG 10 5 50000 0.0006%
For&30&g&mouse
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Table 4.1. Relative IgG Supplementation  
Calculated estimate of the IgG percent in immunocompetent mouse strains. Calculation 
assumes a 30 g mouse and 0.6 mg Ab injection. % of IgG is calculated as 0.6 mg injected 
Ab / total mg IgG * 100%. This value provides a magnitude of the Ab dosage for 
comparison with what is present in immuncompetent animals. Also as a comparison, a 
typical 300µg dose of Rhogam represents 0.0006% of total human IgG. Literature values: 
mouse blood volume1 from (Mitruka and Rowan, 1981), C57BL/6 IgG concentration2 
from (Klein-Schneegans et al., 1989) , humanized NSG IgG concentration3 from (Rajesh 
et al., 2010). 
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Figure 4.2 Ab treatment does not cause significant adverse side effects  
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Figure 4.2 Ab treatment does not cause significant adverse side effects  
(A) Weight throughout duration of study (including pre-treatment, treatment, and post-
treatment). Weight is normalized to weight at date of xenograft implantation. Mice used 
in Mosaic Study. (WT GFP Scr: n=2 mice; CD47 KD++: n=2 mice; Mosaic: n=2 mice; 
Mosaic+Ab: n=4 mice). WT GFP Scr, Mosaic, Mosaic+Ab are grouped together and the 
green solid line reflects the linear fit. CD47 KD++ mice show slightly different weight 
responses as shown by the black solid line. (B) Addition of antibody shows a slight 
decrease in hematocrit, but no change in thrombocrit. (n ≥ 2 per group. Mean ± SEM). 
(C) Minimal opsonization of annucleated PB cells. (n ≥ 2 per group. Mean ± SEM).   
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Figure 4.3 Combined ab + chemotherapy treatment of CD47 knockdown tumors 
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Figure 4.3 Combined Ab + chemotherapy treatment of CD47 knockdown tumors 
(A) Treatment with Ab is efficacious only for CD47 knockdown tumors (similar to Fig. 
1), but paclitaxel loaded polymer worms (TW) shrink tumors regardless of CD47 
expression level. Combining Ab, chemotherapy, and CD47 knockdown shows a slight 
enhancement in tumor responsiveness. Mice were treated 2 times per week (n=2 tumors 
per treatment arm. Mean ± SEM). (A) Quantification of in vitro cytotoxicity of paclitaxel 
loaded polymer worms against wild-type (WT) and knockdown (KD) A549 cells. Data fit 
with the following equation: CV% = A + B/(1+10((log(conc)-log(IC50)))). Fits 
summarized in Fig. S3A. (n=4 independent experiments, Mean ± SEM). (C) Addition of 
taxol to the treatment shows a slight decrease in hematocrit and a more significant 
increase in thrombocrit (n=2 per group. mean ± SEM). (D) Taxol does not significantly 
effect opsonization of anucleated PB cells (n=2 per group. Mean ± SEM). (E) Addition of 
Taxol to Ab treatment results in a slight reduction in CD11b+ leukocytes (n=2 per group. 
Mean ± SEM). 
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Figure 4.4 Ex vivo analysis of mouse tissue following treatment 
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Figure 4.4 Ex vivo analysis of mouse tissue following treatment 
(A) Schematic of method used to assess tumor tissue. Tumors are removed and when 
possible the periphery and core are prepared separately. Following dissociation and 
antibody incubation, samples are analyzed using flow cytometry. (B) Relative CD47 
expression (normalized by human RBC, average of at least triplicate) of various tumor 
types and specific location for CD47 KD+ study. (n ≥ 8 tumors per group. Mean ± SEM). 
(C) Relative CD47 expression, as in B, for specific populations as resolved by WT GFP 
Scr GFP expression (n ≥ 4 per group. Mean ± SEM). (D) Ab binding to various tissue 
types for CD47 KD+ study. Value represents the fraction of a given tissue type that is Ab+ 
per tissue. (n ≥ 10 tumors/spleens per group. Mean ± SEM). (E) Ab binding to various 
tissue types for Mosaic Tumor study. Value represents the fraction of a given tissue type 
that is Ab+ per tissue. (n ≥ 4 tumors, n ≥ 2 spleens per group. Mean ± SEM). (F) 
Quantification of both mature and immature macrophages as represented as the % of total 
non-human cells for the CD47 KD+ and Mosaic Study (left), and Taxol study (right) 
(*P<0.05). 
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Table 4.2 CD47 Cell surface density 
 
 
  
Area%(μm2) CD47%(norm) CD47/μm2 CD47%(norm) CD47/μm2
WT%Scr 5.00±0.04 463 5.5±0.2 509
CD47%KD+ 2.12±0.05 196 4.1±0.1 379
CD47%KD++ 1.26±0.04 117 2.37±0.07 219
GFP+,%CD47hi 6.20±0.02 574 3.9±0.2 361
GFP>,%CD47hi 4.73±0.03 438 2.7±0.2 250
GFP>,%CD47lo 0.41±0.05 38 0.66±0.03 61
hRBC 141±3.0 1.00 250
Engstrom51998 Tsai52008
In#Vitro In#Vivo
382
Mosaic
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Table 4.2 CD47 cell surface density 
In vitro (cells used for xenotransplant) and in vivo (cells recovered from excised tumors) 
CD47 surface density determined by flow cytometry and immunofluorescence. A549 cell 
area was determined by measuring area of well spread cells imaged by 
immunofluorescence. This value was multiplied by two assuming negligible height for 
well spread cells. We acknowledge that this method underestimates cell area and 
calculated values for CD47/µm2 are thus likely overestimates. CD47 intensity was 
determined by flow cytometry mean fluorescence intensity and normalized to human 
RBCs. Arrows indicate IgG treatment responsive cells. We previously reported a CD47 
surface density value for hRBCs (Tsai and Discher, 2008). Multiplying this value by the 
normalized CD47 intensity and scaling by the ratio of A549 area to hRBC area 
previously reported (Engström and Löfvenberg, 1998), results in the values presented in 
the table.  
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Figure 4.5 Assessment of phagocytic activity of mature macrophage subpopulation 
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Figure 4.5 Assessment of phagocytic activity of mature macrophage subpopulation 
(A) Representative flow cytometetry scatter plots of CD11b+F4/80hi populations 
depicting Ab binding (x-axis) and phagocytosis (y-axis, tdTomato+) for untreated (left) 
and Ab treated (right) tumor samples. (B) Breakdown of mature macrophage populations 
as the % of total mature macrophages either tdTomato+ (left) or tdTomato- (right) for 
CD47 KD+ study animals (n ≥ 5 tumors/spleens per group. Mean ± SEM). (C) 
Breakdown of mature macrophage populations as the % of total mature macrophages 
either tdTomato+ (left) or tdTomato- (right) for Mosaic Tumor study animals (n ≥ 4 
tumors/spleens per group. Mean ± SEM). (D) Breakdown of mature macrophage 
populations as the % of total mature macrophages either tdTomato+ (left) or tdTomato- 
(right) for Taxol study animals (n ≥ 4 tumors/spleens per group. Mean ± SEM). 
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4.4 DISCUSSION 
In this study, we provide a mechanistic view of ADCC amplified by the loss of CD47 
expression without adverse effects to anucleated PB cells. Compared with CD47 
knockdown tumors, growth of tumors displaying normal levels of CD47 was unaffected 
by antibody treatment. Additionally, treated tumors resume growing at rates similar to 
those before treatment and are responsive to reapplication of antibody after allowed to 
regrow to sizes similar to those at the onset of the initial treatment period (Fig. 4.1A). 
Response to the second round of treatment shows similar efficacy as the initial treatment 
period indicating the presence of an antibody responsive low CD47 expressing 
component. Treatment with IgG does not directly impact CD47 expression of tumor cells 
as seen by comparing tissue samples ex vivo (Fig. 4.4B, C). Flow cytometry of A549 
cells prior at the time of xenotransplant shows conservative estimates of CD47 surface 
density of knockdown cell types to be much lower (Table 4.2) than what we have 
previously reported for normal human RBCs (Tsai and Discher, 2008). Tsai and Discher 
also reported an inhibition constant of ~20 molecules/µm2 for human THP-1 cells 
phagocytosing human CD47 coated beads (Tsai and Discher, 2008). Considering that the 
values determined in Table 4.1 are likely overestimates and that the affinity of mouse 
SIRPα for human CD47 is likely less than that of human SIRPα for human CD47, the 
CD47 surface density of our knockdown cell agree remarkably well with the Ki 
determined by Tsai and Discher. 
Use of a mosaic tumor composed of GFP+ cells that have normal CD47 levels and 
CD47 knockdown GFP- cells support the view that antibody treatment is dependent on 
the disruption of the CD47-SIRPα interaction. Particularly, the GFP+ : GFP- ratio is 
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unchanged in the absence of Ab, but the ratio is inverted after Ab treatment (1:2.7 vs 
3.3:1, Fig. 4.1F). Surprisingly, we find that CD47 KD++ cells grow more rapidly than WT 
Scr cells (Fig. 4.1C) in vivo. The expression of the prophagocytic surface protein CRT 
has been shown to be highly correlated with CD47 expression for a number of cancers 
(Chao et al., 2010b) and provides a means of selective clearance when treated with anti-
CD47 antibody. It would thus seem that CD47 knockdown would tip the balance toward 
calreticulin, resulting in an increase in phagocytosis and limit or prevent tumor 
progression. The accelerated growth rate of CD 47 KD++ tumors in the present work 
could be a result of concomitant reduction in calreticulin following CD47 knockdown to 
maintain the WT calreticulin:CD47 ratio as has been seen in colorectal cancer (Steinert et 
al., 2014). Alternatively, high levels of calreticulin have been found to be a poor clinical 
prognostic in numerous malignancies (Chao et al., 2010b). Transfection of vasostatin, the 
N-terminal domain of calreticulin, results in downregulation of tumor suppressor genes 
including p53, nm23, Rb, and vinculin as well as enhancement of cell spreading, 
adhesion, and invasion (Liu et al., 2005). Each of these factors could be a driver in 
accelerating tumor growth. It is known that A549 cells have the capacity for some 
plasticity as they express key stem cell transcription factors (Teng et al., 2010), which we 
have confirmed (Fig. 4.S1D). CD47 loss from endothelial cells promotes stemness and 
proliferation with a role for altered adhesion (Kaur et al., 2013). Since the mosaic tumors 
show similar growth kinetics as WT Scr tumors, the mosaic tumors could, in principle, be 
dominated by the adhesive signaling of WT Scr cells which acts to repress stem-like 
proliferation. Combination of the chemotherapeutic drug paclitaxel with Ab treatment, 
while slightly additive, did not significantly improve CD47 knockdown tumor shrinking. 
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Interestingly, taxol treated tumors showed an increase in total mature macrophages at the 
expense of immature macrophages in the spleen (Fig. 4.4F) as well as an increase in 
phagocyotsing opsonized mature macrophages in the tumor (Fig. 4.5D). These results 
may be an effect of macrophage mobilization in response to a taxol induced 
inflammatory signal (Funada et al., 2003; Le et al., 2007; Welsh et al., 2005), or may be 
evidence of a larger effect of taxol on upstream hematopoiesis (Fig. 4.3C), as we also 
observe a slight increase in thrombocrit, decrease in hematocrit, and decrease in PB 
CD11b+ leukocytes (Fig. 4.3E) when mice are treated with taxol. Others have reported 
similar effects of taxol on hematopoiesis in which BFU-E and CFU-GM are drastically 
reduced by taxol in vitro, while CFU-Meg is only minimally effected (Pertusini et al., 
2001). Since taxol induces apoptosis by inhibition of microtubule depolymerization, it 
would be sensible that megakaryocytes, which normally divide without cytokinesis, 
would be less sensitive than other lineages.  
 Others have demonstrated macrophages to be the main effector responsible for 
tumor shrinking during CD47 targeted antibody treatment. Depletion of NK cells or 
complement was not shown to have an affect on tumor clearance, but depletion of 
macrophages did abrogate efficacy (Chao et al., 2010a). Further, with use of Fc truncated 
(F(ab’)2) anti-CD47 antibody or cancer targeted monoclonal F(ab’)2 it was shown that 
treatment with anti-CD47 antibody is FcR-independent, while synergistic phagocytosis is 
only observed with full length monoclonal antibody (Chao et al., 2010a; Pallasch et al., 
2014). These observations indicate opsonization of the tumor cell to be sufficient to 
overcome the CD47-SIRPα interaction in the case of the former, whereas the monoclonal 
antibody acts not through directly binding to the cancer cell, but through engagement of 
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the FcR on the macrophage. We also found that the antibody used to stimulate 
macrophage phagocytosis only needs to be capable of binding tumor cells. Both anti-
human IgG antibody and anti-hRBC antibody showed similar tumor shrinking capacity 
when treating CD47 knockdown tumors (Fig. 4.1B, 4.1E, 4.S1C). Clinical antibodies 
used to treat malignancies are, mostly, highly specific to an epitope upregulated in a 
specific cancer, but also present on normal cells resulting in opsonization of tumor and 
normal tissue and thus destruction of both. The ability to use any polyclonal antibody, as 
in the current work, could provide a cost effective means of treatment if combined with 
selective CD47 expression modulation.  
 Analysis of macrophages harvested from tumors and spleen provides insight into 
the mechanism of CD47 dependent ADCC. These data show mature macrophages to be 
much more highly bound by Ab than their immature brethren. These opsonized mature 
macrophages also show an increase in phagocytosis, as indicated by tdTomato+ by flow 
cytometry (Fig. 4.5B-D). Ab opsonizes human tumor and mouse stroma to a similar level 
(Fig. 4.4D & 4.4E), however no significant anemia, thrombocytopenia, or weight loss is 
observed (Fig. 4.2). With the observation that CD47-low expressing cells are selectively 
eliminated upon antibody treatment, the selective phagocytosis seems to come from a 
combination of suppression of a “don’t eat me” signal (CD47-SIRPα disruption) and the 
addition of an “eat me” signal (FcR engagement by opsonizing antibody).  
One of the limitations of many chemotherapeutic drugs is that they are large 
molecules dependent on the vasculature for delivery to the tumor. This limitation is 
particularly problematic in treating metastases of the brain, as the blood-brain barrier is 
notoriously difficult to traverse. Our laboratory has previously demonstrated this using 
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Tax-loaded polymer filomicelles. Subcutaneous flank tumors were responsive to 
treatment, but cranial xenograft tumors of the same cell type were not responsive 
(Baumann et al., 2013). Cell based means of tumor shrinking can avoid vascular 
dependence since, for example, macrophages are highly motile and capable of invading 
tissue. Despite the tumor core being undervascularized, and commonly necrotic, we see 
similar macrophage and tumor opsonization in core versus periphery, indicating that the 
antibody freely permeates the tumor, as well as similar numbers of phagocytic 
macrophages regardless of tumor site, supporting the view of macrophage invasiveness. 
Tumor-associated macrophages (TAMs) are known to polarize to either anti-tumor M1 
type or pro-angiogenic, and thus pro-tumor, M2 type (Condeelis and Pollard, 2006; 
Mantovani et al., 2002; Murdoch et al., 2008). Perhaps CD47 targeted antibody treatment 
may provide an environment that favors M1 programs.  
Crude polyclonal antibodies have been used for decades, most commonly in the 
suppression of Rh isoimmunization (e.g. (Moise and Argoti, 2012; Tiblad et al., 2013)). 
Products such as RhoGam, introduced in 1968, are initially given to Rh- women who are 
pregnant with their first Rh+ fetus immediately following a sensitizing event typically 
birth, but also including abortion, miscarriage, and ectopic pregnancy. Fetal RBCs cannot 
cross the placenta during development, but during the sensitizing event, Rh+ RBCs from 
the fetus enter the mother’s blood stream. Left unchecked the mother’s immune system 
will begin to make antibodies against the Rh+ RBCs. These antibodies are capable of 
crossing the placenta and could cause complication for each subsequent pregnancy of a 
Rh+ fetus ranging from jaundice and anemia to mental retardation and heart failure. 
RhoGam and similar Rh antibodies bind to fetal Rh+ RBCs and destroy them before the 
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mother’s immune system can start producing her own antibodies despite the dosage of 
IgG representing <1% of total IgG (Table 4.1). Recently, other products, such as 
WinRho (anti-D IgG), have found additional applications including the treatment of 
immune thrombocytopenic purpura (ITP) in Rh+ individuals. Anti-D IgG treatment 
causes a slight decrease in hematocrit and hemoglobin, but treatment is as effective as 
intravenous immunoglobulin thus proving to be a lower cost alternative (Celik et al., 
2013; O’Brien et al., 2007). The hemolytic side effects of anti-D IgG are similar to what 
is observed with administration of our antibody (Fig. 4.2B).  
Recent efforts have readdressed decades old methods of treating cancer with tumor-
derived vaccines. Anti-cancer vaccines in clinical trials (e.g. NCT01995227 and 
NCT00459069 per ClinicalTrials.gov) take advantage of a diversity of complex antigens 
as indicated by proteomic analyses of tumor-derived cells and/or lysates used for such 
vaccines (Mayer-Sonnenfeld et al., 2013). As a consequence, tumor cell sub-populations 
that down-regulate a particular antigen are likely to retain other antigens capable of 
attracting and antagonizing key immune cells, including macrophages, to attack the 
tumor. These broader approaches thus seem robust compared to single antigen 
approaches.   
Ultimately, this work motivates a potential extension wherein tumor CD47 expression 
is attenuated, perhaps by treatment with a CD47 siRNA followed shortly thereafter with a 
macrophage stimulating antibody. Such a scheme of CD47 siRNA delivery has already 
been shown to inhibit tumor growth and metastasis without systemic organ damage or 
anemia (Wang et al., 2013), but they did not treat established tumors nor did they infuse 
an antibody. Alternatively, recent work has shown the ability to generate a “probody” of 
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monoclonal antibody cetuximab (Desnoyers et al., 2013). Such a probody maintains the 
efficacy of cetuximab, but contains a protective linker that is cleaved by proteases 
typically found in abundance in the tumor microenvironment. It seems reasonable to 
propose a strategy wherein anti-CD47 antibody is generated with such protection, 
selectively binds tumor tissue, and then treated with a polyclonal opsonin. We thus have 
demonstrated a mechanism of macrophage stimulation and infiltration efficacious in the 
treatment of solid tumors in which the CD47-SIRPα interaction has been disrupted. 
Demonstration of the efficacy of a crude polyclonal antibody following CD47 expression 
reduction could open up a number of potentially cheaper, safer, and more efficient means 
of treating cancer.  
 
  
	   170	  
Figure 4.S1. Preliminary studies of CD47 knockdown in vitro and in vivo 
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Figure 4.S1. Preliminary studies of CD47 knockdown in vitro and in vivo 
(A) Quantification (left) of immunofluorescence (right) of WT Scr and CD47 KD 
tdTomato cells. (n≥40 cells per group. Scale bar = 10 µm) (B) In vivo growth curves of 
tdTomato xenografts in NSG flank. (n=2 mice, 4 tumors for all tumor types. Mean ± 
SEM) (C) Treatment of CD47 KD tumors from Fig. 4.S1C with polyclonal anti-human 
IgG antibody. (Treated: n=2 mice, 4 tumors; Untreated: n=3 mice, 6 tumors. *P<0.05 
within a cohort compared to the previous day. Mean ± SEM) (D) Western blot of A549 
cells for pluripotency markers Oct4 and Sox2.  
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Figure 4.S2. Anti-human RBC antibody binding and initial treatment study 
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Figure 4.S2. Anti-human RBC antibody binding and initial treatment study 
(A) Flow cytometry (gray=isotype control; black=MEG-01) of 67 nM Ab binding to 
MEG-01 cells. (B) Binding curve for Ab to human RBC (hRBC), mouse RBC (mRBC) 
and MEG-01 (a human megakaryocytic cell line). Fitting parameters indicate that when B 
is similar for mRBC and hRBC K for mRBC >> hRBC indicating weak affinity to 
mRBC. Mixing human and mouse RBCs did not effect binding to either species. Model: 
Y=A+B*X/(K+X); hRBC: A=80, B=35524, K=26.5nM, R2=0.97; mRBC: A=80, 
B=14210, K=323427nM, R2=0.22; MEG-01: A=80, B=262480, K=97nM, R2=0.99. (C) 
Quantification of CD47 following sorting to establish CD47 KD+. (D) Relative average 
intensity of opsonization by Ab for various cell types and location (tumor, peripheral 
blood, and spleen). Intensity normalized to MEG-01 calibration (n>11 per group, Mean ± 
SEM). (E) Scatter plot of individual CD47 KD+ treated tumors. (n=4 mice, 8 tumors). (F) 
Weight throughout treatment period. Weight is normalized to weight at date of treatment 
initiation. Mice used in CD47 KD+ study. 
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Figure 4.S3 Ab + taxol treatment cytotoxicity, animal monitoring, and 
tumor assessment  
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Figure 4.S3 Ab + taxol treatment cytotoxicity, animal monitoring, and 
tumor assessment  
(A) Fitting parameters from in vitro cytotoxicity assay. (B) Summary of taxol doses 
delivered. (C) Monitoring of animal weight during co-therapy does not show any 
significant weight loss. Weight normalized to weight at initiation of co-therapy. (D) 
Individual tumor response presented in Fig. 3A. (E) Relative CD47 expression, 
normalized by human RBC, for Taxol Study tumors (n = 2 per group. Mean ± SEM). (F) 
Opsonization of various tissue types by Ab for Taxol study. Value represents the fraction 
of a given tissue type that is opsonized per tissue. (n ≥ 4 tumors, n = 2 spleens per group. 
Mean ± SEM). 
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Figure 4.S4 Macrophage localization and population breakdown  
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Figure 4.S4 Macrophage localization and population breakdown  
(A) Flow cytometry gating strategy used to analyze mature (CD11b+F4/80hi) and 
immature (CD11b+F4/80int) macrophages. (B-E) Macrophage subpopulation analysis for 
CD47 KD+ study. (B) % mature macrophages relative to total mature macrophages in a 
given tissue/spleen (C) % mature macrophages relative to total murine cells in a given 
tissue/spleen. (D) % immature macrophages relative to total number of immature 
macrophages in a given tissue/spleen. (E) % mature macrophages relative to total murine 
cells in a given tissue/spleen (n ≥ 4 tumors/spleens per group. Mean ± SEM). 
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Figure 4.S5 WT GFP Scr/KD++ mosaic tumor analysis  
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Figure 4.S5 WT GFP Scr/KD++ mosaic tumor analysis  
(A) Scatter plot of individual tumors presented in Figure 1B. (WT GFP Scr: n=2 mice, 4 
tumors; CD47 KD++: n=2 mice, 4 tumors; Mosaic: n=6 mice, 12 tumors). (B) Flow 
cytometry of cells 1 day after xenograft implantation. CD47 intensity is normalized to 
human RBC. (n=3 for all groups. Mean ± SEM).  (C-F) Macrophage subpopulation 
analysis of tumors shown in Fig. 1C, D. (C) % immature macrophages relative to total 
murine cells in a given tissue/spleen. (D) % immature macrophages relative to total 
number of immature macrophages in a given tissue/spleen. (E) % mature macrophages 
relative to total mature macrophages in a given tissue/spleen. (F) % mature macrophages 
relative to total murine cells in a given tissue/spleen  (n ≥ 4 tumors/spleens per group. 
Mean ± SEM). 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
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 The work presented in this dissertation provides evidence for specific roles of 
lamin-A and –B in HSC/P differentiation and trafficking of progeny. Additionally, 
specific roles for MIIA and MIIB in blood cell generation and long-term engraftment 
have been demonstrated. Temporal and spatial control of MIIA function has also been 
shown to be critical to MK proplatelet extension, fragmentation, and generation of 
platelets of normal size and number. Specifically, we have shown that the lamin-A:B 
ratio controls both nuclear viscoelasticity and cell trafficking. High A:B rigidifies 
erythroblast nuclei to favor marrow retention and enhance erythropoiesis. 
Thrombopoiesis is enhanced by intermediate A:B that also opposes cell division thereby 
favoring marrow anchorage of MKs. Moderate lamin levels are seen in HSC/Ps while 
white cells have low lamin levels thus contribute to marrow retention and circulation 
respectively. Our MII results in early hematopoiesis reveals MIIB to be highly polarized 
in HSC/Ps and as a result, is downregulated in differentiated cells through asymmetric 
division. The use of xenograft mouse models has shown that MIIB is required for 
generation of blood, MIIA is required for long-term HSC/P engraftment, and inhibition of 
either MII isoform with blebbistatin enriches for long-term hematopoietic multilineage 
reconstituting cells. Focusing on MKs and platelet generation, we have found an optimal 
shear stress for generation of platelet-like-particles that is enhanced by MII inhibition. 
Furthermore, phosphorylation at S1943 on the MIIA heavy chain is found to be shear 
stress sensitive. Micropipette aspiration confirms the enhancement in MK fragmentation 
following pharmacological inhibition or mutagenic means of introducing a phospho-
mimetic mutation. Extending the work to MYH9-RD mutations, we recapitulate the 
macrothrombocytopenia in vitro using micropipette aspiration. Peripheral blood samples 
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from normal donors treated with blebbistatin is shown to arrest cleavage and generation 
of normal size platelets as seen by an increase in the number of large discoidal 
preplatelets. These blebbistatin treated blood samples share a striking resemblance to 
samples obtained from a MYH9-RD patient supporting our hypothesis that MIIA activity 
is necessary for fission of proplatelets to platelets. Without proper MIIA activity platelets 
are not released and a macrothrombocytopenia results. Thus, macrothrombocytopenia 
resulting from MYH9 mutation is not an effect of pathologic MK extension or initial 
fragmentation, but rather arises from an inability of circulating preplatelets to undergo 
fission.  
 After the investigation of biophysical aspects of hematopoiesis in the marrow and 
PB in Chapters 2 and 3, Chapter 4 explored the ability of leukocytes respond to the 
presence of a tumor and how one subset, the macrophage, can drive tumor clearance. The 
Discher laboratory’s previous work with evading macrophage phagocytosis by display of 
a CD47 peptide (Rodriguez et al., 2013) provided the foundation from which the work 
presented herein built off. Others have previously demonstrated efficacious treatment 
regimens by combining an anti-CD47 antibody (Chao et al., 2010a) or an engineered 
SIRPα variant (Weiskopf et al., 2013) with a monoclonal tumor-specific antibody. 
However, since CD47 is nearly ubiquitously expressed on all cells, these treatment 
methods are typically accompanied by anemia and other adverse hematological side 
effects. Additionally, evidence exists for tumor clearance being driven by macrophages, 
but a direct observation of macrophages internalizing tumor cells is lacking. We proposed 
that if CD47 is blocked or knocked down on the tumor cell then any IgG antibody 
capable of opsonizing the surface of the tumor would be sufficient to stimulate 
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phagocytosis by macrophages. We, in fact, see such an effect. Treatment of mice bearing 
human xenograft tumors with CD47 expression knocked down showed drastic reduction 
in tumor size following administration of a general human specific polyclonal antibody 
while tumors expressing normal levels of CD47 were unaffected by treatment. 
Additionally, significant adverse hematological side effects are not observed. By spiking 
a known fraction of GFP-expressing normal CD47 cells into our CD47 knockdown 
tumors we observe an enrichment of GFP cells after Ab treatment demonstrated upon 
tumor excision indicating, the selective removal of CD47 knockdown cells. Macrophages 
from CD47 knockdown Ab treated tumors show an increase in the presence of tdTomato 
(fluorescent protein expressed by tumor cells) and co-localization is increased when 
macrophages are also positive for the Ab. These observations provide direct evidence that 
macrophages are engaging the CD47 knockdown cells, being further stimulated to eat by 
the treatment antibody, and then proceed to phagocytose the target cell.  
 The results of these recent tumor studies provide the potential for an efficacious 
treatment without significant side-effects. Granted, we are starting with tumors in which 
CD47 is already knocked down, whereas normal tumors typically express elevated levels 
of CD47 (Majeti et al., 2009). Methods of delivering siRNA directed toward CD47 may 
prove to be the solution. Other have delivered liposomes containing CD47 siRNA and 
have shown inhibition of tumor establishment without hematopoietic toxicity (Wang et 
al., 2013). However, siRNA was not delivered to animals carrying already established 
tumors, siRNA was administered concurrently with tumor inoculation, nor did they 
simultaneously treat with an antibody. Our laboratory is in the early stages of developing 
a non-toxic siRNA against CD47 that we would use in our xenograft tumor model and 
	   184	  
accompany with antibody treatment. siRNA seems to be a safe and efficacious means of 
tumor CD47 knockdown as anucleated RBCs and platelets would be unaffected by 
siRNA. There is a possibility of siRNA incorporating into circulating leukocytes, marrow 
cells, or even the endothelium lining the circulation. Incorporation into HSC/Ps could be 
particularly harmful as the progeny of these cells would also display reduced CD47 levels 
and be rapidly phagocytosed as they frequently encounter macrophages in the circulation. 
These potential issues could be resolved by proper delivery design, dosing schedule, 
and/or specificity in targeting only tumor cells.  
 A second study that we are currently undertaking is the generation of an Fc 
truncated version of the treatment antibody. Others have demonstrated that F(ab’)2 
fragments of anti-cancer antibodies are capable of binding tumor cells with similar 
affinity as their full length version, however, the loss of the Fc portion abrogates 
macrophage engagement and thus treatment efficacy is greatly impaired (Pallasch et al., 
2014). We hope to show similar effects in vitro and in vivo using our xenograft model. If 
successful, it will prove that CD47 knockdown removes the normal “don’t eat me” signal 
through interaction with SIRPα while the presence of the treatment antibody provides an 
additional “eat me” stimulus through engagement of the Fc receptor on the macrophage.  
 Another potentially exciting avenue that may be pursued is the generation of a 
anti-CD47 probody similar to the cetuximab analog developed recently by CytomX 
Therapeutics. The cetuximab probody, an anti-epidermal growth factor receptor antibody, 
is synthesized with a masking peptide linked to the Fab arm of the antibody that is 
cleaved by proteases commonly found in the tumor microenvironment. They show 
reduced EGFR binding and inhibitory activity of the probody, but upon cleavage, binding 
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and inhibitory activity is similar to cetuximab (Desnoyers et al., 2013). We hypothesize 
that instead of using CD47 siRNA or unprotected anti-CD47 antibodies that would 
interact with normal tissue as well as cancerous tissue, we would generate a protected 
anti-CD47 antibody that can only be deprotected in the tumor microenvironment. 
Simultaneous administration of polyclonal IgG would then provide the additional 
stimulatory signal necessary for efficient macrophage clearance of CD47 masked, IgG 
opsonized cancer cells.  
 In total, the work presented in this dissertation and the efforts currently being 
undertaken demonstrate significant contributions to the understanding of biophysical 
principles in hematopoiesis through lamin and MII. Using a combination of in vitro and 
in vivo methods as well as patient samples, we were able to provide insight into the roles 
of lamin-A and –B in HSC/P differentiation and trafficking, MIIA and MIIB in 
generation of blood cells and long-term engraftment, and MK fragmentation and platelet 
generation. We additionally provide a mechanism for understanding CD47 modulated 
antibody treatment of cancer through phagocytosis of tumor cells by macrophages. Such 
a treatment option may prove applicable beyond the NSG mouse, but for now it offers an 
in vivo means of exploring immunotherapy and a platform from which we can explore 
less harmful treatment options than chemotherapy and radiation.    
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